

Nivolumab for Recurrent Squamous-Cell Carcinoma of

New England Journal of Medicine

375, 1856-1867

DOI: [10.1056/nejmoa1602252](https://doi.org/10.1056/nejmoa1602252)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Squamous cell carcinoma of the oral cavity, oropharynx and upper oesophagus. <i>Medicine</i> , 2015, 43, 197-201.	0.2	3
2	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
3	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	2.0	55
4	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 219-226.	2.0	6
5	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. <i>Clinical Skin Cancer</i> , 2016, 1, 75-81.	0.1	7
6	Nivolumab for recurrent squamous-cell carcinoma of the head and neck. <i>British Dental Journal</i> , 2016, 221, 632-632.	0.3	7
7	Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 62, 147-148.	0.8	32
8	More gain, less pain. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 716-716.	12.5	0
9	Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 946-954.	1.1	24
10	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. <i>Modern Pathology</i> , 2017, 30, 577-586.	2.9	132
11	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116.	2.0	33
12	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	3.4	46
13	The latest prospects of investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 265-268.	1.9	3
14	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
15	How to treat recurrent/metastatic head and neck cancer: the economic issue in real-world practice. <i>Current Medical Research and Opinion</i> , 2017, 33, 779-780.	0.9	0
16	Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. <i>Medical Oncology</i> , 2017, 34, 28.	1.2	9
17	Buparlisib and the continued quest for the ideal cure. <i>Lancet Oncology</i> , The, 2017, 18, 273-274.	5.1	0
18	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	5.1	173

#	ARTICLE	IF	CITATIONS
19	Immunoprofiling as a predictor of patient's response to cancer therapy" promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
20	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 4270-4279.	3.2	117
21	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. Journal of Geriatric Oncology, 2017, 8, 229-235.	0.5	108
22	Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Current Opinion in Immunology, 2017, 45, 52-59.	2.4	19
23	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
24	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 67, 61-69.	0.8	42
25	Approvals in 2016: the march of the checkpoint inhibitors. Nature Reviews Clinical Oncology, 2017, 14, 131-132.	12.5	16
26	Response Evaluation in Head and Neck Oncology: Definition and Prediction. Orl, 2017, 79, 14-23.	0.6	7
27	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy, 2017, 9, 261-272.	1.0	32
28	Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond. Orl, 2017, 79, 24-33.	0.6	6
29	Candidate immune biomarkers for radioimmunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 58-68.	3.3	14
30	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
31	Immunotherapy drug improves survival for patients with head and neck cancer. Cancer, 2017, 123, 545-545.	2.0	0
32	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Current Hematologic Malignancy Reports, 2017, 12, 44-50.	1.2	12
33	Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival. Oral Oncology, 2017, 67, 1-9.	0.8	70
34	Nivolumab for Squamous-Cell Cancer of Head and Neck. New England Journal of Medicine, 2017, 376, 595-596.	13.9	31
35	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews, 2017, 276, 9-25.	2.8	13
36	Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report. International Journal of STD and AIDS, 2017, 28, 932-936.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123.	2.0	5
38	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017, 69, 33-37.	0.8	16
39	Management of Recurrent and Metastatic HPV-Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 69-76.	1.1	26
40	European Society for Medical Oncology Copenhagen update: potential practice-changing findings. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 4-12.	1.4	0
41	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
42	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). <i>Oral Oncology</i> , 2017, 70, 65-72.	0.8	8
43	The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. <i>Oncotimmunology</i> , 2017, 6, e1288329.	2.1	16
44	Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 408-416.	1.6	84
45	Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?. <i>Journal of Oncological Science</i> , 2017, 3, 52-56.	0.1	88
46	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	0.5	27
47	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
48	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
49	The swinging pendulum of cancer immunotherapy personalization. <i>Personalized Medicine</i> , 2017, 14, 259-270.	0.8	3
50	The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. <i>Annals of Oncology</i> , 2017, 28, 1934-1941.	0.6	76
51	Programmed cell death ligand 1 as a biomarker in head and neck cancer. <i>Cancer Cytopathology</i> , 2017, 125, 529-533.	1.4	1
52	Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 50-58.	2.0	38
53	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1605-1611.	0.6	474
54	Management of elderly patients with locoregionally confined head and neck cancer. <i>Lancet Oncology, The</i> , 2017, 18, e274-e283.	5.1	51

#	ARTICLE	IF	CITATIONS
55	Potential for low-value palliative care of patients with recurrent head and neck cancer. <i>Lancet Oncology</i> , 2017, 18, e284-e289.	5.1	26
56	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1588-1595.	1.9	18
58	Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1257-1268.	1.9	32
59	Does chemoselection open the door for immunotherapy?. <i>Annals of Oncology</i> , 2017, 28, 1697-1699.	0.6	0
60	Trends in Surgical Research in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 38.	1.3	13
61	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
62	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23
63	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
64	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. <i>Oncolimmunology</i> , 2017, 6, e1329071.	2.1	85
65	Assessment of nivolumab benefit/risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. <i>Annals of Oncology</i> , 2017, 28, 2002-2008.	0.6	152
66	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
67	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
68	Human papillomavirus-related oropharyngeal cancer. <i>Annals of Oncology</i> , 2017, 28, 2386-2398.	0.6	270
69	Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. <i>Laryngoscope</i> , 2017, 127, 2565-2569.	1.1	25
71	CD45RA ^{hi} Foxp3 ^{high} regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1275-1285.	2.0	35
72	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
74	NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 761-770.	2.3	263
75	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38

#	ARTICLE	IF	CITATIONS
76	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
77	Regional immunotherapy for liver and peritoneal metastases. <i>Journal of Surgical Oncology</i> , 2017, 116, 46-54.	0.8	6
78	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. <i>Thyroid</i> , 2017, 27, 894-901.	2.4	123
79	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1705-1717.	2.5	56
80	Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 685-694.	1.5	22
81	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 725-736.	1.4	22
82	Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 19, 194-201.	1.3	41
83	The promising impact of molecular profiling on treatment strategies in oral cancers. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2017, 118, 242-247.	0.5	13
84	Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 432-438.	1.1	18
85	STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. <i>Journal of Dental Research</i> , 2017, 96, 1027-1034.	2.5	147
86	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , 2017, 9, 579-587.	1.0	11
87	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	1.9	74
88	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 647-655.	1.1	14
89	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6002-6011.	3.2	26
90	New insights into the role of <sc>EMT</sc> in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
91	Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma â€œ How far have we achieved?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 13-23.	2.0	39
92	Immunotherapy for head and neck cancer: the future of treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 701-708.	1.4	24
93	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. <i>Drugs</i> , 2017, 77, 843-857.	4.9	40

#	ARTICLE	IF	CITATIONS
94	Head and neck surgeons at the vanguard of immunotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 123, 517-518.	0.2	1
95	Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. <i>Cancer</i> , 2017, 123, 2219-2229.	2.0	284
96	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
97	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 631-639.	5.1	324
98	3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes. <i>FEBS Journal</i> , 2017, 284, 2705-2731.	2.2	16
99	Radiotherapy plus EGFR inhibitors: synergistic modalities. <i>Cancers of the Head & Neck</i> , 2017, 2, 2.	6.2	8
100	A watershed year for improvements in treatment?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 76-78.	12.5	20
101	Genomic sequencing and precision medicine in head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2017, 43, 884-892.	0.5	12
102	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. <i>OncoImmunology</i> , 2017, 6, e1261779.	2.1	235
103	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 319-327.	1.0	11
104	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342	1.0	42
105	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 1175-1183.	1.0	32
106	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 73, 65-69.	0.8	40
107	Modulation of antigen presenting cell functions during chronic HPV infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 58-65.	4.5	48
108	Long term outcome after resection of liver metastases from squamous cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2129-2134.	0.5	11
109	Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 310-319.	0.6	12
110	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	6.3	1,749
111	Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. <i>Oral Oncology</i> , 2017, 74, 49-55.	0.8	37

#	ARTICLE	IF	CITATIONS
112	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
113	GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. <i>OncolImmunology</i> , 2017, 6, e1353860.	2.1	26
114	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
115	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	13.5	1,515
117	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	1.6	131
118	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	0.7	53
119	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 13-21.	2.0	56
120	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017, 28, 2820-2826.	0.6	66
121	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017, 86, 257-265.	1.3	31
122	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017, 28, 2860-2865.	0.6	115
123	Circulating tumour cell PD-L1 test for head and neck cancers. <i>Oral Oncology</i> , 2017, 75, 6-7.	0.8	15
124	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
125	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	1.3	132
126	mTOR co-targeting strategies for head and neck cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 491-502.	2.7	46
127	Resistance to dasatinib is associated with the activation of Akt in oral squamous cell carcinoma. <i>Translational Research in Oral Oncology</i> , 2017, 2, 2057178X1770292.	2.3	1
128	Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. <i>Brachytherapy</i> , 2017, 16, 1246-1251.	0.2	32
130	Trial watch: Immune checkpoint blockers for cancer therapy. <i>OncolImmunology</i> , 2017, 6, e1373237.	2.1	62
131	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	3.2	46

#	ARTICLE	IF	CITATIONS
132	Nivolumab Exposureâ€“Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5394-5405.	3.2	76
134	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	0.8	57
135	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. <i>Biochemistry</i> , 2017, 56, 5428-5439.	1.2	23
136	PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. <i>Cancer Research</i> , 2017, 77, 6353-6364.	0.4	161
137	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
138	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
139	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigatorâ€™s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	0.8	90
141	Neurological Complications of Immunotherapiesâ€“Beware of the Checkpoint Ahead. <i>JAMA Neurology</i> , 2017, 74, 1176.	4.5	2
142	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1512-1520.	2.8	56
143	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
144	Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions. <i>Current Psychiatry Reports</i> , 2017, 19, 56.	2.1	49
146	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 219-222.	1.0	18
147	Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. <i>American Journal of Roentgenology</i> , 2017, 209, 289-303.	1.0	103
148	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	3.4	88
149	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1238-1246.	0.6	116
150	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
151	Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 775-782.	0.5	12
152	Immunotherapy. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 867-874.	0.5	4

#	ARTICLE	IF	CITATIONS
153	The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 3757-3765.	0.8	51
154	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
155	Four <scp>PTEN</scp>-targeting co-expressed mi<scp>RNA</scp>s and <scp>ACTN</scp>-targeting mi<scp>R</scp> are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. <i>International Journal of Cancer</i> , 2017, 141, 2318-2328.	2.3	20
156	Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas. <i>Journal of Pathology</i> , 2017, 243, 354-365.	2.1	14
157	Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2017, 134, 197-203.	1.4	7
158	The importance for immunoregulation for long-term cancer control. <i>Future Oncology</i> , 2017, 13, 1619-1632.	1.1	9
159	A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. <i>Oral Oncology</i> , 2017, 73, 21-26.	0.8	20
160	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	2.9	81
161	Immunotherapy for penile cancer. <i>Future Science OA</i> , 2017, 3, FSO195.	0.9	9
162	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
163	The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. <i>Oncolimmunology</i> , 2017, 6, e1356148.	2.1	247
164	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. <i>Head and Neck</i> , 2017, 39, 2329-2349.	0.9	26
165	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	2.1	54
166	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <i>European Respiratory Journal</i> , 2017, 50, 1700050.	3.1	301
167	Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2017, 19, 65.	1.8	29
168	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> . 2017. 24, 311-335.	2.4	530
169	Hypothyroid ataxia complicating monoclonal antibody therapy. <i>Practical Neurology</i> , 2017, 17, 482-484.	0.5	4
171	Immunotherapy in head and neck cancer: evidence and perspectives. <i>Immunotherapy</i> , 2017, 9, 1351-1358.	1.0	16

#	ARTICLE	IF	CITATIONS
172	Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer. <i>International Journal of Oncology</i> , 2018, 52, 155-165.	1.4	39
173	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 235-244.	0.6	2
174	Targeting immune checkpoints in breast cancer: an update of early results. <i>ESMO Open</i> , 2017, 2, e000255.	2.0	118
175	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology, The</i> , 2017, 18, e731-e741.	5.1	568
176	The Next Frontier: Head and Neck Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 681-683.	0.7	9
177	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. <i>Oral Oncology</i> , 2017, 75, 54-60.	0.8	11
178	First person: Maura L. Gillison, MD, PhD. <i>Cancer</i> , 2017, 123, 4307-4307.	2.0	0
179	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2017, 5, 1141-1151.	1.6	160
180	Large population study quantifies chances of pregnancy after cancer treatment. <i>Cancer</i> , 2017, 123, 4308-4308.	2.0	0
181	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1104-1115.	5.1	325
183	Novel Treatment Options in Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 342-346.	0.8	9
184	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , 2017, 82, 155-166.	1.3	148
185	Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 969-973.	0.4	3
186	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. <i>Oncolmunology</i> , 2017, 6, e1341030.	2.1	36
187	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. <i>Cell Metabolism</i> , 2017, 26, 94-109.	7.2	374
189	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
192	Quality of life after nivolumab treatment for head and neck cancer. <i>Lancet Oncology, The</i> , 2017, 18, 993-994.	5.1	3
194	Immunotherapy in head and neck cancer: aiming at EXTREME precision. <i>BMC Medicine</i> , 2017, 15, 110.	2.3	64

#	ARTICLE	IF	CITATIONS
195	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. , 2017, 5, 49.		29
196	Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecologic Oncology Research and Practice, 2017, 4, 3.	3.6	64
197	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 2017, 9, 681-692.	1.0	94
198	The second wave of immune checkpoint inhibitor tsunamis: advance, challenges and perspectives. Immunotherapy, 2017, 9, 647-657.	1.0	19
200	Putting T cells to workâ€”outsourcing neoantigen detection in head and neck cancers?. Oral Diseases, 2017, 23, 820-821.	1.5	0
201	Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. Oral Oncology, 2017, 64, e1-e3.	0.8	13
202	Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (United States), 2017, 96, e9519.	0.4	5
203	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. Medicine (United States), 2017, 96, e8931.	0.4	21
205	Update on squamous cell carcinoma of the head and neck. Memo - Magazine of European Medical Oncology, 2017, 10, 220-223.	0.3	22
207	Brain metastasis from oral cancer. Journal of Japanese Society of Oral Oncology, 2017, 29, 66-70.	0.0	0
208	Chemotherapy for the older patient with oral cancer. Journal of Japanese Society of Oral Oncology, 2017, 29, 182-188.	0.0	0
210	Cordycepin and a preparation from <i>Cordyceps militaris</i> inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model. Oncotarget, 2017, 8, 93712-93728.	0.8	28
211	Cancer Immunotherapy in Older Patients. Cancer Journal (Sudbury, Mass), 2017, 23, 219-222.	1.0	4
212	Clinical use of immune checkpoint inhibitors. , 2017, , .		0
213	High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. Blood Advances, 2017, 1, 1306-1308.	2.5	20
214	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2017, 8, 49.	1.6	459
215	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Pharmacology, 2017, 8, 730.	1.6	350
216	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1259-1271.	0.9	16

#	ARTICLE	IF	CITATIONS
217	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101
218	Using PROMs to guide patients and practitioners through the head and neck cancer journey. <i>Patient Related Outcome Measures</i> , 2017, Volume 8, 133-142.	0.7	37
219	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2537-2549.	2.0	6
220	Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2007-2014.	2.0	50
221	Head and neck cancer: improving outcomes with a multidisciplinary approach. <i>Cancer Management and Research</i> , 2017, Volume 9, 363-371.	0.9	150
222	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	1.8	72
223	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
224	Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 332.	1.6	25
225	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
226	Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. <i>Cancers</i> , 2017, 9, 39.	1.7	47
227	Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment. <i>Cancers</i> , 2017, 9, 62.	1.7	9
228	Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. <i>Cancers</i> , 2017, 9, 113.	1.7	19
229	Activated HGF-c-Met Axis in Head and Neck Cancer. <i>Cancers</i> , 2017, 9, 169.	1.7	51
230	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017, 8, 35.	1.0	27
231	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
232	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017, 7, 72.	1.3	122
233	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. <i>Frontiers in Oncology</i> , 2017, 7, 121.	1.3	48
234	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection. <i>Frontiers in Oncology</i> , 2017, 7, 147.	1.3	24

#	ARTICLE	IF	CITATIONS
235	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017, 2017, 1-9.	0.6	4
236	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2017, 8, 1460-1465.	1.2	13
237	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. <i>JCI Insight</i> , 2017, 2, .	2.3	203
238	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. <i>Current Cancer Therapy Reviews</i> , 2017, 13, .	0.2	0
239	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. <i>PLoS ONE</i> , 2017, 12, e0180995.	1.1	15
240	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>Oncolmmunology</i> , 2017, 6, e1344805.	2.1	142
241	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
242	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, 5, 53.		688
243	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
244	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
245	Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS111â€“001. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 10.	3.6	37
246	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance. <i>Journal of Biomedical Sciences</i> , 2017, 06, .	0.3	0
247	Severe Esophagitis and Gastritis from Nivolumab Therapy. <i>ACG Case Reports Journal</i> , 2017, 4, e57.	0.2	67
248	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 96649-96655.	0.8	22
249	Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2017, 08, .	0.4	25
250	Surgical Treatment for Pulmonary Metastasis of Head and Neck Cancer: Study of 58 Cases. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2017, 23, 169-174.	0.3	12
251	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	1.3	13
252	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 447-456.	1.1	2

#	ARTICLE	IF	CITATIONS
253	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 92699-92714.	0.8	29
254	High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i> , <i>Lactobacillus gasseri/johnsonii</i> , and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. <i>Oncotarget</i> , 2017, 8, 110931-110948.	0.8	79
255	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQqO O OrgBT /Overlock 10 T		
256	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527
257	Checkpoint cluster: biomarkers of response. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 501-508.	1.1	0
259	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. <i>Journal of Onco-Nephrology</i> , 2017, 1, 132-142.	0.3	4
260	Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. <i>Translational Andrology and Urology</i> , 2017, 6, 791-802.	0.6	68
261	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
263	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. <i>JAMA Oncology</i> , 2018, 4, 522.	3.4	92
264	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1321-1334.	0.9	11
265	Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 445-457.	2.5	19
266	Anti PD-L1 Durvalumab combined with Cetuximab and Radiotherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 42-47.	0.9	32
267	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. <i>Cancer Immunology Research</i> , 2018, 6, 250-254.	1.6	6
268	Multidisciplinary Care of the Head and Neck Cancer Patient. <i>Cancer Treatment and Research</i> , 2018, , .	0.2	10
269	Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer. <i>World Journal of Surgery</i> , 2018, 42, 2542-2550.	0.8	22
270	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	1.7	48
271	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. <i>Future Oncology</i> , 2018, 14, 1547-1558.	1.1	4
272	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. <i>Annals of Oncology</i> , 2018, 29, 1320-1324.	0.6	37

#	ARTICLE	IF	CITATIONS
273	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 410-420.	1.0	50
274	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	2.0	15
275	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 805-814.	2.0	41
276	Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma. <i>Oral Diseases</i> , 2018, 24, 120-123.	1.5	13
277	Oral leukoplakia remains a challenging condition. <i>Oral Diseases</i> , 2018, 24, 179-183.	1.5	42
278	CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis. <i>Journal of Dental Research</i> , 2018, 97, 787-794.	2.5	14
279	The molecular landscape of head and neck cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 269-282.	12.8	897
280	Durvalumab in urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 311-318.	1.1	8
281	Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Journal of Dental Research</i> , 2018, 97, 622-626.	2.5	16
282	Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. <i>Cancer</i> , 2018, 124, 1859-1866.	2.0	48
283	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. <i>Clinical Cancer Research</i> , 2018, 24, 2505-2516.	3.2	32
285	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. <i>Oral Oncology</i> , 2018, 78, 186-193.	0.8	42
286	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 22.	1.8	131
287	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. <i>Cancer Treatment Reviews</i> , 2018, 65, 54-64.	3.4	51
288	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	1.3	5
289	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
290	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2018, 59, 328-338.	1.7	19
291	New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018, 4, 385-396.	3.8	50

#	ARTICLE	IF	CITATIONS
292	Reirradiation of head and neck cancer using modern highly conformal techniques. <i>Head and Neck</i> , 2018, 40, 2078-2093.	0.9	39
293	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1386-1392.	3.0	137
294	High-Risk Cutaneous Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 2018, 6, 120-128.	0.2	2
295	Specific blockade of CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 1494-1504.	2.3	31
296	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	0.8	589
297	Detailed analysis of adenosine A2a receptor (<i>ADORA2A</i>) and CD73 (5'-nucleotidase, Tj ETQq1 1 0.784314 rgBT /Overlock 10) in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1452579.	2.1	19
298	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	1.8	184
299	PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 343-346.	1.1	9
300	IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class II-Deficient Tumors. <i>Cancer Immunology Research</i> , 2018, 6, 685-695.	1.6	39
301	Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database. <i>Clinical Therapeutics</i> , 2018, 40, 562-573.	1.1	10
302	Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 80, 104-107.	0.8	19
303	Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. <i>Molecular Oncology</i> , 2018, 12, 830-854.	2.1	36
304	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
305	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	0.6	10
306	Immunotherapy in head and neck cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 385-386.	0.7	0
307	Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. <i>Journal of Dental Research</i> , 2018, 97, 683-690.	2.5	15
308	Precision Therapy of Head and Neck Squamous Cell Carcinoma. <i>Journal of Dental Research</i> , 2018, 97, 614-621.	2.5	44
309	Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review. <i>Neoplasia</i> , 2018, 20, 227-232.	2.3	42

#	ARTICLE	IF	CITATIONS
310	Immunotherapy for recurrent/metastatic head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 152-156.	0.8	28
311	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
312	Targeted cancer therapies. <i>Journal of the American Dental Association</i> , 2018, 149, 100-111.	0.7	12
313	Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure. <i>Oncologist</i> , 2018, 23, 147-149.	1.9	2
314	Salvage of recurrence after surgery and adjuvant therapy: A systematic review. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 223-227.	0.6	15
315	Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2018, 47, 836-845.	0.7	66
317	Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. <i>Oncolmmunology</i> , 2018, 7, e1398877.	2.1	74
318	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432
319	Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 679-686.	1.1	15
320	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
321	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52
322	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
323	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. <i>Immunotherapy</i> , 2018, 10, 221-234.	1.0	7
324	Radiation effects on antitumor immune responses: current perspectives and challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774257.	1.4	185
325	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
326	Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. <i>Head and Neck</i> , 2018, 40, 818-827.	0.9	39
327	Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 2473-2481.	3.2	49
328	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β 2. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	386

#	ARTICLE	IF	CITATIONS
329	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). <i>Annals of Oncology</i> , 2018, 29, 1004-1009.	0.6	68
330	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186.	3.2	402
331	Leveraging Genomics for Head and Neck Cancer Treatment. <i>Journal of Dental Research</i> , 2018, 97, 603-613.	2.5	8
332	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	0.6	73
333	Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. <i>Oncolmmunology</i> , 2018, 7, e1404216.	2.1	26
334	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	1.6	56
336	Perspectives in Head and Neck Medical Oncology. <i>Cancer Treatment and Research</i> , 2018, 174, 163-185.	0.2	5
337	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
338	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	2.0	62
339	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8
340	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 141-152.	0.7	54
341	Correlation of Inflammatory Markers, Survival, and COX2 Expression in Oral Cancer and Implications for Prognosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 667-676.	1.1	25
342	Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 194-204.	0.5	85
343	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. <i>Immunotherapy</i> , 2018, 10, 85-91.	1.0	34
344	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. <i>Immunotherapy</i> , 2018, 10, 139-148.	1.0	13
345	Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018, 46, 492-497.	0.7	6
346	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018, 77, 92-97.	0.8	7
347	Acute pancreatitis: An unexpected toxicity when combining nivolumab and stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2018, 8, e234-e238.	1.1	6

#	ARTICLE	IF	CITATIONS
348	Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis. <i>Respiratory Investigation</i> , 2018, 56, 195-198.	0.9	9
349	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. <i>Case Reports in Oncology</i> , 2018, 10, 998-1005.	0.3	10
350	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
351	Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 77, 83-89.	0.8	53
352	Pembrolizumab for the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 107-114.	1.1	12
353	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
354	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. , 2018, , 565-578.		1
355	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	1.9	21
356	Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies. <i>Translational Oncology</i> , 2018, 11, 132-139.	1.7	5
357	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. <i>Clinical Cancer Research</i> , 2018, 24, 2268-2275.	3.2	116
358	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 163-170.	1.9	5
360	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
361	Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. <i>Molecular Pathology Library</i> , 2018, , 95-113.	0.1	1
362	Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. <i>Scientific Reports</i> , 2018, 8, 105.	1.6	47
363	Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway. <i>Oral Oncology</i> , 2018, 76, 34-41.	0.8	50
364	PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability. <i>Journal of the National Cancer Institute</i> , 2018, 110, 221-222.	3.0	5
365	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. <i>International Immunology</i> , 2018, 30, 13-22.	1.8	74
366	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	0.6	364

#	ARTICLE	IF	CITATIONS
367	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304
368	Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2018, 110, 479-485.	3.0	49
369	The Basics of Cancer Immunotherapy. , 2018, , .		5
370	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
371	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
372	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.4	438
373	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4529-4538.	3.2	82
374	First-line treatment of ovarian cancer: questions and controversies to address. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	1.4	32
375	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 395.	1.1	15
376	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
377	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	3.2	70
379	Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 272-280.	0.8	35
380	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527.	3.2	80
381	Pembrolizumab-induced autoimmune type 1 diabetes in a patient with metastatic melanoma. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 262-264.	0.5	4
382	The binding of an anti-PD-1 antibody to Fc γ R1 TM has a profound impact on its biological functions. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1079-1090.	2.0	162
383	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	2.9	49
384	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
385	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1204-1212.	0.5	46

#	ARTICLE	IF	CITATIONS
386	Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. <i>Oral Oncology</i> , 2018, 81, 116-118.	0.8	17
387	Correlates of immune and clinical activity of novel cancer vaccines. <i>Seminars in Immunology</i> , 2018, 39, 119-136.	2.7	54
388	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
389	Liquid Biopsies and Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 78-83.	1.0	18
390	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1059-1068.	0.8	95
391	Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 80, 33-39.	0.8	5
392	Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer. <i>Journal of Dental Research</i> , 2018, 97, 627-634.	2.5	31
393	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
394	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018, 65, 78-86.	3.4	32
395	Regulation and Function of the PD-L1 Checkpoint. <i>Immunity</i> , 2018, 48, 434-452.	6.6	1,437
396	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	1.1	9
397	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 451-458.	0.5	19
398	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
399	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
400	Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Oncologist</i> , 2018, 23, 764-e86.	1.9	6
401	Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1743-1751.	0.9	7
402	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 241-251.	0.1	146
403	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. <i>Biochemistry and Biophysics Reports</i> , 2018, 13, 123-128.	0.7	4

#	ARTICLE	IF	CITATIONS
404	4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1091-1100.	4.2	197
405	AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 676-686.	0.9	16
406	Current studies of immunotherapy in head and neck cancer. <i>Clinical Otolaryngology</i> , 2018, 43, 13-21.	0.6	63
407	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 318-331.	2.3	22
408	MerTK as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 92-102.	0.6	62
409	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a027086.	2.9	11
410	Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e257-e258.	1.3	25
411	Tumor Metabolic Features Identified by ¹⁸ F-FDG PET Correlate with Gene Networks of Immune Cell Microenvironment in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 31-37.	2.8	31
412	Head and Neck Carcinoma Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 6-13.	3.2	71
413	Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 225-233.	1.9	30
414	Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26837.	0.8	16
415	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. <i>Clinical Cancer Research</i> , 2018, 24, 62-72.	3.2	64
416	Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1392427.	2.1	45
417	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253
418	Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2018, 10, 802-808.	0.3	5
419	Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis. <i>Head and Neck</i> , 2018, 40, 647-655.	0.9	85
420	Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2018, 47, 568-577.	0.7	41
421	Chemotherapy for Oral Cancer. <i>Dental Clinics of North America</i> , 2018, 62, 87-97.	0.8	88

#	ARTICLE	IF	CITATIONS
422	A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment, 2018, 167, 485-493.	1.1	71
423	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 89-101.	1.8	40
424	MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer. Clinical Oral Investigations, 2018, 22, 1477-1486.	1.4	13
425	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. International Journal of Hyperthermia, 2018, 34, 840-852.	1.1	24
426	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. OncoImmunology, 2018, 7, e1386362.	2.1	62
427	Endocrinopathies with use of cancer immunotherapies. Clinical Endocrinology, 2018, 88, 327-332.	1.2	20
428	The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60.	0.9	10
429	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2018, 12, 221-229.	1.3	27
430	Is it time for the weighted log-rank test to play a more important role in confirmatory trials?. Contemporary Clinical Trials Communications, 2018, 10, A1-A2.	0.5	8
431	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. Neuro-Oncology, 2018, 20, 44-54.	0.6	51
432	Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. European Journal of Internal Medicine, 2018, 47, 6-13.	1.0	52
433	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathology and Oncology Research, 2018, 24, 701-716.	0.9	17
434	Psychosocial Impact of Personalized Therapies in Oncology. Recent Results in Cancer Research, 2018, 210, 181-190.	1.8	2
435	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 124-133.	0.5	52
436	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 2-11.	1.0	23
437	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. Seminars in Radiation Oncology, 2018, 28, 17-26.	1.0	16
438	Role of Immunotherapy in Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 12-16.	1.0	62
439	Nivolumab in recurrent/metastatic head and neck cancers. Future Oncology, 2018, 14, 603-609.	1.1	3

#	ARTICLE	IF	CITATIONS
440	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. <i>Oncolmunology</i> , 2018, 7, e1395996.	2.1	90
441	Mechanisms of Tumor Cellâ€œIntrinsic Immune Evasion. <i>Annual Review of Cancer Biology</i> , 2018, 2, 213-228.	2.3	65
442	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
443	Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 896-905.	3.2	464
444	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
445	Expression of programmed deathâ€œ1 in sentinel lymph nodes of breast cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1131-1136.	0.8	3
446	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
447	Product review on the Anti-PD-L1 antibody atezolizumab. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 269-276.	1.4	41
448	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38
449	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
450	Why overall survival and not progression free survival improves in era of program death inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 398-399.	0.5	1
452	Radiographic Evaluation of Immunotherapy. <i>Current Cancer Research</i> , 2018, , 115-131.	0.2	0
453	Modulators of Redox Metabolism in Head and Neck Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1660-1690.	2.5	14
454	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. <i>Journal of Immunology</i> , 2018, 200, 347-354.	0.4	181
455	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
456	Hepatocellular carcinoma in the era of immunotherapy. <i>Current Problems in Cancer</i> , 2018, 42, 40-48.	1.0	135
457	SEOM clinical guidelines for the treatment of head and neck cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 75-83.	1.2	27
458	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289

#	ARTICLE	IF	CITATIONS
459	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. Journal of Clinical Pharmacology, 2018, 58, 7-24.	1.0	23
460	Response to "Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after patients on antiprogrammed cell death" inhibition with nivolumab™. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e61-e62.	1.3	4
461	Update 2018. Clinical Nuclear Medicine, 2018, 43, e439-e452.	0.7	15
462	Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed?. Journal of Oncology Practice, 2018, 14, 594-602.	2.5	29
463	Frameshift events predict anti"PD-1/L1 response in head and neck cancer. JCI Insight, 2018, 3, .	2.3	190
464	<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget, 2018, 9, 641-650.	0.8	50
465	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 2018, 36, 1412-1418.	0.8	324
466	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. Journal of Clinical Oncology, 2018, 36, 3553-3559.	0.8	49
467	Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 169-178.	1.8	196
469	Immunotherapy in pancreatic adenocarcinoma"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
470	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. Journal of Thoracic Disease, 2018, 10, 1276-1279.	0.6	4
471	Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493.	0.6	42
472	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Translational Lung Cancer Research, 2018, 7, 50-68.	1.3	96
473	Immunotherapy in colorectal cancer: for the select few or all?. Journal of Gastrointestinal Oncology, 2018, 9, 170-179.	0.6	51
474	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell"dependent antitumor activity following radiation. Journal of Clinical Investigation, 2018, 128, 3926-3940.	3.9	136
475	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. Translational Lung Cancer Research, 2018, 7, S198-S201.	1.3	8
477	Exosome"delivered TRPP2 siRNA inhibits the epithelial"mesenchymal transition of FaDu cells. Oncology Letters, 2018, 17, 1953-1961.	0.8	29
478	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. Hematologie, 2018, 24, 183-193.	0.0	0

#	ARTICLE	IF	CITATIONS
479	Neutrophil-Mediated Endogenous Analgesia Contributes to Sex Differences in Oral Cancer Pain. <i>Frontiers in Integrative Neuroscience</i> , 2018, 12, 52.	1.0	34
481	Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?. <i>Cancers of the Head & Neck</i> , 2018, 3, 8.	6.2	3
485	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4226.	2.4	362
487	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
488	Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2018, 10, 466.	1.7	23
489	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7529-7542.	1.0	29
490	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8239-8250.	1.0	32
491	Treatment of Elderly Patients with Head and Neck Cancer. , 2018, , 285-307.		0
492	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
493	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?. , 2018, , 181-212.		0
494	Combination of PD-1 blockade and RetroNectin ^Å -activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. <i>Immunotherapy</i> , 2018, 10, 1315-1323.	1.0	6
495	Persistent Head and Neck Cancer Following First-Line Treatment. <i>Cancers</i> , 2018, 10, 421.	1.7	14
496	Harnessing immune checkpoints for cancer therapy. <i>Immunotherapy</i> , 2018, 10, 1265-1284.	1.0	9
497	Are There Alternative Chemotherapy Regimens for EXTREME in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN)?. , 2018, , 267-276.		0
498	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC). , 2018, , 341-355.		2
501	Cellular and Molecular Pathology in Head and Neck Cancer. , 2018, , 15-26.		1
502	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. <i>Oncolmmunology</i> , 2018, 7, e1500108.	2.1	52
503	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41

#	ARTICLE	IF	CITATIONS
504	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. <i>Current Oncology</i> , 2018, 25, 373-384.	0.9	109
506	Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6379-6389.	0.9	8
507	How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2941.	2.2	20
508	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
509	Good local tumor control but lethal hemorrhage after apatinib treatment for intractable squamous carcinoma of the floor of the mouth: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8909-8913.	1.0	5
510	PI3K kinase pathway biomarkers in oral cancer and tumor immune cells. <i>Head and Neck</i> , 2018, 41, 615-622.	0.9	4
511	Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 130-138.	0.9	9
512	Isolated adrenocorticotrophic hormone deficiency potentially induced by nivolumab following pseudo progression in clear cell renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 304-308.	0.4	10
513	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
514	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. <i>Immune Network</i> , 2018, 18, e45.	1.6	10
515	The prognostic significance of circulating tumor cells in head and neck and non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 5910-5919.	1.3	91
516	Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC). <i>Frontiers in Oncology</i> , 2018, 8, 588.	1.3	4
517	PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection. <i>Frontiers in Oncology</i> , 2018, 8, 604.	1.3	15
518	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 563.	1.3	35
519	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
520	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
521	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. , 2018, 6, 130.		10
522	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , 2018, 3, .	2.3	110

#	ARTICLE	IF	CITATIONS
523	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. <i>Frontiers in Oncology</i> , 2018, 8, 532.	1.3	27
524	AHNS series: Do you know your guidelines? Guideline recommendations for recurrent and persistent head and neck cancer after primary treatment. <i>Head and Neck</i> , 2019, 41, 7-15.	0.9	9
525	Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?. <i>Cancer</i> , 2018, 124, 4163-4164.	2.0	6
526	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. <i>European Journal of Cancer</i> , 2018, 103, 259-266.	1.3	13
527	Clinical Implications of Head and Neck Cancer. , 2018, , 227-228.		0
528	Precision medicine in head and neck cancer. <i>Drug Resistance Updates</i> , 2018, 40, 13-16.	6.5	121
529	Immunological and classical subtypes of oral premalignant lesions. <i>Oncolmmunology</i> , 2018, 7, e1496880.	2.1	35
530	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	1.6	59
532	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. <i>Journal of Clinical Pathology</i> , 2018, 71, 1078-1083.	1.0	33
533	Hypopharyngeal cancer: A state of the art review. <i>Oral Oncology</i> , 2018, 86, 244-250.	0.8	91
534	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. <i>Oncolmmunology</i> , 2018, 7, e1494112.	2.1	29
535	Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. , 2018, 6, 101.		31
536	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
537	PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2018, 6, 1548-1560.	1.6	122
538	Head and Neck Cancer Research and Support Foundations. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2018, 30, 459-469.	0.4	12
539	On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
540	Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not. <i>Oral Oncology</i> , 2018, 86, 273-277.	0.8	3
541	Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer. <i>British Journal of Cancer</i> , 2018, 119, 1191-1199.	2.9	33

#	ARTICLE	IF	CITATIONS
542	Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. <i>Current Treatment Options in Oncology</i> , 2018, 19, 68.	1.3	14
543	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
544	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. <i>PLoS ONE</i> , 2018, 13, e0206223.	1.1	149
545	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018, 25, 1318-1331.e4.	2.9	56
546	Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. , 2018, 22, 17-149.		11
547	Oral cancers: Current status. <i>Oral Oncology</i> , 2018, 87, 64-69.	0.8	68
548	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	12.5	304
549	Aging, immune senescence, and immunotherapy: A comprehensive review. <i>Seminars in Oncology</i> , 2018, 45, 187-200.	0.8	60
550	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. <i>Annals of Oncology</i> , 2018, 29, 2313-2327.	0.6	47
552	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. <i>Cancer Science</i> , 2018, 109, 3583-3590.	1.7	118
553	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
554	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75
555	Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 409.	1.3	11
556	Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. <i>Frontiers in Oncology</i> , 2018, 8, 439.	1.3	20
557	Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. <i>Oral Oncology</i> , 2018, 87, 207-209.	0.8	3
558	The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1223-1233.	1.4	19
559	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. <i>Annals of Oncology</i> , 2018, 29, 2247-2253.	0.6	101
560	Cost-effectiveness of nivolumab in the treatment of head and neck cancer. <i>Oral Oncology</i> , 2018, 87, 104-110.	0.8	16

#	ARTICLE	IF	CITATIONS
561	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	1.0	44
562	Underexpression of $\hat{\pm}$ -1-microglobulin/bikunin precursor predicts a poor prognosis in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 2605-2614.	1.4	13
564	Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2018, 8, 339.	1.3	21
565	Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. <i>BioScience Trends</i> , 2018, 12, 412-418.	1.1	13
566	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 7-16.	1.3	63
567	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <i>Future Oncology</i> , 2018, 14, 3187-3198.	1.1	9
568	Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. <i>Oral Oncology</i> , 2018, 86, 1-7.	0.8	27
569	TIGIT: a novel immunotherapy target moving from bench to bedside. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1659-1667.	2.0	152
570	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2018, 86, 81-90.	0.8	95
571	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 362, k3529.	2.4	354
572	Epigallocatechin-3-gallate affects the proliferation, apoptosis, migration and invasion of tongue squamous cell carcinoma through the hippo-TAZ signaling pathway. <i>International Journal of Molecular Medicine</i> , 2018, 42, 2615-2627.	1.8	17
573	A gene expression profile associated with perineural invasion identifies a subset of HNSCC at risk of post-surgical recurrence. <i>Oral Oncology</i> , 2018, 86, 53-60.	0.8	35
574	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. <i>PLoS ONE</i> , 2018, 13, e0203402.	1.1	22
575	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. <i>Lancet Oncology, The</i> , 2018, 19, 1338-1350.	5.1	337
576	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018, 29, 2175-2182.	0.6	20
577	Immune Checkpoint Inhibition in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 310.	1.3	103
578	Effectiveness Outcomes in Patients With Recurrent or Refractory Head and Neck Cancers: Retrospective Analysis of Data From a Community Oncology Database. <i>Clinical Therapeutics</i> , 2018, 40, 1522-1537.	1.1	5
579	Downregulation of DHRS9 is associated with poor prognosis in oral squamous cell carcinoma. <i>Pathology</i> , 2018, 50, 642-647.	0.3	16

#	ARTICLE	IF	CITATIONS
580	Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. <i>Cancer Research</i> , 2018, 78, 6159-6170.	0.4	61
581	Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. , 2018, 6, 84.		83
582	Head and Neck Tumors. , 2018, , 1-136.		1
583	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 1685-1690.	0.9	25
584	The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2018, 81, 100-108.	0.8	25
585	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. <i>Clinical Cancer Research</i> , 2018, 24, 4242-4255.	3.2	114
586	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	0.6	14
587	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
588	Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. <i>Radiotherapy and Oncology</i> , 2018, 128, 467-471.	0.3	18
589	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29
590	HPV – Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
591	Combining ADCs with Immuno-Oncology Agents. <i>Cancer Drug Discovery and Development</i> , 2018, , 11-44.	0.2	5
592	Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 399-404.	0.6	22
593	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2018, 19, 737-746.	5.1	622
594	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
595	Nivolumab for the treatment of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 611-618.	1.1	52
596	Chemotherapy plus nivolumab-associated acute kidney injury in a patient with non-oropharyngeal head and neck squamous cell carcinoma with renal metastasis. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 116-118.	0.2	1
597	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.	0.9	22

#	ARTICLE	IF	CITATIONS
598	Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47.	1.4	11
599	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.4	24
600	Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. Surgical Oncology, 2018, 27, 259-265.	0.8	14
601	Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives. Journal of Investigative Medicine, 2018, 66, 1023-1030.	0.7	26
602	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 2018, 119, 153-159.	2.9	329
603	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. JAMA Network Open, 2018, 1, e180416.	2.8	45
604	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology, 2018, 4, 1583.	3.4	84
605	Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	27
606	Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck “ clinical results from the cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer” Radiation Oncology, 2018, 13, 123.	1.2	24
607	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. Drug Design, Development and Therapy, 2018, Volume 12, 1645-1657.	2.0	19
608	Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treatment Reviews, 2018, 70, 75-87.	3.4	19
609	Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. Journal of Clinical Medicine, 2018, 7, 10.	1.0	41
610	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. Journal of Cancer, 2018, 9, 2302-2307.	1.2	23
611	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagnostic Pathology, 2018, 13, 47.	0.9	29
613	The human papillomavirus (HPV)-related cancer biology: An overview. Biomedicine and Pharmacotherapy, 2018, 106, 1537-1556.	2.5	96
614	Future Directions in Esophageal Cancer. , 2018, , 193-200.		0
615	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. Frontiers in Immunology, 2018, 9, 374.	2.2	51
616	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Frontiers in Oncology, 2018, 8, 18.	1.3	34

#	ARTICLE	IF	CITATIONS
617	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
618	A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine. <i>Frontiers in Oncology</i> , 2018, 8, 243.	1.3	5
619	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
620	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
621	Current Strategies to Enhance Anti-Tumour Immunity. <i>Biomedicines</i> , 2018, 6, 37.	1.4	11
622	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
623	Snail-overexpressing Cancer Cells Promote M2-Like Polarization of Tumor-Associated Macrophages by Delivering MiR-21-Abundant Exosomes. <i>Neoplasia</i> , 2018, 20, 775-788.	2.3	139
624	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 903-908.	2.3	10
625	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
626	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq1 1 0.784314 rgBT 12		
627	Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer. <i>Scientific Reports</i> , 2018, 8, 10716.	1.6	9
628	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
629	A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect. <i>Biometrics</i> , 2018, 74, 1292-1300.	0.8	13
630	Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0200509.	1.1	6
631	Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1417-1424.	2.0	17
632	Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 901-915.	1.1	40
633	Hyperprogression as a distinct outcome after immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 16-21.	3.4	89
635	Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. , 2018, 6, 22.		45

#	ARTICLE	IF	CITATIONS
636	PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1059-1066.	2.1	79
637	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 7497-7505.	0.8	50
638	High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. <i>BMC Pulmonary Medicine</i> , 2018, 18, 23.	0.8	21
639	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
642	<scp>PD</scp> and <scp>PD</scp> expression in <scp>HNSCC</scp> primary cancer and related lymph node metastasis – impact on clinical outcome. <i>Histopathology</i> , 2018, 73, 573-584.	1.6	68
643	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	0.8	10
644	A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. , 2018, 6, 33.		21
646	The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2018, 10, 267.	1.7	81
647	Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2018, 63, 292-298.	1.7	83
648	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer – recent developments and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 811-822.	1.9	5
649	Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 36-43.	2.0	3
650	Economic sustainability of immune-checkpoint inhibitors: the looming threat. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 721-722.	12.5	17
651	Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2413.	1.8	171
652	Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsinghua Open Pool Reactor. <i>Cancer Communications</i> , 2018, 38, 1-7.	3.7	65
653	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
654	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2245-2261.	1.2	28
655	CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. <i>EBioMedicine</i> , 2018, 35, 233-243.	2.7	97
656	Manejo del c�ncer avanzado de v�a a�rea-digestiva superior: magnitud de terapias requeridas, resultados oncol�gicos, funcionales y est�ticos. <i>Revista M�dica Cl�nica Las Condes</i> , 2018, 29, 427-434.	0.2	0

#	ARTICLE	IF	CITATIONS
657	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. <i>JAMA Oncology</i> , 2018, 4, 1437.	3.4	3
658	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 324-334.	0.9	56
659	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	0.8	58
660	Cancers of the Oral Cavity: Diagnosis and Treatment. , 2018, , .		0
661	Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. <i>European Journal of Cancer</i> , 2018, 102, 23-30.	1.3	62
662	The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy. <i>Micromachines</i> , 2018, 9, 397.	1.4	50
663	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. <i>Journal of Cancer</i> , 2018, 9, 1614-1622.	1.2	17
664	New developments in the management of head and neck cancer – impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 295-303.	0.9	55
665	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. <i>Frontiers in Immunology</i> , 2018, 9, 1769.	2.2	15
666	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) Tj ETQq1 1 0.784314 rgBT / Dv cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 47-52.	0.9	12
667	Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. <i>Brachytherapy</i> , 2018, 17, 995-1003.	0.2	23
668	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). <i>Cancers of the Head & Neck</i> , 2018, 3, 3.	6.2	58
669	CheckMate 141: 1â€Year Update and Subgroup Analysis of Nivolumab as Firstâ€Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	1.9	70
670	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131
671	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	0.8	15
672	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
673	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. <i>Medical Oncology</i> , 2018, 35, 132.	1.2	52
674	Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1651-1663.	1.3	20

#	ARTICLE	IF	CITATIONS
675	PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin “ case report. BMC Nephrology, 2018, 19, 210.	0.8	30
676	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
677	Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. Oral Oncology, 2018, 82, 75-82.	0.8	13
679	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology, 2018, 41, 114-121.	1.7	97
680	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 205-213.	0.4	7
681	Precision Medicine in Head and Neck Cancer: Myth or Reality?. Clinical Medicine Insights: Oncology, 2018, 12, 117955491877958.	0.6	18
682	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4
683	Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2018, 39, 642-645.	0.6	33
684	Recent progress in therapeutic antibodies for cancer immunotherapy. Current Opinion in Chemical Biology, 2018, 44, 56-65.	2.8	21
685	Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. Oncoimmunology, 2018, 7, e1466771.	2.1	14
686	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. Oncoimmunology, 2018, 7, e1471440.	2.1	43
687	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Scientific Reports, 2018, 8, 8810.	1.6	13
688	Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabetic Medicine, 2018, 35, 1283-1290.	1.2	25
689	Immune check-point in cervical cancer. Critical Reviews in Oncology/Hematology, 2018, 129, 40-43.	2.0	38
690	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2018, 82, 83-90.	0.8	19
691	Immunotherapy of Cancer. , 2019, , 1033-1048.e1.		3
692	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43
693	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrology Dialysis Transplantation, 2019, 34, 108-117.	0.4	137

#	ARTICLE	IF	CITATIONS
694	Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma. <i>International Journal of Cancer</i> , 2019, 144, 169-177.	2.3	9
695	10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2019, 24, e38-e45.	1.9	57
696	Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 45-54.	1.0	3
697	Impact of tumour profiling on clinical trials in salivary gland cancer. <i>Clinical Otolaryngology</i> , 2019, 44, 1-6.	0.6	1
698	Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1261-1264.	0.5	1
699	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	0.8	35
700	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. <i>Frontiers in Genetics</i> , 2019, 10, 724.	1.1	12
701	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
702	Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects. <i>Cancers</i> , 2019, 11, 1115.	1.7	28
703	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. <i>Aging</i> , 2019, 11, 501-522.	1.4	25
704	Pneumonitis as a complication of immune system targeting drugs? a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 521-534.	0.6	16
705	Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. <i>Oral Science International</i> , 2019, 16, 49-68.	0.3	2
706	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. <i>Head and Neck</i> , 2019, 41, 4036-4050.	0.9	3
707	CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression. <i>Oncogene</i> , 2019, 38, 7166-7180.	2.6	38
708	Microshell Enhanced Acoustic Adjuvants for Immunotherapy in Glioblastoma. <i>Advanced Therapeutics</i> , 2019, 2, 1900066.	1.6	6
709	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. <i>OncImmunology</i> , 2019, 8, e1638207.	2.1	39
710	Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?. <i>Annals of Oncology</i> , 2019, 30, 1751-1759.	0.6	13
711	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2019, 25, 5752-5758.	3.2	24

#	ARTICLE	IF	CITATIONS
712	Immunotherapeutic approaches in nasopharyngeal carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1165-1172.	1.4	40
713	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 96, 140-147.	0.8	46
714	The Expression and Effecton of MicroRNA-499a in High-Tobacco Exposed Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 678.	1.3	26
715	Targeting inhibitors of apoptosis in oral squamous cell carcinoma inÂvitro. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2019, 47, 1589-1599.	0.7	8
716	Carotid dosimetry after re-irradiation with 131Cs permanent implant brachytherapy in recurrent, resected head and neck cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 221-226.	0.4	4
717	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
718	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
719	How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?. <i>Oncologist</i> , 2019, 24, 867-871.	1.9	11
721	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	3.4	431
722	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	3.4	417
723	Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1171-1181.	1.0	42
724	The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. <i>Clinical Oncology</i> , 2019, 31, 834-843.	0.6	48
725	Pembrolizumab for the treatment of cervical cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 871-877.	1.4	24
726	Kidney Complications of Immune Checkpoint Inhibitors: A Review. <i>American Journal of Kidney Diseases</i> , 2019, 74, 529-537.	2.1	55
727	Challenges in the re-irradiation of locally advanced head and neck cancers: outcomes and toxicities. <i>Journal of Radiation Oncology</i> , 2019, 8, 259-266.	0.7	1
728	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019, 9, 668.	1.3	33
729	Immune profiles in primary squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2019, 96, 77-88.	0.8	57
730	Clinical update on head and neck cancer: molecular biology and ongoing challenges. <i>Cell Death and Disease</i> , 2019, 10, 540.	2.7	339

#	ARTICLE	IF	CITATIONS
731	The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 8-16.	3.4	47
732	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
733	Pembrolizumab for the treatment of head and neck squamous cell cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 879-885.	1.4	8
734	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <i>Cells</i> , 2019, 8, 747.	1.8	68
735	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1295-1305.	5.1	87
736	The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. <i>Cancer Discovery</i> , 2019, 9, 1422-1437.	7.7	210
737	Palbociclib: a new partner for cetuximab?. <i>Lancet Oncology</i> , The, 2019, 20, 1195-1196.	5.1	1
738	Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. <i>Journal of Dental Research</i> , 2019, 98, 1073-1080.	2.5	9
739	Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients. <i>International Journal of Biological Sciences</i> , 2019, 15, 1336-1344.	2.6	11
740	Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer. <i>Auris Nasus Larynx</i> , 2019, 46, 896-901.	0.5	7
741	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019, 96, 7-14.	0.8	45
742	Radioimmunotherapy for the treatment of head and neck cancer. <i>Lancet Oncology</i> , The, 2019, 20, e404-e416.	5.1	74
743	The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 634.	1.3	3
744	In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. <i>Experimental Cell Research</i> , 2019, 383, 111508.	1.2	37
745	The immune response-related mutational signatures and driver genes in non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 2348-2356.	1.7	86
746	<p></p>Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France</p></p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 441-451.	0.7	7
747	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	3.2	115
748	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	2.0	64

#	ARTICLE	IF	CITATIONS
749	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
750	Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer. <i>International Immunopharmacology</i> , 2019, 74, 105709.	1.7	7
752	ATR inhibition sensitizes HPV ⁺ and HPV ⁻ head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019, 95, 35-42.	0.8	34
753	A nomogram to estimate the risk of developing distant metastases in parotid cancer. <i>Head and Neck</i> , 2019, 41, 3309-3316.	0.9	1
754	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
755	Palliative Radiation Therapy for Head and Neck Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 254-266.	0.4	52
756	Quantitative high-throughput screening assays for the discovery and development of SIRP [±] -CD47 interaction inhibitors. <i>PLoS ONE</i> , 2019, 14, e0218897.	1.1	28
757	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8 ⁺ T cells. , 2019, 7, 261.		82
758	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
759	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019, 11, 1409-1422.	1.0	28
760	Immune gene expression in head and neck squamous cell carcinoma patients. <i>European Journal of Cancer</i> , 2019, 121, 210-223.	1.3	45
761	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , 2019, 71, 671-697.	7.1	13
762	Advances in Diagnosis and Multidisciplinary Management of Oropharyngeal Squamous Cell Carcinoma: State of the Art. <i>Radiographics</i> , 2019, 39, 2055-2068.	1.4	19
764	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients ^{â€™} survival, immune cell infiltrates, mutational load, and interferon β signature. <i>EBioMedicine</i> , 2019, 48, 341-352.	2.7	22
765	Targeting cancer stem cells in squamous cell carcinoma. <i>Precision Clinical Medicine</i> , 2019, 2, 152-165.	1.3	67
766	p16 status and choice of chemotherapy in the KEYNOTE-040 study. <i>Lancet, The</i> , 2019, 394, 1321-1322.	6.3	1
767	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1506-1517.	5.1	767
768	Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients ^{â€™} characteristics: an analysis in real-world setting. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 957-964.	0.6	4

#	ARTICLE	IF	CITATIONS
769	p16 status and choice of chemotherapy in the KEYNOTE-040 study. <i>Lancet, The</i> , 2019, 394, 1322-1323.	6.3	3
770	p16 status and choice of chemotherapy in the KEYNOTE-040 study – Authors' reply. <i>Lancet, The</i> , 2019, 394, 1323.	6.3	0
771	Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. <i>Frontiers in Oncology</i> , 2019, 9, 944.	1.3	17
772	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1063.	1.6	7
773	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study – Part 3 (Medical Oncology). <i>Frontiers in Oncology</i> , 2019, 9, 1127.	1.3	1
774	Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. <i>Theranostics</i> , 2019, 9, 7648-7665.	4.6	106
775	Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. <i>International Immunopharmacology</i> , 2019, 77, 105942.	1.7	11
776	An update: circulating tumor cells in head and neck cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1109-1115.	1.5	21
777	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1699.	1.7	81
778	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
780	Immunotherapy in head and neck cancer: The great challenge of patient selection. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102829.	2.0	14
781	The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis. <i>Journal of Laryngology and Otology</i> , 2019, 133, 936-942.	0.4	9
782	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32
783	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	6.3	1,804
784	Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. <i>International Journal of Biological Markers</i> , 2019, 34, 398-405.	0.7	34
785	Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5399.	1.8	35
787	The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2457.	2.2	16
788	Efficacy and Feasibility of Salvage Re-Irradiation with CyberKnife for In-Field Neck Lymph Node Recurrence: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1911.	1.0	0

#	ARTICLE	IF	CITATIONS
789	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , 2019, 394, 1882-1884.	6.3	16
790	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019, 99, 104460.	0.8	202
791	Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1055.	1.3	18
792	Single-cell sequencing and its applications in head and neck cancer. <i>Oral Oncology</i> , 2019, 99, 104441.	0.8	65
793	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1833.	1.0	19
794	The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. <i>Immunotherapy</i> , 2019, 11, 1481-1490.	1.0	14
795	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
796	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 3633-3646.	1.1	8
799	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
800	A pilot study of the pan- α class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. <i>Head and Neck</i> , 2019, 41, 3842-3849.	0.9	18
801	Novel immune-modulating drugs for advanced head and neck cancer. <i>Head and Neck</i> , 2019, 41, 46-56.	0.9	5
802	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. <i>Head and Neck</i> , 2019, 41, 4-18.	0.9	40
803	Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. <i>Head and Neck</i> , 2019, 41, 19-45.	0.9	70
804	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. <i>European Journal of Cancer</i> , 2019, 122, 72-90.	1.3	97
805	Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma. <i>Pathology</i> , 2019, 51, 688-695.	0.3	13
806	Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report. <i>Cancer Investigation</i> , 2019, 37, 531-534.	0.6	0
807	Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision. <i>Advances in Dental Research</i> , 2019, 30, 45-49.	3.6	13
808	Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2019, 27, 19-28.	0.8	15

#	ARTICLE	IF	CITATIONS
809	Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. , 2019, 7, 79.		28
810	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. Cancer Medicine, 2019, 8, 5969-5978.	1.3	26
811	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	2.0	13
813	Checkpoint inhibitors in head and neck cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 249-252.	0.3	0
814	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. Annals of Intensive Care, 2019, 9, 25.	2.2	46
815	Investigation of Recurrent Cases of Head and Neck Cancer after Initial Treatment. International Journal of Practical Otolaryngology, 2019, 02, e11-e17.	0.2	0
816	Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study. Acta Oto-Laryngologica, 2019, 139, 918-925.	0.3	44
817	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 866.	1.3	25
818	Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules, 2019, 24, 3214.	1.7	106
819	Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy. Scientific Reports, 2019, 9, 12913.	1.6	7
820	Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers, 2019, 11, 1317.	1.7	28
821	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1585-1596.	2.0	37
822	Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Annals of Oncology, 2019, 30, 1831-1839.	0.6	37
823	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 815.	1.3	53
824	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. , 2019, 7, 252.		57
825	Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. European Journal of Cancer, 2019, 119, 44-56.	1.3	26
826	Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 803-811.	0.4	40
827	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. Journal of Clinical Oncology, 2019, 37, 3032-3041.	0.8	51

#	ARTICLE	IF	CITATIONS
828	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
829	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer, 2019, 137, 108-112.	0.9	10
830	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. JNCI Cancer Spectrum, 2019, 3, pkz055.	1.4	34
831	HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 13404.	1.6	103
832	CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer. Cancers, 2019, 11, 1398.	1.7	65
833	Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers, 2019, 11, 1400.	1.7	45
834	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4705.	1.8	48
835	Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. Frontiers in Oncology, 2019, 9, 827.	1.3	126
836	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer, 2019, 121, 123-129.	1.3	115
837	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis, 2019, 8, 54.	2.1	12
838	Exosomes in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 894.	1.3	42
839	HNSCC and Immunotherapy: The Beginning of a Long Story. Journal of Molecular Biomarkers & Diagnosis, 2019, 10, .	0.4	0
840	Who is who in oral cancer?. Experimental Cell Research, 2019, 384, 111634.	1.2	38
841	Prognostic significance of PD-1 expression in patients with oral squamous cell carcinoma—a comparison to the PD-L1 expression profile. Cancer Medicine, 2019, 8, 1124-1134.	1.3	18
842	Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Medical Oncology, 2019, 36, 21.	1.2	32
843	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	7.0	51
844	The evolving role of immunooncology for the treatment of head and neck cancer. Laryngoscope Investigative Otolaryngology, 2019, 4, 62-69.	0.6	3
845	Head and Neck Tumors. , 2019, , 627-762.		0

#	ARTICLE	IF	CITATIONS
846	Head and Neck Cancers. , 2019, , 133-196.		0
847	EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. <i>Clinical Lung Cancer</i> , 2019, 20, e238-e241.	1.1	21
848	The Prognostic and Therapeutic Value of PD-L1 in Glioma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1503.	1.6	85
849	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. <i>Immunotherapy</i> , 2019, 11, 429-441.	1.0	44
850	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
851	<i>Pseudomonas</i> Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019, 11, 20.	1.5	37
854	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019, 109, 21-27.	1.3	188
855	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 291-300.	2.0	14
856	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 909-923.	1.1	10
857	Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. <i>Oncolimmunology</i> , 2019, 8, 1535293.	2.1	97
858	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 401-413.	1.6	99
859	Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 794-800.	3.3	11
860	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
861	Novel patterns of response under immunotherapy. <i>Annals of Oncology</i> , 2019, 30, 385-396.	0.6	343
862	Not CD68 but stabilin-1 expression is associated with the risk of recurrence in patients with oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2058-2064.	0.9	8
863	Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2019, 19, 482.	1.1	12
864	Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Oncology Letters</i> , 2019, 17, 5064-5072.	0.8	0
865	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 498.	1.3	33

#	ARTICLE	IF	CITATIONS
866	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. <i>Journal of Cancer</i> , 2019, 10, 1764-1771.	1.2	11
867	Immunohistochemistry-Enabled Precision Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 111-135.	0.2	5
868	Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. <i>Trends in Cancer</i> , 2019, 5, 365-390.	3.8	11
869	Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?. <i>Annals of Translational Medicine</i> , 2019, 7, S14-S14.	0.7	1
870	Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1-21.	0.6	33
871	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
872	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	1.8	13
873	Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas. <i>Cancer Immunology Research</i> , 2019, 7, 1318-1331.	1.6	53
874	The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. <i>Histopathology</i> , 2019, 75, 672-682.	1.6	43
875	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
876	Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. <i>Frontiers in Immunology</i> , 2019, 10, 1113.	2.2	128
877	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre-retrospective study of the German Cancer Consortium Radiation Oncology Group. <i>European Journal of Cancer</i> , 2019, 116, 67-76.	1.3	58
878	Hyperprogression during immunotherapy: do we really want to know?. <i>Annals of Oncology</i> , 2019, 30, 1028-1031.	0.6	17
879	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
880	Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 3039-3046.	0.5	27
881	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5315-5328.	3.2	81
882	Heterogeneity of Head and Neck Squamous Cell Carcinoma Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 23-40.	0.8	9
883	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333

#	ARTICLE	IF	CITATIONS
884	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	1.0	19
885	The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 596-603.	0.6	10
886	Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 403.	1.3	7
887	The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. <i>Cancer Letters</i> , 2019, 459, 268-276.	3.2	28
888	Assessment of Subcutaneous vs Intravenous Administration of Anti-“PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2019, 5, 999.	3.4	47
889	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1133-1141.	2.0	14
890	Development of active tuberculosis during treatment of head and neck carcinoma: a case series. <i>Journal of Medical Case Reports</i> , 2019, 13, 162.	0.4	4
891	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
892	Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). <i>Oral Oncology</i> , 2019, 94, 93-100.	0.8	12
893	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
894	Immune checkpoint inhibitors in the treatment of virus-associated cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 58.	6.9	43
895	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
896	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 919-928.	2.6	21
898	Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. <i>Pharmaceutical Medicine</i> , 2019, 33, 269-289.	1.0	10
899	The changing therapeutic landscape of head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 669-683.	12.5	454
900	Oropharyngeal Cancers in the East and the West “ Implications of Aetiopathogenesis on Prognosis and Research. <i>Clinical Oncology</i> , 2019, 31, 510-519.	0.6	3
901	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
902	The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. <i>Oral Oncology</i> , 2019, 94, 125-127.	0.8	2

#	ARTICLE	IF	CITATIONS
903	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 7680.	1.6	36
904	P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma. <i>Molecular and Cellular Toxicology</i> , 2019, 15, 137-143.	0.8	6
905	Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 942-952.	0.4	23
906	Co-SLD suppressed the growth of oral squamous cell carcinoma via disrupting mitochondrial function. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 1746-1757.	1.9	1
907	Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 3-10.	1.8	173
908	Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. <i>Oncologist</i> , 2019, 24, 829-835.	1.9	8
909	Challenges in the Isolation and Proteomic Analysis of Cancer Exosomes—Implications for Translational Research. <i>Proteomes</i> , 2019, 7, 22.	1.7	20
910	Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer — Future Perspectives. <i>Clinical Oncology</i> , 2019, 31, 424-431.	0.6	0
911	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 352-363.	1.8	28
912	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e110-e120.	1.8	11
913	Real-World Systemic Therapy Treatment Patterns for Squamous Cell Carcinoma of the Head and Neck in Canada. <i>Current Oncology</i> , 2019, 26, 167-174.	0.9	11
914	Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. <i>Pancreatology</i> , 2019, 19, 587-594.	0.5	62
915	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
916	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15
917	Nivolumab in the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN): A Report of 16 Cases at a Single Institution. <i>International Journal of Practical Otolaryngology</i> , 2019, 02, e7-e10.	0.2	0
918	The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. <i>Oncimmunology</i> , 2019, 8, 1608132.	2.1	37
919	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 76, 51-56.	3.4	36
920	<p><p>Assessment of tumor mutation burden calculation from gene panel sequencing data</p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3401-3409.	1.0	38

#	ARTICLE	IF	CITATIONS
921	Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti-PD-1 Therapy. <i>Laryngoscope</i> , 2019, 129, E428-E433.	1.1	4
922	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. <i>Trends in Cancer</i> , 2019, 5, 208-232.	3.8	54
923	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	3.2	66
924	Co-delivery of TRAIL and siHSP70 using hierarchically modular assembly formulations achieves enhanced TRAIL-resistant cancer therapy. <i>Journal of Controlled Release</i> , 2019, 304, 111-124.	4.8	20
925	Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 511.	1.6	56
926	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
927	Cardiac Metastasis in a Patient with Head and Neck Cancer: A Case Report and Review of the Literature. <i>Case Reports in Otolaryngology</i> , 2019, 2019, 1-8.	0.1	8
928	Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2019, 136, 257-261.	0.4	8
929	A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer. <i>Journal of Dental Research</i> , 2019, 98, 489-497.	2.5	6
930	Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment. <i>Journal of Visualized Experiments</i> , 2019, .	0.2	7
931	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
932	Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 541.	1.7	77
933	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
934	A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. <i>Oncologist</i> , 2019, 24, 891-e431.	1.9	25
935	Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 279-288.	0.4	24
936	Local inflammatory reaction to benign, pre-malignant and malignant glottic lesions: A matched case-control study. <i>Clinical Otolaryngology</i> , 2019, 44, 628-638.	0.6	4
937	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	1.0	17
938	Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 41-52.	2.0	7

#	ARTICLE	IF	CITATIONS
939	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
940	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
941	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. <i>Cancers</i> , 2019, 11, 472.	1.7	24
942	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	1.6	76
943	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	1.1	24
944	Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019, 37, 1578-1589.	0.8	50
945	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. <i>PLoS ONE</i> , 2019, 14, e0215381.	1.1	73
946	Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1449-1454.	0.8	8
947	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 52.	1.8	222
948	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 156.	1.3	119
949	Dynamic host immune response in virus-associated cancers. <i>Communications Biology</i> , 2019, 2, 109.	2.0	34
950	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. <i>Oncimmunology</i> , 2019, 8, e1588085.	2.1	17
951	Future Perspectives in Hypopharyngeal Cancer Care. <i>Advances in Oto-Rhino-Laryngology</i> , 2019, 83, 167-175.	1.6	3
952	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 84-91.	2.0	55
953	Quality insurance in head and neck cancer multidisciplinary team meetings: A watchful eye on real-life experience. <i>Oral Oncology</i> , 2019, 91, 35-38.	0.8	6
954	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. <i>Oncology Letters</i> , 2019, 17, 4011-4015.	0.8	8
955	Molecular Diagnostics in Head and Neck Squamous Cell Carcinoma. , 2019, , 165-185.		3
956	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. <i>Visceral Medicine</i> , 2019, 35, 28-37.	0.5	7

#	ARTICLE	IF	CITATIONS
957	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2591-2601.	0.9	12
958	Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. <i>Head and Neck</i> , 2019, 41, 2610-2618.	0.9	40
959	Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-Institutional Study. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 74-81.	1.1	16
960	Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. <i>Oncolmunology</i> , 2019, 8, e1581529.	2.1	43
961	An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. <i>Apmis</i> , 2019, 127, 240-264.	0.9	26
962	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. <i>Oncologist</i> , 2019, 24, S11-S20.	1.9	2
963	Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2484-2491.	0.9	33
964	Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 1465-1473.	0.8	10
965	Selective Neck Dissection and Survival in Pathologically Node-Positive Oral Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 269.	1.7	13
966	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32
967	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3528-3537.	3.2	136
968	Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. <i>Head and Neck</i> , 2019, 41, 2574-2580.	0.9	9
969	General Principles of Head and Neck Cancer Treatment. , 2019, , 3-14.		0
970	Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. <i>Cancer Letters</i> , 2019, 452, 51-58.	3.2	16
971	Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 137-156.e1.	0.6	39
972	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 122.	1.3	63
973	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56
974	Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. <i>Neuro-Oncology Practice</i> , 2019, 6, 402-409.	1.0	43

#	ARTICLE	IF	CITATIONS
975	Association of Posttreatment Lymphopenia and Elevated Neutrophil-to-Lymphocyte Ratio With Poor Clinical Outcomes in Patients With Human Papillomavirus–Negative Oropharyngeal Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 413.	1.2	39
976	Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1109-1124.	0.4	140
977	Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2019, 26, 111-114.	0.9	23
978	A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 63-69.	0.6	75
979	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Hormone and Metabolic Research</i> , 2019, 51, 145-156.	0.7	234
980	Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma. <i>Histopathology</i> , 2019, 75, 118-127.	1.6	11
981	PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. <i>Scientific Reports</i> , 2019, 9, 4633.	1.6	37
982	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). <i>BMC Cancer</i> , 2019, 19, 231.	1.1	19
984	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 917-926.	2.0	59
985	Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 31.	1.3	10
986	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 301-321.	0.9	19
987	Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 30.	1.3	24
988	Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy. <i>International Cancer Conference Journal</i> , 2019, 8, 86-88.	0.2	1
989	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	2.9	109
990	A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. <i>Pharmacoeconomics</i> , 2019, 37, 1041-1047.	1.7	7
992	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1104-1113.	0.6	205
993	Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 191.	1.3	12
994	Cancer Immunotherapy for Nasopharyngeal Carcinoma. , 2019, , 337-351.		1

#	ARTICLE	IF	CITATIONS
995	The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients's sex. <i>International Journal of Cancer</i> , 2019, 145, 2840-2849.	2.3	60
996	Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. <i>Oral Oncology</i> , 2019, 93, 1-7.	0.8	32
997	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
998	Squamous cell carcinoma of the oral cavity, oropharynx and upper oesophagus. <i>Medicine</i> , 2019, 47, 269-274.	0.2	1
999	Immune check-point in glioblastoma multiforme. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 60-69.	2.0	14
1000	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). , 2019, 7, 96.		34
1001	Treatment Options for Hypopharyngeal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2019, 83, 47-53.	1.6	23
1002	Systemic Therapy, Palliation and Supportive Care of Patients with Hypopharyngeal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2019, 83, 148-158.	1.6	0
1003	Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1753-1774.	0.8	204
1004	Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single institution outcomes. <i>Head and Neck</i> , 2019, 41, 2309-2314.	0.9	37
1005	Mouse Models of Innate Immunity. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	4
1006	Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. <i>Acta Oto-Laryngologica</i> , 2019, 139, 201-205.	0.3	10
1007	Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation. <i>Methods in Molecular Biology</i> , 2019, 1960, 93-99.	0.4	36
1008	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
1011	Met inhibition revokes IFN γ -induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019, 120, 527-536.	2.9	34
1012	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
1013	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019, 109, 154-161.	1.3	64
1014	The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. <i>Oral Oncology</i> , 2019, 90, 67-73.	0.8	52

#	ARTICLE	IF	CITATIONS
1015	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	1.3	18
1016	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	1.9	18
1017	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 76-84.	2.0	9
1018	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221.	1.0	122
1019	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
1020	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
1021	The 4717Câ€™>â€™G polymorphism in periplakin modulates sensitivity to EGFR inhibitors. <i>Scientific Reports</i> , 2019, 9, 2357.	1.6	5
1022	Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models. <i>Targeted Oncology</i> , 2019, 14, 223-235.	1.7	8
1023	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	3.2	85
1024	Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2019, 58, 1747-1752.	0.3	23
1025	Importance of the immune system in head and neck cancer. <i>Head and Neck</i> , 2019, 41, 2789-2800.	0.9	28
1027	Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. <i>Human Pathology</i> , 2019, 87, 11-17.	1.1	40
1028	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.	7.7	555
1029	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 108.	2.2	117
1030	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta OncolÃ³gica</i> , 2019, 58, 1-8.	0.8	14
1031	Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinomaâ€™A single institution analysis of 54 patients. <i>Clinical Otolaryngology</i> , 2019, 44, 639-643.	0.6	5
1032	Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. <i>Oncolmmunology</i> , 2019, 8, e1568809.	2.1	22
1033	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Gastroenterology</i> , 2019, 156, 890-903.	0.6	48

#	ARTICLE	IF	CITATIONS
1034	Emerging patient-specific treatment modalities in head and neck cancer – a systematic review. Expert Opinion on Investigational Drugs, 2019, 28, 365-376.	1.9	3
1035	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs, 2019, 28, 351-363.	1.9	14
1036	Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer. BMJ Case Reports, 2019, 12, e229963.	0.2	9
1037	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
1038	PD-1 Inhibitors in the Advanced Esophageal Cancer. Frontiers in Pharmacology, 2019, 10, 1418.	1.6	22
1039	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials. JCO Precision Oncology, 2019, 3, 1-10.	1.5	51
1040	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. Molecular Cancer Therapeutics, 2019, 18, 1909-1915.	1.9	21
1041	MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. Oncologist, 2019, 24, 1305-1308.	1.9	3
1042	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. Immunotherapy, 2019, 11, 1193-1203.	1.0	3
1043	A Hidden Epidemic of –Intermediate Risk–Oropharynx Cancer. Laryngoscope Investigative Otolaryngology, 2019, 4, 617-623.	0.6	11
1044	Rare entities in head-and-neck cancer: salvage re-irradiation with carbon ions. Radiation Oncology, 2019, 14, 202.	1.2	6
1045	Immunotherapy and Radiation. Hematology/Oncology Clinics of North America, 2019, 33, 1057-1069.	0.9	2
1046	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
1047	Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306.	1.4	62
1048	Pulmonary papillary squamous cell carcinoma: a population-based analysis of incidence, treatment, and prognosis. Journal of Thoracic Disease, 2019, 11, 4271-4281.	0.6	1
1049	PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer. Clinical Journal of Oncology Nursing, 2019, 23, 627-638.	0.3	1
1050	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
1051	20 Carcinoma of the Nasal Cavity and Anterior Skull Base. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
1052	Atypisches Ansprechen mit Pseudoprogression im Knochen unter Nivolumab bei einem Patienten mit fortgeschrittenem kutanem Plattenepithelkarzinom. <i>Karger Kompass Dermatologie</i> , 2019, 7, 149-153.	0.0	0
1053	Rechallenge en sels de platine aprÃ©s radiochimiothÃ©rapie pour les rÃ©cidives de carcinome Ã©pidermoÃ©de des voies aÃ©rodigestives supÃ©rieures. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2019, 136, 255-260.	0.0	0
1054	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019, 17, 429.	1.8	5
1055	The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 160-168.	1.1	3
1056	Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. <i>World Journal of Surgical Oncology</i> , 2019, 17, 198.	0.8	31
1057	Ten-year Clinical Trends among 575 Consecutive Oral Cancer Patients at Tokyo Dental College Oral Cancer Center. <i>Bulletin of Tokyo Dental College</i> , The, 2019, 60, 251-260.	0.1	1
1059	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	1.8	46
1060	Regulation of Oncogenic Targets by miR-99a-3p (Passenger Strand of miR-99a-Duplex) in Head and Neck Squamous Cell Carcinoma. <i>Cells</i> , 2019, 8, 1535.	1.8	32
1061	PD-L1 Detectionâ€”Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
1062	Concurrent Radiation and Immunotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 208-214.	0.6	11
1063	Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 711-716.	0.6	2
1064	A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 937.	1.3	16
1065	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
1067	Management of pulmonary toxicity associated with immune checkpoint inhibitors. <i>European Respiratory Review</i> , 2019, 28, 190012.	3.0	54
1068	Treatment of inoperable elderly head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2019, 31, 152-159.	1.1	11
1069	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	1.8	57
1070	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
1071	A systematic analysis of immune genes and overall survival in cancer patients. <i>BMC Cancer</i> , 2019, 19, 1225.	1.1	30

#	ARTICLE	IF	CITATIONS
1072	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546.	5.8	98
1073	Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. <i>Current Opinion in Oncology</i> , 2019, 31, 146-151.	1.1	25
1074	Hyperthermia and immunotherapy: clinical opportunities. <i>International Journal of Hyperthermia</i> , 2019, 36, 4-9.	1.1	51
1075	Tumour flare reaction in cancer treatments. <i>Anti-Cancer Drugs</i> , 2019, 30, 953-958.	0.7	17
1076	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2019, 27, 142-150.	0.8	24
1077	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors. <i>Neurologist</i> , 2019, 24, 75-83.	0.4	31
1078	Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan. <i>Anticancer Research</i> , 2019, 39, 6819-6827.	0.5	21
1079	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
1080	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
1081	Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 149-152.	0.7	7
1082	Setting the scene â€” a future â€”epidemicâ€™ of immune-related adverse events in association with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii1-vii6.	0.9	3
1084	Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacyâ€”A Systematic Review. <i>Current Oncology</i> , 2019, 26, 395-403.	0.9	44
1085	33 Targeted Therapy for the Treatment of Advanced Squamous Cell Carcinoma of the Larynx. , 2019, , .		0
1086	Predictive potential and need for standardization of PD-L1 immunohistochemistry. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 475-484.	1.4	32
1087	<i>In vitro</i> evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 167-178.	1.4	8
1088	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
1089	Cancers of the Head and Neck. , 2019, , 103-114.		0
1090	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2

#	ARTICLE	IF	CITATIONS
1091	Association between loss of Y chromosome and poor prognosis in male head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 993-1006.	0.9	22
1092	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2019, 107, 142-152.	1.3	208
1093	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	3.4	192
1094	Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 317-330.	2.9	47
1095	A novel approach to candidemia? The potential role of checkpoint inhibition. <i>Medical Mycology</i> , 2019, 57, 151-154.	0.3	9
1096	HPV-Associated Anal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 183-209.	0.2	41
1097	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	3.3	12
1098	Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice. <i>Journal of Chemotherapy</i> , 2019, 31, 90-94.	0.7	12
1099	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). <i>Annals of Oncology</i> , 2019, 30, 250-258.	0.6	230
1100	Hypopharyngeal carcinoma: Do you know your guidelines?. <i>Head and Neck</i> , 2019, 41, 569-576.	0.9	43
1101	Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. <i>Laryngoscope</i> , 2019, 129, 1836-1843.	1.1	21
1102	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
1103	Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 41-42.	0.2	20
1104	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
1105	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. <i>Future Oncology</i> , 2019, 15, 687-694.	1.1	41
1106	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 8.	1.2	16
1107	Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators?. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 942-947.	0.6	23
1108	Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 835-847.	2.0	94

#	ARTICLE	IF	CITATIONS
1109	Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. <i>Annals of Oncology</i> , 2019, 30, 68-75.	0.6	196
1110	Immunotherapy for Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2019, 31, 85-100.	0.4	36
1111	Current Concepts in Chemotherapy for Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2019, 31, 145-154.	0.4	34
1112	Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares. <i>Head and Neck</i> , 2019, 41, 584-591.	0.9	19
1113	Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report. <i>Auris Nasus Larynx</i> , 2019, 46, 813-817.	0.5	4
1114	High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. <i>Cell Proliferation</i> , 2019, 52, e12537.	2.4	43
1115	Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. <i>Clinical Cancer Research</i> , 2019, 25, 1156-1164.	3.2	66
1116	Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma: a Virtual Reality™ of the tumor microenvironment?. <i>Annals of Oncology</i> , 2019, 30, 8-10.	0.6	6
1117	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
1118	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	1.3	37
1119	A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. <i>Journal of Medical Economics</i> , 2019, 22, 205-214.	1.0	17
1120	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
1121	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 722-731.	1.2	22
1122	Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression. <i>Head and Neck</i> , 2019, 41, E42-E47.	0.9	10
1123	Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e360-e364.	0.9	9
1124	Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. <i>BMC Cancer</i> , 2019, 19, 68.	1.1	44
1125	Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer. <i>Head and Neck</i> , 2019, 41, E86-E92.	0.9	2
1126	CheckMate 141 trial: all that glitters is not gold. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 169-171.	1.4	11

#	ARTICLE	IF	CITATIONS
1127	Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 2549-2559.	3.2	46
1128	Evaluation of a community-based dental screening program prior to radiotherapy for head and neck cancer: a single-center experience. <i>Supportive Care in Cancer</i> , 2019, 27, 3331-3336.	1.0	4
1129	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	2.7	124
1130	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. <i>Head and Neck</i> , 2019, 41, 1725-1737.	0.9	69
1131	Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. <i>Head and Neck</i> , 2019, 41, 1703-1712.	0.9	13
1132	Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. <i>American Journal of Ophthalmology</i> , 2019, 200, 226-241.	1.7	15
1133	High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 88, 9-15.	0.8	34
1134	Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. <i>Oral Oncology</i> , 2019, 89, 150-152.	0.8	0
1135	26 Systemic Therapies in the Management of Head and Neck Cancer. , 2019, , .		0
1136	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019, 210, 47-53.	0.8	53
1137	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 16.	3.5	27
1138	Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 221-232.	2.0	41
1139	The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. <i>Clinical Oncology</i> , 2019, 31, 81-90.	0.6	30
1140	Clinical immunotherapeutic approaches for the treatment of head and neck cancer. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2019, 48, 419-436.	0.7	10
1141	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
1142	New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. <i>Annual Review of Medicine</i> , 2019, 70, 409-424.	5.0	50
1143	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
1144	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1

#	ARTICLE	IF	CITATIONS
1145	Predictive Biomarkers and Targeted Therapies in Head and Neck Cancer. , 2019, , 457-462.		1
1146	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. Journal of Immunology, 2019, 202, 278-291.	0.4	61
1147	The value of immunotherapy in head and neck cancer. Expert Opinion on Biological Therapy, 2019, 19, 35-43.	1.4	14
1148	Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Future Oncology, 2019, 15, 739-751.	1.1	14
1149	Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2 max) of >180 Gy for patients with recurrent head and neck cancer. Head and Neck, 2019, 41, E48-E54.	0.9	4
1150	Oral cancer prevention worldwide: Challenges and perspectives. Oral Oncology, 2019, 88, 91-94.	0.8	7
1151	Genomic Applications in Head and Neck Cancers. , 2019, , 309-324.		0
1152	Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. Head and Neck, 2019, 41, 1237-1245.	0.9	5
1153	HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, 2019, , .	0.2	0
1154	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88
1155	A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clinical Cancer Research, 2019, 25, 1486-1493.	3.2	174
1156	Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunology Research, 2019, 7, 282-291.	1.6	38
1157	Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. Tumori, 2019, 105, 151-154.	0.6	0
1158	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	23.0	237
1159	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	6.3	1,153
1160	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 546-554.	1.1	53
1161	Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. International Journal of Cancer, 2019, 144, 2811-2822.	2.3	35
1162	PD-1 antibodies in head-and-neck cancer. Lancet, The, 2019, 393, 108-109.	6.3	8

#	ARTICLE	IF	CITATIONS
1163	Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 110-124.	3.2	102
1164	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2019, 18, e20-e38.	1.0	62
1165	FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250.	3.3	194
1166	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	3.2	96
1167	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
1168	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. <i>Oncolimmunology</i> , 2019, 8, e1515057.	2.1	54
1169	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	3.4	344
1170	CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 99-106.	1.3	77
1171	Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. <i>Pathology and Oncology Research</i> , 2020, 26, 735-742.	0.9	24
1172	Tumor-infiltrating lymphocyte quantification stratifies early-stage human papillomavirus oropharynx cancer prognosis. <i>Laryngoscope</i> , 2020, 130, 930-938.	1.1	24
1173	Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer. <i>Laryngoscope</i> , 2020, 130, E140-E143.	1.1	8
1174	Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. <i>Laryngoscope</i> , 2020, 130, 907-910.	1.1	10
1175	Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer. <i>Auris Nasus Larynx</i> , 2020, 47, 309-313.	0.5	11
1176	Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 116-122.	0.5	33
1177	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
1178	<i>Therapeutic Antibodies and Immunologic Conjugates</i> . , 2020, , 486-499.e8.		2
1179	An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. <i>Oral Diseases</i> , 2020, 26, 511-526.	1.5	44
1180	Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 26-42.	1.8	40

#	ARTICLE	IF	CITATIONS
1181	Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents. <i>Journal of Medical Economics</i> , 2020, 23, 125-131.	1.0	1
1182	Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. <i>Clinical and Translational Oncology</i> , 2020, 22, 919-927.	1.2	45
1183	The impact of smoking on the effectiveness of immune checkpoint inhibitors – a systematic review and meta-analysis. <i>Acta OncolÃ³gica</i> , 2020, 59, 96-100.	0.8	13
1184	Translational genomics and recent advances in oral squamous cell carcinoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 71-83.	4.3	150
1185	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	0.6	24
1186	Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2020, 41, 984-992.	1.3	14
1187	Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. <i>Radiotherapy and Oncology</i> , 2020, 142, 79-84.	0.3	37
1188	Targeting DNA repair in cancer: current state and novel approaches. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 677-703.	2.4	65
1189	Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient. <i>Case Reports in Oncology</i> , 2020, 12, 709-714.	0.3	3
1190	Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 327-336.	2.8	27
1191	Nivolumab in patients with rare head and neck carcinomas: A single center’s experience. <i>Oral Oncology</i> , 2020, 101, 104359.	0.8	13
1192	<i>Z</i> test for delayed effect in immuno-oncology clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 244-266.	0.4	2
1193	Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104366.	0.8	19
1194	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020, 41, 625-633.	1.3	60
1195	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	4.3	146
1196	Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck. <i>Auris Nasus Larynx</i> , 2020, 47, 485-488.	0.5	9
1197	Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis. <i>Methods in Molecular Biology</i> , 2020, 2055, 521-562.	0.4	33
1198	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16

#	ARTICLE	IF	CITATIONS
1199	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. <i>Tumori</i> , 2020, 106, 177-189.	0.6	1
1200	PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2020, 14, 657-665.	1.3	21
1201	Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. <i>Oral Oncology</i> , 2020, 102, 104440.	0.8	6
1202	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	3.4	68
1203	Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 577-584.	0.8	5
1204	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
1205	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
1208	Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2020, 147, 116-127.	2.3	53
1209	Metformin Effects on FOXP3 + and CD8 + T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2020, 130, E490-E498.	1.1	24
1211	Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor β^2 complementarity-determining region 3. <i>Journal of Immunological Methods</i> , 2020, 476, 112679.	0.6	3
1212	Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. <i>Head and Neck</i> , 2020, 42, 625-635.	0.9	2
1213	Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. <i>Oral Oncology</i> , 2020, 101, 104525.	0.8	39
1214	Molecular biology of oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 102, 104552.	0.8	20
1215	Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 17-29.	1.1	17
1216	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	3.2	49
1217	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26
1219	Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Annals of Oncology</i> , 2020, 31, 50-60.	0.6	109
1220	iRECIST: how to do it. <i>Cancer Imaging</i> , 2020, 20, 2.	1.2	41

#	ARTICLE	IF	CITATIONS
1221	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
1222	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
1223	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
1224	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. <i>Translational Oncology</i> , 2020, 13, 262-274.	1.7	49
1225	Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. <i>Stem Cells and Development</i> , 2020, 29, 327-335.	1.1	11
1226	Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 60-72.	13.9	1,197
1227	Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. <i>Oral Oncology</i> , 2020, 101, 104554.	0.8	18
1228	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104523.	0.8	38
1229	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 165-174.	1.0	27
1230	18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects. <i>PET Clinics</i> , 2020, 15, 1-10.	1.5	20
1231	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 408-414.	1.0	19
1232	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	4.6	68
1233	Cancer of the Head and Neck. , 2020, , 999-1033.e7.		3
1234	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. <i>Immunity</i> , 2020, 52, 183-199.e9.	6.6	383
1235	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 2908-2920.	3.2	30
1236	A case of nivolumab-induced hypopituitarism in a head and neck cancer patient. <i>Otolaryngology Case Reports</i> , 2020, 14, 100141.	0.0	1
1237	Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 1200-1206.	1.2	52
1238	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 837-845.	3.2	120

#	ARTICLE	IF	CITATIONS
1239	Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. <i>Oral Oncology</i> , 2020, 101, 104492.	0.8	44
1240	The Cytosolic DNA-Sensing cGAS/STING Pathway in Cancer. <i>Cancer Discovery</i> , 2020, 10, 26-39.	7.7	558
1241	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. <i>Oral Oncology</i> , 2020, 100, 104477.	0.8	9
1242	HPV33+HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes. <i>Oral Oncology</i> , 2020, 100, 104488.	0.8	33
1243	Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards. <i>Biometrics</i> , 2020, 76, 939-950.	0.8	10
1244	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
1245	Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?. <i>Anti-Cancer Drugs</i> , 2020, 31, 97-100.	0.7	3
1246	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	2.2	36
1247	Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab. <i>Acta Oto-Laryngologica</i> , 2020, 140, 181-187.	0.3	24
1248	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
1249	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
1250	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	0.8	28
1251	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
1252	Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma? Systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 774-786.	0.9	52
1253	Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 128.	1.2	42
1254	The Evolving Role of Radiotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 91-108.	0.9	13
1255	Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 193-202.	0.6	16
1256	CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 334-344.	1.6	155

#	ARTICLE	IF	CITATIONS
1257	Hyperprogressive Disease in Patients with Non- ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 821-826.	2.8	73
1258	Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. <i>International Immunopharmacology</i> , 2020, 79, 106088.	1.7	39
1259	Criteria of metabolic response to immunotherapy. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 51-56.	0.1	0
1260	Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. <i>BMC Cancer</i> , 2020, 20, 933.	1.1	11
1261	Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?. <i>Cancers</i> , 2020, 12, 2781.	1.7	16
1262	Extracellular Vesicles as Biomarkers in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2825.	1.7	66
1263	Late and Long-Term Treatment-Related Effects and Survivorship for Head and Neck Cancer Patients. <i>Current Treatment Options in Oncology</i> , 2020, 21, 92.	1.3	14
1264	Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, 47, 676-686.	0.5	11
1265	Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 2177.	2.2	23
1266	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	1.0	5
1267	DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, , .	0.5	1
1268	Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 587089.	2.2	40
1270	Combination therapy and outcomes in head and neck cancer. , 2020, , 143-163.		0
1271	Treatment after progression in the era of immunotherapy. <i>Lancet Oncology</i> , The, 2020, 21, e463-e476.	5.1	115
1272	The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study. <i>Oral Oncology</i> , 2020, 110, 104943.	0.8	63
1273	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	1.0	39
1274	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
1275	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8

#	ARTICLE	IF	CITATIONS
1276	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
1277	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22555.	0.4	2
1278	Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13494-13506.	1.6	4
1279	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7621.	1.8	12
1280	Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1462-1475.	0.6	359
1281	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
1282	The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers. <i>Life</i> , 2020, 10, 228.	1.1	21
1283	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	1.4	3
1284	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
1285	Immunotherapy in older patients with cancer. <i>Biomedical Journal</i> , 2021, 44, 260-271.	1.4	19
1286	Squamous cell carcinoma of the buccal mucosa with multiple distant metastases. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2020, 32, 488-492.	0.2	1
1287	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1721.	2.2	61
1288	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 566297.	1.3	39
1289	Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. <i>Scientific Reports</i> , 2020, 10, 16988.	1.6	32
1290	HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?. <i>Frontiers in Oncology</i> , 2020, 10, 1751.	1.3	39
1291	Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. <i>Oral Oncology</i> , 2020, 111, 105013.	0.8	10
1292	Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2880-2886.	0.9	10
1293	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9

#	ARTICLE	IF	CITATIONS
1294	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	3.2	163
1295	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
1296	Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 109, 104776.	0.8	10
1297	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	1.2	12
1298	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
1299	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3620-e3627.	1.8	24
1300	Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1947-1958.	2.0	7
1301	Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. <i>International Journal of Hematology</i> , 2020, 112, 524-534.	0.7	1
1302	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. <i>Archives of Biochemistry and Biophysics</i> , 2020, 690, 108479.	1.4	30
1303	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	5.6	36
1304	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
1305	Clinical surveillance in immunotherapy-treated patient. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 493-495.	0.1	0
1306	Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. , 2020, 8, e000582.		23
1307	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
1308	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	3.2	58
1309	Immune Checkpoint Inhibitors for Patients Aged ≥75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. <i>Drugs and Aging</i> , 2020, 37, 747-754.	1.3	24
1310	Innovations in Metastatic Brain Tumor Treatment. , 2020, , .		1
1311	Trials and tribulations: Clinical trials and the future. , 2020, , 197-215.		0

#	ARTICLE	IF	CITATIONS
1312	mRNA and miRNA Profiles of Exosomes from Cultured Tumor Cells Reveal Biomarkers Specific for HPV16-Positive and HPV16-Negative Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8570.	1.8	16
1313	Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3377.	1.7	35
1314	An increase of CD8+T cell infiltration following recurrence is a good prognosticator in HNSCC. <i>Scientific Reports</i> , 2020, 10, 20059.	1.6	34
1315	Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. <i>Cancers</i> , 2020, 12, 3427.	1.7	17
1316	Cancro dell'orofaringe. <i>EMC - Otorinolaringoiatria</i> , 2020, 19, 1-17.	0.0	0
1317	Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers. <i>Cancer Management and Research</i> , 2020, Volume 12, 11743-11749.	0.9	5
1318	Digitalized healthcare for head and neck cancer patients. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2020, 122, 434-440.	0.5	8
1319	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	18.1	1,649
1320	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 501-514.	1.0	7
1321	Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. <i>Frontiers in Oncology</i> , 2020, 10, 566315.	1.3	24
1322	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we don't know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	3.5	44
1323	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 559596.	1.3	9
1324	Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. <i>Cancer Control</i> , 2020, 27, 107327482097711.	0.7	14
1325	Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 591139.	2.2	23
1326	Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 608969.	1.8	29
1327	Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11221-11235.	1.0	11
1328	Increased Expression of SHMT2 Is Associated With Poor Prognosis and Advanced Pathological Grade in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 588530.	1.3	14
1329	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85

#	ARTICLE	IF	CITATIONS
1330	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
1331	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570080.	1.3	5
1332	The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review. <i>Frontiers in Oncology</i> , 2020, 10, 1402.	1.3	7
1333	Exosomes in head and neck cancer: Roles, mechanisms and applications. <i>Cancer Letters</i> , 2020, 494, 7-16.	3.2	27
1334	Associations between histogram analysis parameters derived from dynamic-contrast enhanced MRI and PD L1-expression in head and neck squamous cell carcinomas. A preliminary study. <i>Magnetic Resonance Imaging</i> , 2020, 72, 117-121.	1.0	5
1335	Why the Outcome of Anti-tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers. <i>BioEssays</i> , 2020, 42, 2000024.	1.2	9
1336	Further clinical interpretation and implications of KEYNOTE-048 findings. <i>Lancet, The</i> , 2020, 396, 379.	6.3	8
1337	Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 559-566.	0.6	6
1338	The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer. <i>Oral Oncology</i> , 2020, 111, 104945.	0.8	4
1339	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1063-1068.	1.0	1
1340	Association between APOBEC3H-Mediated Demethylation and Immune Landscape in Head and Neck Squamous Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-17.	0.9	7
1341	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
1342	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020, 20, 727.	1.1	17
1343	Future directions in advanced penile cancer – mechanisms of carcinogenesis and a search for targeted therapy. <i>Future Oncology</i> , 2020, 16, 2357-2369.	1.1	6
1344	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53
1345	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	1.7	7
1346	BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse. <i>Cell Stem Cell</i> , 2020, 27, 238-253.e6.	5.2	87
1347	Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer. <i>Clinical Medicine Insights: Case Reports</i> , 2020, 13, 117954762090885.	0.3	3

#	ARTICLE	IF	CITATIONS
1348	Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review. <i>Cancers</i> , 2020, 12, 1937.	1.7	48
1349	A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors. <i>Oral Oncology</i> , 2020, 110, 104900.	0.8	6
1350	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 1508.	2.2	60
1351	Salvage surgery with second free flap reconstruction for recurrent oral squamous cell carcinoma. <i>Heliyon</i> , 2020, 6, e04014.	1.4	3
1352	PD-L1 Expression Affects Neoantigen Presentation. <i>IScience</i> , 2020, 23, 101238.	1.9	9
1353	Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma. , 2020, 8, e000444.		50
1354	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
1355	PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5228.	1.8	19
1356	Tumor infiltrating lymphocytes after neoadjuvant IRIX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. <i>Oral Oncology</i> , 2020, 111, 104928.	0.8	9
1357	Role of programmed deathâ€“ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3275-3281.	0.9	8
1358	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2020, 151, 141-148.	0.3	62
1359	An Assessment of the Treatment Effect in Treatment of Physician Choice Trials. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 103-113.	0.6	0
1360	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. <i>Cancers of the Head & Neck</i> , 2020, 5, 9.	6.2	25
1361	Immunotherapy for squamous cell carcinoma of the head and neck. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1089-1096.	0.6	39
1362	Different patterns of treatmentâ€“related adverse events of programmed cell deathâ€“1 and its ligandâ€“1 inhibitors in different cancer types: A metaâ€“analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
1363	Further clinical interpretation and implications of KEYNOTE-048 findings. <i>Lancet, The</i> , 2020, 396, 378-379.	6.3	4
1364	Genomic-based treatment of patients with head and neck cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 401-408.	0.4	0
1365	Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). <i>Cancers</i> , 2020, 12, 3110.	1.7	11

#	ARTICLE	IF	CITATIONS
1367	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , 2020, 21, 263.	3.8	15
1369	Transoral Robotic Surgery for Residual and Recurrent Oropharyngeal Cancers. <i>Otolaryngologic Clinics of North America</i> , 2020, 53, 1091-1108.	0.5	6
1370	High Abundance of Intratumoral $\gamma\delta$ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 573920.	2.2	22
1371	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020, 123, 1720-1729.	2.9	18
1372	Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy. <i>Cancer Treatment Reviews</i> , 2020, 91, 102116.	3.4	12
1373	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
1374	Clinical trial design in head and neck cancer-challenges and opportunities. , 2020, , 335-345.		0
1375	Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. <i>Anticancer Research</i> , 2020, 40, 5277-5283.	0.5	24
1376	Molecular and Cellular Modelling of Salivary Gland Tumors Open New Landscapes in Diagnosis and Treatment. <i>Cancers</i> , 2020, 12, 3107.	1.7	19
1377	Avelumab+cetuximab+radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). <i>European Journal of Cancer</i> , 2020, 141, 21-29.	1.3	48
1378	FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28287-28296.	3.3	24
1379	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
1380	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000775.	2.0	22
1381	Dynamic RMST curves for survival analysis in clinical trials. <i>BMC Medical Research Methodology</i> , 2020, 20, 218.	1.4	11
1382	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	2.8	122
1383	Thrombocytosis and Effects of IL-6 Knock-Out in a Colitis-Associated Cancer Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6218.	1.8	12
1384	Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma. <i>In Vivo</i> , 2020, 34, 2967-2972.	0.6	11
1385	Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1404.	1.3	8

#	ARTICLE	IF	CITATIONS
1386	Tuberculosisâ€“Cancer Parallels in Immune Response Regulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6136.	1.8	9
1387	Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. <i>Scientific Reports</i> , 2020, 10, 14470.	1.6	11
1388	Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases. <i>Case Reports in Oncology</i> , 2020, 13, 835-842.	0.3	1
1389	Nivolumabâ€“related tracheobronchial chondritis: Extremely rare manifestation of an immuneâ€“related adverse effect. <i>Head and Neck</i> , 2020, 42, E43-E48.	0.9	10
1390	Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma. <i>Orl</i> , 2020, 82, 343-350.	0.6	0
1391	Recent advances in the development of proteinâ€“protein interactions modulators: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 213.	7.1	387
1392	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2691.	1.7	39
1393	CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma. <i>International Immunopharmacology</i> , 2020, 88, 106864.	1.7	17
1394	Establishment of an immune microenvironment-based prognostic predictive model for gastric cancer. <i>Life Sciences</i> , 2020, 261, 118402.	2.0	10
1395	Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer. <i>Onc Immunology</i> , 2020, 9, 1809960.	2.1	10
1396	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. <i>Cells</i> , 2020, 9, 2103.	1.8	48
1397	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. <i>British Journal of Ophthalmology</i> , 2021, 105, 1263-1271.	2.1	36
1398	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 3001-3006.	0.8	5
1399	Translating KEYNOTE-048 into practice recommendations for head and neck cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 975-975.	0.7	25
1400	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
1401	Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 819-822.	1.1	6
1402	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	3.4	198
1403	Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 11973.	1.6	4

#	ARTICLE	IF	CITATIONS
1404	Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report. <i>Tumori</i> , 2020, 106, NP23-NP28.	0.6	3
1405	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3269-3279.	1.2	30
1406	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
1407	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 322-328.	0.6	51
1409	Staphylococcal Enterotoxin C2 Mutantâ€œDirected Fatty Acid and Mitochondrial Energy Metabolic Programs Regulate CD8+ T Cell Activation. <i>Journal of Immunology</i> , 2020, 205, 2066-2076.	0.4	9
1410	The Prognostic Significance of Immune-Related Metabolic Enzyme MTHFD2 in Head and Neck Squamous Cell Carcinoma. <i>Diagnostics</i> , 2020, 10, 689.	1.3	9
1411	Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2020, 12, 24.	3.6	67
1412	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20
1413	A rare case of immunotherapy-induced cholangitis and gastritis. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1083-1090.	0.4	11
1414	Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 2653-2657.	0.6	7
1415	Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3035-3043.	1.1	18
1416	<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
1417	Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration. <i>BMC Cancer</i> , 2020, 20, 823.	1.1	9
1418	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 732.	1.8	22
1419	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	2.8	72
1421	Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck. <i>International Journal of Biological Sciences</i> , 2020, 16, 2506-2517.	2.6	9
1422	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. <i>Theranostics</i> , 2020, 10, 9395-9406.	4.6	16
1423	Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. <i>Acta Oto-Laryngologica</i> , 2020, 140, 1043-1048.	0.3	8

#	ARTICLE	IF	CITATIONS
1424	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
1425	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556.	1.1	21
1427	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
1428	Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 21573.	1.6	15
1429	Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. <i>Frontiers in Immunology</i> , 2020, 11, 558757.	2.2	16
1430	Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?â€”Lessons From Value Assessment With ASCO-VF and ESMO-MCBS. <i>Frontiers in Pharmacology</i> , 2020, 11, 574511.	1.6	5
1431	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 545385.	1.3	14
1432	NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. <i>Cells</i> , 2020, 9, 2677.	1.8	37
1433	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 595655.	2.2	8
1434	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020, 11, 600886.	2.2	43
1435	The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis. <i>Annals of Palliative Medicine</i> , 2020, 9, 4081-4088.	0.5	5
1436	Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382097970.	0.8	5
1437	Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers. <i>Frontiers in Oncology</i> , 2020, 10, 528957.	1.3	11
1438	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3743.	1.7	19
1439	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	0.6	13
1441	Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research. <i>Acta Clinica Belgica</i> , 2022, 77, 406-409.	0.5	0
1442	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1844403.	2.1	18
1443	New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?. <i>Therapeutic Radiology and Oncology</i> , 0, 4, 5-5.	0.2	1

#	ARTICLE	IF	CITATIONS
1444	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi® [®] , AstraZeneca UK) Tj ETQq0 020rgBT /Omerlock 10		
1445	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8229.	1.8	7
1446	Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3197.	1.7	16
1447	PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8089.	1.8	25
1448	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. <i>Frontiers in Immunology</i> , 2020, 11, 587014.	2.2	56
1451	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 402-402.	0.7	8
1452	Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz8985.	4.7	93
1453	Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 16-19.	0.9	6
1454	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.2	8
1455	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
1456	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	3.4	805
1457	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
1458	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
1459	Qualität in der Kopf-Hals-Onkologie. <i>Laryngo- Rhino- Otologie</i> , 2020, 99, S60-S106.	0.2	1
1460	Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. <i>Cancers of the Head & Neck</i> , 2020, 5, 6.	6.2	52
1461	Plasma medical oncology: Immunological interpretation of head and neck squamous cell carcinoma. <i>Plasma Processes and Polymers</i> , 2020, 17, 1900258.	1.6	19
1462	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. , 2020, 8, e000146.		49
1463	Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease. <i>Cancer Medicine</i> , 2020, 9, 4791-4807.	1.3	21

#	ARTICLE	IF	CITATIONS
1464	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. <i>BioDrugs</i> , 2020, 34, 463-476.	2.2	49
1466	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
1467	Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. <i>Theranostics</i> , 2020, 10, 6095-6112.	4.6	18
1468	Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> , 2020, 12, 587-603.	1.0	21
1469	PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis. <i>Oral Diseases</i> , 2020, 26, 1414-1423.	1.5	7
1470	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
1471	Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy. <i>Seminars in Radiation Oncology</i> , 2020, 30, 158-172.	1.0	10
1472	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	1.2	15
1473	Activation PDGFR-1/AKT Mediated Signaling Pathways in Oral Squamous Cell Carcinoma by Mesenchymal Stem/Stromal Cells Promotes Anti-apoptosis and Decreased Sensitivity to Cisplatin. <i>Frontiers in Oncology</i> , 2020, 10, 552.	1.3	11
1474	Primary thyroid squamous cell carcinoma " a Scottish National Case Series. <i>Scottish Medical Journal</i> , 2020, 65, 60-63.	0.7	1
1475	Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. <i>International Cancer Conference Journal</i> , 2020, 9, 127-132.	0.2	3
1476	An Analysis of 1-Year Charges for Head and Neck Cancer: Targets for Value-Based Interventions. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 546-553.	1.1	4
1477	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
1478	Long Non-coding RNA LINC02195 as a Regulator of MHC I Molecules and Favorable Prognostic Marker for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 615.	1.3	31
1479	Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. <i>International Journal of Cancer</i> , 2020, 147, 2293-2302.	2.3	10
1480	Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 108, 104753.	0.8	27
1481	Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2020, 12, 16.	3.6	108
1482	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 927-934.	1.0	5

#	ARTICLE	IF	CITATIONS
1483	Immune Checkpoint Inhibitors in Genitourinary Malignancies. <i>Current Oncology</i> , 2020, 27, 69-77.	0.9	13
1484	Genomic Signature of Mismatch Repair Deficiency in Areca Nut-Related Oral Cancer. <i>Journal of Dental Research</i> , 2020, 99, 1252-1261.	2.5	8
1485	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 74.	6.9	17
1486	The efficacy and safety comparison of PD-1/PD-L1 antibody, chemotherapy and supportive treatment for pretreated advanced esophagogastric cancer: a network meta-analysis. <i>Annals of Palliative Medicine</i> , 2020, 9, 1770-1781.	0.5	5
1487	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
1488	The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 196-203.	1.2	36
1489	Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Journal of Translational Medicine</i> , 2020, 18, 235.	1.8	39
1490	Optimality of testing procedures for survival data in the nonproportional hazards setting. <i>Biometrics</i> , 2021, 77, 587-598.	0.8	5
1491	Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1274-1288.	2.3	27
1492	Phase I Study of Ficlatazumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 1537.	1.7	19
1493	Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102984.	2.0	36
1494	Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa027.	0.2	16
1495	Management of squamous cell carcinomas of the skull-base. <i>Journal of Neuro-Oncology</i> , 2020, 150, 377-386.	1.4	1
1496	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	0.9	15
1497	CD8 ⁺ CD73 ⁺ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. <i>European Journal of Immunology</i> , 2020, 50, 2055-2066.	1.6	7
1498	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
1499	Sensitization of head and neck squamous cell carcinoma to apoptosis by combinational SMAC mimetic and Fas ligand-Fc treatment in vitro. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2020, 48, 685-693.	0.7	2
1500	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15

#	ARTICLE	IF	CITATIONS
1501	The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4072.	1.8	48
1502	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
1503	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
1504	Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1345-1354.	0.8	16
1505	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
1506	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	1.3	11
1507	Healthcare and Artificial Intelligence. , 2020, , .		15
1508	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
1509	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 435-445.	1.0	5
1510	â€˜The same old storyâ€™: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
1511	Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3616-3628.	3.2	31
1512	Adenosine-producing regulatory B cells in head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1205-1216.	2.0	24
1513	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
1514	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2020, 40, 1219-1227.	0.5	26
1515	Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immunotherapy. <i>Head and Neck</i> , 2020, 42, 2030-2038.	0.9	1
1516	The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC. <i>Cancers of the Head & Neck</i> , 2020, 5, 4.	6.2	30
1517	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
1518	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	1.1	13

#	ARTICLE	IF	CITATIONS
1519	CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2020, 20, 240.	1.1	15
1520	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	3.2	117
1521	OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. <i>British Journal of Cancer</i> , 2020, 122, 1507-1517.	2.9	48
1522	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	0.8	16
1523	Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 257-269.	1.8	18
1524	Effect of HPV Status on Survival of Oropharynx Cancer with Distant Metastasis. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 372-374.	1.1	6
1525	Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?. <i>JCO Oncology Practice</i> , 2020, 16, e779-e790.	1.4	3
1526	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020, 122, 1649-1660.	2.9	17
1527	Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2341-2347.	0.8	16
1528	Nivolumab for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 687-693.	1.4	30
1529	CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1273-1280.	0.8	25
1530	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 688.	1.8	58
1531	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 268.	1.3	68
1532	GPCRs in head and neck squamous cell carcinoma. , 2020, , 317-334.		1
1533	The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments. <i>Head and Neck Pathology</i> , 2020, 14, 330-340.	1.3	26
1534	Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?. <i>Oral Oncology</i> , 2020, 107, 104860.	0.8	2
1535	Nonsurgical management of resectable oral cavity cancer in the wake of COVID-19: A rapid review and meta-analysis. <i>Oral Oncology</i> , 2020, 109, 104849.	0.8	16
1536	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. <i>Oncolimmunology</i> , 2020, 9, 1781333.	2.1	34

#	ARTICLE	IF	CITATIONS
1537	Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature. <i>Immunotherapy</i> , 2020, 12, 777-784.	1.0	6
1538	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	2.0	29
1539	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
1540	Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz058.	0.4	12
1541	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
1542	Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1777.	1.7	9
1544	Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 340-347.	0.7	9
1545	ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 252.	1.8	16
1546	Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. <i>BMC Ophthalmology</i> , 2020, 20, 252.	0.6	21
1547	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). <i>Head and Neck</i> , 2020, 42, 2852-2862.	0.9	26
1548	Genetic Screening for Novel Regulators of Immune Checkpoint Molecules. <i>Trends in Immunology</i> , 2020, 41, 692-705.	2.9	2
1549	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
1550	Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry. <i>Immuno-Oncology Technology</i> , 2020, 6, 2-8.	0.2	26
1551	The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	2.0	13
1552	Fewer tumour-specific PD-1+CD8+ TILs in high-risk infiltrating HPV+ HNSCC. <i>British Journal of Cancer</i> , 2020, 123, 932-941.	2.9	7
1553	ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 269.	1.8	26
1554	The impact of the COVID-19 pandemic on head and neck cancer patients. <i>Oral Oncology</i> , 2020, 110, 104881.	0.8	4
1555	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104

#	ARTICLE	IF	CITATIONS
1556	Intracardiac metastasis from head and neck squamous cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e234691.	0.2	0
1557	Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature. <i>Dermatologic Therapy</i> , 2020, 33, e13250.	0.8	7
1558	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	8
1559	A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1550-1558.	1.2	17
1560	Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 6942-6953.	2.0	8
1561	Chemotherapy in the definitive management of oral cancers: Where do we stand today?. <i>Oral Oncology</i> , 2020, 102, 104584.	0.8	8
1562	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 2083.	1.6	124
1563	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	1.9	30
1564	Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. <i>Annals of Oncology</i> , 2020, 31, 302-309.	0.6	47
1565	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. <i>Oncologist</i> , 2020, 25, 369-374.	1.9	13
1566	Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1778-1785.	1.2	10
1567	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 800-809.	0.6	12
1568	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	3.2	75
1569	Establishment of epigenetic markers to predict irradiation efficacy against oropharyngeal cancer. <i>Cancer Science</i> , 2020, 111, 1407-1416.	1.7	11
1570	The promise of immunotherapy in the treatment of young adults with oral tongue cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 235-242.	0.6	4
1571	XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. <i>Oncogene</i> , 2020, 39, 3541-3554.	2.6	26
1572	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. <i>Scientific Reports</i> , 2020, 10, 3565.	1.6	29
1573	Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 113-116.	0.6	3

#	ARTICLE	IF	CITATIONS
1574	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
1575	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. <i>Life Sciences</i> , 2020, 247, 117437.	2.0	33
1576	Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma. <i>Immunity and Ageing</i> , 2020, 17, 3.	1.8	34
1577	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102896.	2.0	10
1578	Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. <i>Acta Oncologica</i> , 2020, 59, 666-672.	0.8	10
1579	Multispectral imaging technology: Visualize, analyze, phenotyping, and quantify immune cells in situ. <i>International Journal of Biological Markers</i> , 2020, 35, 26-30.	0.7	3
1580	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
1582	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1047-1060.	5.7	50
1583	Betel quid-associated cancer: Prevention strategies and targeted treatment. <i>Cancer Letters</i> , 2020, 477, 60-69.	3.2	17
1584	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
1585	Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 650-657.	0.5	16
1586	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <i>Internal Medicine</i> , 2020, 59, 1105-1109.	0.3	6
1587	The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. <i>Frontiers in Oncology</i> , 2020, 10, 7.	1.3	30
1588	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2020, 11, 369-379.	0.5	20
1589	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
1590	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	1.0	16
1591	Immune profile and immunosurveillance in treatment-naïve and neoadjuvantly treated esophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 523-533.	2.0	19
1592	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. <i>Cells</i> , 2020, 9, 263.	1.8	43

#	ARTICLE	IF	CITATIONS
1593	Immune checkpoint inhibitors in advanced non-small cell lung cancer: A multicentric experience from India. <i>Current Problems in Cancer</i> , 2020, 44, 100549.	1.0	4
1594	Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma. <i>Acta Oto-Laryngologica</i> , 2020, 140, 175-180.	0.3	11
1595	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0227344.	1.1	26
1596	Criterios de respuesta metabólica a la inmunoterapia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 51-56.	0.0	0
1597	Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma. <i>Cancer Cell International</i> , 2020, 20, 22.	1.8	58
1598	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	2.3	44
1599	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 356-367.	1.0	8
1600	Prospective feasibility analysis of salvage surgery in recurrent oral cancer in terms of quality of life. <i>Oral Oncology</i> , 2020, 102, 104580.	0.8	19
1601	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 235-245.	0.7	7
1602	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	1.7	20
1603	Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 581-591.	2.0	21
1604	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. <i>Frontiers in Oncology</i> , 2019, 9, 1470.	1.3	19
1605	Biomarkers for immunotherapy response in head and neck cancer. <i>Cancer Treatment Reviews</i> , 2020, 84, 101977.	3.4	153
1606	CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. <i>Scientific Reports</i> , 2020, 10, 243.	1.6	18
1607	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 15.	0.8	58
1608	Immunotherapeutics for head and neck squamous cell carcinoma stem cells. <i>Hno</i> , 2020, 68, 94-99.	0.4	6
1609	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
1611	Tumor immune microenvironment in head and neck cancers. <i>Molecular Carcinogenesis</i> , 2020, 59, 766-774.	1.3	90

#	ARTICLE	IF	CITATIONS
1612	Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 48.	1.3	63
1613	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
1614	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	0.8	469
1615	Post-Treatment HPV Surface Brushings and Risk of Relapse in Oropharyngeal Carcinoma. <i>Cancers</i> , 2020, 12, 1069.	1.7	8
1616	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	1.7	40
1617	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
1618	Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. <i>International Immunopharmacology</i> , 2020, 83, 106478.	1.7	28
1619	Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-lymphoblastic leukemia, especially in relapse and at diagnosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 336-347.	0.7	10
1620	Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. <i>International Journal of Clinical Oncology</i> , 2020, 25, 801-809.	1.0	115
1621	Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1270-1277.	1.0	12
1622	Genomics and precision surgery for head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2020, 481, 45-54.	3.2	10
1623	Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. <i>Oral Oncology</i> , 2020, 105, 104652.	0.8	60
1624	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 105, 104676.	0.8	16
1625	Update on oral and oropharyngeal cancer staging – International perspectives. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2020, 6, 66-75.	0.7	39
1626	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+ tumour-infiltrating lymphocytes in oral squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1686-1694.	2.9	38
1627	CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity. <i>Oncolimmunology</i> , 2020, 9, 1747732.	2.1	40
1628	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44
1629	Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. <i>Current Opinion in Oncology</i> , 2020, 32, 203-209.	1.1	8

#	ARTICLE	IF	CITATIONS
1630	Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?. <i>Current Opinion in Oncology</i> , 2020, 32, 196-202.	1.1	9
1631	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients's Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	1.2	7
1632	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
1633	Future Challenges in Cancer Resistance to Immunotherapy. <i>Cancers</i> , 2020, 12, 935.	1.7	41
1634	Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. <i>Vaccines</i> , 2020, 8, 182.	2.1	14
1635	The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. <i>Theranostics</i> , 2020, 10, 4383-4394.	4.6	29
1636	GPR39 Overexpression in OSCC Promotes YAP-Sustained Malignant Progression. <i>Journal of Dental Research</i> , 2020, 99, 949-958.	2.5	22
1637	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e47-e57.	1.8	30
1638	Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 299-309.	1.6	49
1639	Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat. <i>Cancers</i> , 2020, 12, 975.	1.7	30
1640	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	2.1	10
1641	The primary tumor resection in patients with distant metastatic laryngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2859-2868.	0.8	1
1642	Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102966.	2.0	45
1643	The role of transforming growth factor β in immune suppression and chronic inflammation of squamous cell carcinomas. <i>Molecular Carcinogenesis</i> , 2020, 59, 745-753.	1.3	14
1644	Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2787-2795.	3.3	21
1645	Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy. <i>Targeted Oncology</i> , 2020, 15, 317-325.	1.7	19
1646	HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. <i>Cancer Research</i> , 2020, 80, 732-746.	0.4	36
1647	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1474-1485.	3.2	62

#	ARTICLE	IF	CITATIONS
1648	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020, 26, 3211-3219.	3.2	64
1649	A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. <i>Trials</i> , 2020, 21, 315.	0.7	21
1650	A homogeneous SIRP±-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. <i>PLoS ONE</i> , 2020, 15, e0226661.	1.1	19
1651	<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3047-3059.	1.0	25
1652	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
1653	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
1654	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021, 113, 171-181.	3.0	25
1655	<sc>Antiâ€C1GALT1</sc> Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E196-E202.	1.1	2
1656	Staging more important than grading? Evaluation of malignancy grading, depth of invasion, and resection margins in oral squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2021, 25, 1169-1182.	1.4	17
1657	The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E151-E156.	1.1	34
1658	An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 135-144.	0.9	5
1659	PDâ€L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
1660	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with<i>PIK3CA</i>-Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	3.2	22
1661	Immune checkpoint expression in <sc>HNSCC</sc> patients before and after definitive chemoradiotherapy. <i>Head and Neck</i> , 2021, 43, 778-787.	0.9	12
1662	Model Informed Dosing Regimen and Phase I Results of the Antiâ€PDâ€1 Antibody Budigalimab (ABBVâ€181). <i>Clinical and Translational Science</i> , 2021, 14, 277-287.	1.5	5
1663	Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma. <i>Postgraduate Medicine</i> , 2021, 133, 377-384.	0.9	4
1664	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	0.7	18
1665	Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). <i>Modern Pathology</i> , 2021, 34, 1125-1132.	2.9	75

#	ARTICLE	IF	CITATIONS
1666	PD-L1 expression in tongue squamous cell carcinoma. <i>Medical Molecular Morphology</i> , 2021, 54, 52-59.	0.4	6
1667	Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 582-590.	1.2	5
1668	Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 534-543.	0.9	7
1669	Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 1-3.	0.8	29
1670	Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria. <i>Cancer</i> , 2021, 127, 219-228.	2.0	16
1671	Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update. <i>European Journal of Pharmacology</i> , 2021, 890, 173657.	1.7	38
1672	An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 330-341.	3.2	148
1673	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. <i>Immunotherapy</i> , 2021, 13, 67-77.	1.0	2
1674	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , 2021, 137, 1669-1678.	0.6	123
1675	Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database. <i>Oral Oncology</i> , 2021, 112, 105088.	0.8	17
1676	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	3.3	7
1678	The nuclear export protein XPO1 "from biology to targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 152-169.	12.5	114
1679	Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 494-506.	1.0	40
1680	Radiotherapy in Metastatic Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021, 131, E1847-E1853.	1.1	1
1681	Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151657.	0.6	21
1682	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1803-1811.	1.2	24
1683	AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 357-372.	2.1	7
1684	Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. <i>Cancer Science</i> , 2021, 112, 339-346.	1.7	28

#	ARTICLE	IF	CITATIONS
1685	Pasotuxizumab, a BiTE [®] immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. <i>Immunotherapy</i> , 2021, 13, 125-141.	1.0	72
1686	Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. <i>Advanced Functional Materials</i> , 2021, 31, 2006220.	7.8	63
1687	Immunotherapy in Head and Neck Cancer—Ready for Prime Time or More Research Needed?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 647-650.	0.4	1
1688	The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 608609.	1.3	18
1689	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2021, 149, 277-286.	2.3	7
1690	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14
1691	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). <i>International Journal of Cancer</i> , 2021, 148, 2023-2035.	2.3	6
1692	Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 282-297.	1.0	6
1693	Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570736.	1.3	25
1694	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1227-1237.	2.0	23
1695	Evidence for different molecular parameters in head and neck squamous cell carcinoma of nonsmokers and nondrinkers: Systematic review and meta-analysis on <sc>HPV</sc>, <sc>p16</sc>, and <sc>i>TP53</i></sc>. <i>Head and Neck</i> , 2021, 43, 303-322.	0.9	12
1696	Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>International Journal of Clinical Oncology</i> , 2021, 26, 51-58.	1.0	0
1697	Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. <i>Oral Oncology</i> , 2021, 113, 105042.	0.8	18
1698	Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. <i>Laryngoscope</i> , 2021, 131, E1481-E1488.	1.1	15
1699	Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). <i>International Journal of Clinical Oncology</i> , 2021, 26, 316-325.	1.0	7
1700	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
1702	A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 743-753.	2.0	18
1703	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9

#	ARTICLE	IF	CITATIONS
1704	Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. <i>Molecular Imaging and Biology</i> , 2021, 23, 139-147.	1.3	12
1705	Immune checkpoint: The novel target for antitumor therapy. <i>Genes and Diseases</i> , 2021, 8, 25-37.	1.5	27
1706	Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. <i>Oncology & Hematology Review</i> , 2021, 16, 90.	0.2	0
1707	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 607349.	1.3	22
1708	A case of lower gingival squamous cell carcinoma showing complete response after the multidisciplinary therapy including Nivolumab. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 47-54.	0.0	0
1709	Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2625-2635.	1.2	0
1710	Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. <i>Head and Neck</i> , 2021, 43, 1509-1520.	0.9	12
1711	Salvage brachytherapy with or without external beam radiotherapy for oral or oropharyngeal squamous cell carcinomas in previously irradiated areas: carcinologic and toxicity outcomes of 25 patients. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 402-409.	0.4	1
1712	Radioimmunotherapy: future prospects from the perspective of brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 458-467.	0.4	6
1713	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
1714	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2773-2781.	3.2	55
1715	<i>YKT6</i>, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration. <i>Oncolmmunology</i> , 2021, 10, 1938890.	2.1	46
1716	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Oncolmmunology</i> , 2021, 10, 1950411.	2.1	22
1717	Radiotherapy, Chemotherapy, and Quality of Life. , 2021, , 329-342.		0
1718	Treatment for Head and Neck Cancer. <i>Juntendo Medical Journal</i> , 2021, 67, 196-200.	0.1	0
1719	Head and neck cancer: Current challenges and future perspectives. <i>Advances in Cancer Research</i> , 2021, 152, 67-102.	1.9	41
1720	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. <i>Frontiers in Immunology</i> , 2020, 11, 563258.	2.2	24
1721	Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110355.	0.6	45

#	ARTICLE	IF	CITATIONS
1722	A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas. <i>Scientific Reports</i> , 2021, 11, 502.	1.6	9
1723	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592094941.	1.4	35
1724	Promising response to immunotherapy in metastatic nasopharyngeal carcinoma associated with hepatitis C virus – a case report. <i>ORL Ro</i> , 2021, 2, 30.	0.0	0
1725	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
1726	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098406.	1.4	8
1727	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	4.6	19
1728	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
1729	Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 338.	1.7	70
1730	Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer. , 2021, , 63-120.		1
1731	Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. <i>International Journal of Medical Sciences</i> , 2021, 18, 226-238.	1.1	35
1732	Complications Related to Radical Neck Dissections and Management of Recurrent Neck Disease. , 2021, , 111-141.		0
1733	Multiplexed Imaging for Immune Profiling on Human FFPE Material. <i>Methods in Molecular Biology</i> , 2021, 2350, 125-144.	0.4	0
1734	Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma. <i>Global Health & Medicine</i> , 2021, 3, 378-385.	0.6	8
1735	Robust rank aggregation and cibersort algorithm applied to the identification of key genes in head and neck squamous cell cancer. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 4491-4507.	1.0	3
1736	Integrating CD4 ⁺ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. <i>Oncolmunology</i> , 2021, 10, 1958589.	2.1	9
1737	Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021, 14, 10.	6.9	281
1738	Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer. , 2021, , 297-306.		0
1739	Cabozantinib, a Promising Therapeutic Strategy for Resistant Head and Neck Squamous Cell Carcinoma Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1740	Grundlagen der Tumorchirurgie. , 2021, , 489-512.		0
1741	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	4.6	324
1742	Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient. <i>Anti-Cancer Drugs</i> , 2021, 32, 580-584.	0.7	4
1743	Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model. <i>Oncotarget</i> , 2021, 12, 37-48.	0.8	4
1744	Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L1-expression in head and neck squamous cell carcinomas: a preliminary study. <i>Radiology and Oncology</i> , 2021, 55, 150-157.	0.6	6
1745	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta- analysis. <i>Translational Cancer Research</i> , 2021, 10, 310-326.	0.4	1
1747	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
1748	Distinct difference in tumor-infiltrating immune cells between Wilmsâ€™ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab091.	0.4	2
1749	The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the â€œinflamed tumorâ€•to the â€œinflamed patientâ€•. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1930-1934.	1.4	10
1750	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. <i>Oncogenesis</i> , 2021, 10, 3.	2.1	25
1751	Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1307-1313.	1.2	24
1752	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2021, 39, 860-870.	1.2	12
1753	Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. <i>Theranostics</i> , 2021, 11, 4957-4974.	4.6	4
1754	A case of recurrent oral cancer treated with interchangeable administrations of immune checkpoint inhibitors and chemotherapy agents. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 75-80.	0.0	1
1755	Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironment. <i>Visualized Cancer Medicine</i> , 2021, 2, 1.	0.5	9
1756	Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 286.	1.7	22
1757	Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. , 2021, 9, e001615.		18
1760	Are radiologists ready to evaluate true response to immunotherapy?. <i>Insights Into Imaging</i> , 2021, 12, 29.	1.6	5

#	ARTICLE	IF	CITATIONS
1761	On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design. <i>Statistics in Medicine</i> , 2021, 40, 2321-2338.	0.8	2
1762	Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. <i>Auris Nasus Larynx</i> , 2021, 48, 161-165.	0.5	0
1763	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
1764	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2741-2750.	1.2	4
1765	Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1045-1053.	1.0	3
1766	Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. <i>Auris Nasus Larynx</i> , 2022, 49, 721-726.	0.5	7
1767	One Size Does Not Fit All: The Need for Population-Specific Palliative Care Interventions. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1449-1450.	3.0	1
1768	Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors. <i>Laryngoscope</i> , 2021, 131, E2413-E2419.	1.1	5
1769	Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021, 29, 168-177.	0.8	7
1770	The Epithelial-Mesenchymal Transcription Factor Slug Predicts Survival Benefit of Up-Front Surgery in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 772.	1.7	8
1771	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1228-1237.	3.0	14
1772	CD4 ⁺ and CD8 ⁺ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 1048-1059.	1.7	15
1773	Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 929-936.	1.0	2
1775	Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab. <i>Oral Oncology</i> , 2021, 113, 105129.	0.8	6
1776	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 152, 109-118.	0.9	14
1777	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. <i>Nature Communications</i> , 2021, 12, 1047.	5.8	96
1778	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
1779	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	7.7	103

#	ARTICLE	IF	CITATIONS
1780	New Insights Into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2252.	1.8	44
1781	Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors. <i>Investigational New Drugs</i> , 2021, 39, 1132-1138.	1.2	14
1782	Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck. <i>Frontiers in Oncology</i> , 2021, 11, 623964.	1.3	4
1783	Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. <i>Scientific Reports</i> , 2021, 11, 2741.	1.6	16
1784	Prognostic Significance of Cytoplasmic SPNS2 Expression in Patients with Oral Squamous Cell Carcinoma. <i>Medicina (Lithuania)</i> , 2021, 57, 164.	0.8	2
1785	PILE: a candidate prognostic score in cancer patients treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1630-1636.	1.2	14
1786	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2559-2576.	2.0	40
1787	Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. <i>Cancer</i> , 2021, 127, 1796-1804.	2.0	22
1788	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614332.	1.3	33
1789	Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. , 2021, 9, e001177.		0
1790	Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint. <i>Pharmaceutical Statistics</i> , 2021, 20, 721-736.	0.7	1
1791	The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100008.	2.0	5
1792	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 608772.	1.3	30
1793	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
1794	SEOM clinical guidelines for the treatment of head and neck cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 913-921.	1.2	40
1795	The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2545-2557.	2.0	9
1796	Immunohistochemical Differences in Squamous Precancerous and Cancerous Lesions of the Oral Cavity and the Larynx: Preliminary Data. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 2048.	1.3	3
1797	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021, 15, 510-519.	1.9	14

#	ARTICLE	IF	CITATIONS
1799	The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. <i>IUBMB Life</i> , 2021, 73, 618-642.	1.5	19
1800	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
1801	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 144-150.	0.6	8
1802	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
1803	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. <i>Cancers</i> , 2021, 13, 1065.	1.7	5
1804	Inmunoterapia, c�ncer y PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.0	0
1805	Recurrent respiratory papillomatosis: A 2020 perspective. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 340-345.	0.6	36
1806	Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait. <i>European Journal of Cancer</i> , 2021, 145, 155-157.	1.3	2
1808	Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	4
1809	Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 616629.	1.3	33
1810	AKT3 Is a Novel Regulator of Cancer-Associated Fibroblasts in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1233.	1.7	12
1811	Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma. <i>Case Reports in Oncology</i> , 2021, 14, 343-346.	0.3	2
1812	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2957-2972.	5.7	34
1813	CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1993-2001.	1.2	9
1814	Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 1214-1221.	0.4	3
1815	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). <i>Journal of Clinical Oncology</i> , 2021, 39, 704-712.	0.8	156
1816	Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions. <i>Cancers</i> , 2021, 13, 1418.	1.7	12
1817	Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. <i>Cancers</i> , 2021, 13, 1471.	1.7	6

#	ARTICLE	IF	CITATIONS
1818	Cancro dell'ipofaringe. EMC - Otorinolaringoiatria, 2021, 20, 1-19.	0.0	0
1819	Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2021, 12, 534-548.	0.8	6
1820	Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. <i>Oral Oncology</i> , 2021, 114, 105164.	0.8	11
1821	At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oral Health</i> , 2021, 2, 647980.	1.2	4
1822	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). <i>Anticancer Research</i> , 2021, 41, 1123-1141.	0.5	6
1823	Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 342-351.	2.0	40
1824	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	3.4	14
1825	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1251.	1.0	21
1826	Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 361-367.	0.6	17
1827	Percutaneous Management of Recurrent Head and Neck Cancer: Current Role and Evolving Principles in the Multidisciplinary Setting. <i>Current Oncology Reports</i> , 2021, 23, 52.	1.8	3
1828	Remarkable Response of Toripalimab Combined with Chemotherapy in Sarcomatoid Carcinoma of Palatine Tonsil: A Case Report. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 599-604.	1.1	1
1829	Cellular SPION Uptake and Toxicity in Various Head and Neck Cancer Cell Lines. <i>Nanomaterials</i> , 2021, 11, 726.	1.9	14
1830	Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. <i>Oncology</i> , 2021, 99, 464-470.	0.9	11
1831	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
1832	Risk factors for distant metastasis in locoregionally controlled oral squamous cell carcinoma: a retrospective study. <i>Scientific Reports</i> , 2021, 11, 5213.	1.6	16
1833	Interferon- β induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. <i>Molecular Cell</i> , 2021, 81, 1216-1230.e9.	4.5	114
1834	Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1162.	1.7	16
1835	Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx. <i>Oral Oncology</i> , 2021, 114, 105142.	0.8	4

#	ARTICLE	IF	CITATIONS
1836	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
1837	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 1413.	1.7	13
1839	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
1840	Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC. , 2021, 9, e001259.		9
1841	Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. <i>Cancers</i> , 2021, 13, 1148.	1.7	19
1842	The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2053-2064.	1.0	12
1843	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
1844	Immunotherapy, cancer and PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.1	1
1845	Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1018.	1.7	16
1846	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. <i>Cancers</i> , 2021, 13, 1180.	1.7	29
1847	Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. <i>Frontiers in Oncology</i> , 2021, 11, 624780.	1.3	14
1848	Dioscin inhibits SCC15 cell proliferation via the RASSF1A/MST2/YAP axis. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	3
1849	Total Laryngectomyâ€™Still Cutting-Edge?. <i>Cancers</i> , 2021, 13, 1405.	1.7	13
1850	The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity. <i>BMC Cancer</i> , 2021, 21, 240.	1.1	14
1851	Profound and durable responses with PD-1 immune checkpoint inhibitors in patients with metastatic penile squamous cell carcinoma. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100045.	0.1	4
1852	Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. <i>Frontiers in Oncology</i> , 2021, 11, 596290.	1.3	18
1853	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
1854	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29

#	ARTICLE	IF	CITATIONS
1855	Current Immunotherapies for Glioblastoma Multiforme. <i>Frontiers in Immunology</i> , 2020, 11, 603911.	2.2	77
1856	Immune Checkpoint Inhibitors in the Treatment of Cancer. <i>Current Clinical Pharmacology</i> , 2022, 17, 103-113.	0.2	18
1857	Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF- κ B pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 87.	3.5	36
1858	Nivolumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-7.	1.4	9
1859	Characterization of Immune Infiltration and Construction of a Prediction Model for Overall Survival in Melanoma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 639059.	1.3	6
1860	Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. <i>Aging</i> , 2021, 13, 11257-11280.	1.4	11
1861	Discordant Immune Marker Expression Between Preoperatively Biopsied and Matched Surgically Resected Specimens in Patients With Oral Squamous Cell Carcinoma. <i>Cureus</i> , 2021, 13, e14423.	0.2	1
1862	Human papillomavirus-mediated carcinogenesis and tumor progression. <i>Genome Instability & Disease</i> , 2021, 2, 71-91.	0.5	0
1863	Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. <i>Oncologist</i> , 2021, 26, e1018-e1035.	1.9	21
1864	Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 541-555.	1.0	1
1865	PD-L1 expression in recurrent head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 343-351.	0.8	6
1866	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
1867	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
1868	Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. <i>Pharmaceutics</i> , 2021, 13, 520.	2.0	25
1869	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
1870	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). <i>Clinical and Translational Oncology</i> , 2021, 23, 1782-1793.	1.2	9
1871	Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 645745.	1.3	15
1872	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656611.	1.3	4

#	ARTICLE	IF	CITATIONS
1873	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	0.8	15
1874	Modified TPEX as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 2045-2051.	0.5	3
1875	Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. , 2021, 9, e001752.		34
1876	Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105192.	0.8	22
1877	Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Clinical Otolaryngology</i> , 2021, 46, 1013-1020.	0.6	3
1878	Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis. <i>Brazilian Journal of Otorhinolaryngology</i> , 2021, , .	0.4	2
1879	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	0.6	2
1880	Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. <i>Cancer Letters</i> , 2021, 502, 84-96.	3.2	80
1881	Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. , 2021, 9, e002371.		44
1882	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. <i>Nature Communications</i> , 2021, 12, 2383.	5.8	39
1883	Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer. <i>South Asian Journal of Cancer</i> , 2021, 10, 72-75.	0.2	3
1884	Therapeutic cancer vaccines. <i>Nature Reviews Cancer</i> , 2021, 21, 360-378.	12.8	630
1885	Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab. <i>Auris Nasus Larynx</i> , 2021, 48, 322-326.	0.5	4
1886	Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 640515.	1.2	13
1887	The role of pulmonary metastasectomy for pulmonary metastasis from head and neck cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 2643-2648.	0.6	10
1888	Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration. <i>Frontiers in Immunology</i> , 2021, 12, 659184.	2.2	13
1889	Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. <i>Advances in Therapy</i> , 2021, 38, 2613-2630.	1.3	7
1890	A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. <i>Internal Medicine</i> , 2021, 60, 1011-1017.	0.3	7

#	ARTICLE	IF	CITATIONS
1891	TNPO1-Mediated Nuclear Import of FUBP1 Contributes to Tumor Immune Evasion by Increasing NRP1 Expression in Cervical Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-12.	0.9	8
1892	Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 408-414.	0.3	4
1893	Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1049-1056.	1.0	4
1894	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 1714.	1.7	14
1896	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
1897	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1959.	1.7	11
1898	Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. <i>Lancet Oncology, The</i> , 2021, 22, 413-415.	5.1	12
1899	Squamous cell carcinoma of the tongue with cardiac metastasis on 18F-FDG PET/CT. <i>Medicine (United Tj ETQq1 1 0,784314,rgBT /Over</i>	0.4	5
1900	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. <i>BMC Cancer</i> , 2021, 21, 514.	1.1	10
1901	Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4981.	1.8	33
1902	Nivolumab monotherapy after induction chemotherapy, bioradiotherapy, and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report. <i>Oral Science International</i> , 2022, 19, 72-76.	0.3	3
1903	CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674467.	1.8	22
1904	Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment. <i>Journal of Personalized Medicine</i> , 2021, 11, 393.	1.1	6
1905	Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2573.	1.7	12
1906	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. <i>Modern Pathology</i> , 2021, 34, 1719-1727.	2.9	48
1907	circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation. <i>Advanced Science</i> , 2021, 8, 2003376.	5.6	63
1908	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. <i>Scientific Reports</i> , 2021, 11, 10264.	1.6	0
1909	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. , 2021, 9, e002088.		59

#	ARTICLE	IF	CITATIONS
1910	Immune evasion in HPV^{âˆ†} head and neck precancerâ€œcancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	45
1911	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clinical and Translational Radiation Oncology, 2021, 28, 71-78.	0.9	6
1912	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers, 2021, 13, 2371.	1.7	35
1913	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Frontiers in Oncology, 2021, 11, 621639.	1.3	12
1914	Vaginal mucositis related to immunotherapy in endometrial cancer. Gynecologic Oncology Reports, 2021, 36, 100742.	0.3	1
1915	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharmaceutica Sinica B, 2021, 11, 1083-1097.	5.7	23
1916	Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 605941.	1.3	7
1917	Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research, 2021, 10, 2571-2585.	0.4	4
1918	Progress of molecular targeted therapy for head and neck cancer in clinical aspects. Molecular Biomedicine, 2021, 2, 15.	1.7	4
1919	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage <scp>Colony-Stimulating</scp> Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist, 2021, 26, e1508-e1513.	1.9	16
1920	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology, 2021, 12, 680021.	1.6	33
1921	Local Antiâ€œPD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prevention Research, 2021, 14, 767-778.	0.7	13
1922	Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology, 2022, 279, 25-35.	0.8	15
1923	Narrative review of immunotherapy and radiation therapy in elderly patients. Translational Cancer Research, 2021, 10, 2620-2631.	0.4	1
1924	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Nonâ€œSmall Cell Lung Cancer. JAMA Network Open, 2021, 4, e2111113.	2.8	17
1925	Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 640392.	1.3	31
1926	A Case of DILD Likely Induced by Molecular-Targeted Therapy Following Administration of an Immune Checkpoint Inhibitor Against Metastatic Lung Lesions from Tongue Cancer. SN Comprehensive Clinical Medicine, 2021, 3, 1809-1812.	0.3	1
1927	Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma. Oncologist, 2021, 26, e1250-e1255.	1.9	31

#	ARTICLE	IF	CITATIONS
1928	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. <i>Translational Oncology</i> , 2021, 14, 101056.	1.7	17
1929	Radiomic biomarkers of tumor immune biology and immunotherapy response. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 97-115.	0.9	22
1930	A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. <i>BioData Mining</i> , 2021, 14, 29.	2.2	7
1931	CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2021, 116, 105259.	0.8	22
1932	Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization. <i>Cancers</i> , 2021, 13, 2635.	1.7	19
1933	Tumor Immunity and Immunotherapy for HPV-Related Cancers. <i>Cancer Discovery</i> , 2021, 11, 1896-1912.	7.7	71
1934	The Pattern of Care of Use of Nivolumab in Head and Neck Cancers—Audit From a Tertiary Cancer Centre. <i>Clinical Oncology</i> , 2021, 33, 342.	0.6	5
1935	Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials. <i>Microorganisms</i> , 2021, 9, 1001.	1.6	6
1936	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
1937	Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. <i>Current Treatment Options in Oncology</i> , 2021, 22, 52.	1.3	1
1938	Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 622.	1.1	16
1939	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , 2021, 13, 2638.	1.7	32
1940	Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1449-1459.	1.0	7
1941	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
1942	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	1.3	3
1943	Systemic immune responses are associated with molecular characteristics of circulating tumor cells in head and neck squamous cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 15, 147.	0.4	2
1944	Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. <i>Cancer Medicine</i> , 2021, 10, 3952-3963.	1.3	5
1945	Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. <i>Molecular Cell</i> , 2021, 81, 2148-2165.e9.	4.5	30

#	ARTICLE	IF	CITATIONS
1946	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
1947	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. <i>Liver Cancer</i> , 2021, 10, 500-509.	4.2	9
1948	Advances in pharmacotherapy for head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2007-2018.	0.9	5
1949	Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer. <i>BMC Cancer</i> , 2021, 21, 663.	1.1	1
1950	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102172.	3.4	27
1952	Neoantigen evolution in head and neck cancer progression: where do we go from here?. <i>Oncotarget</i> , 2021, 12, 1124-1125.	0.8	0
1953	The prospects of nanotherapeutic approaches for targeting tumor-associated macrophages in oral cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 34, 102371.	1.7	6
1955	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 3083.	1.7	9
1956	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102192.	3.4	15
1957	Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 699668.	1.3	10
1958	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. <i>European Journal of Radiology</i> , 2021, 139, 109668.	1.2	4
1959	Intrinsic radiomic expression patterns after 20 Gy demonstrate early metabolic response of oropharyngeal cancers. <i>Medical Physics</i> , 2021, 48, 3767-3777.	1.6	16
1960	Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1619-1627.	1.0	6
1961	Identification of Tumor Suppressive Genes Regulated by miR-31-5p and miR-31-3p in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6199.	1.8	17
1962	Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 100.	6.9	21
1963	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 883-892.	5.1	116
1964	Immune checkpoint analysis in lip cancer. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2021, 49, 950-958.	0.7	4
1965	Dynamic changes in practical inflammation and immunity markers in cancer patients receiving immune-enhancing nutritional supplementation during concurrent chemoradiotherapy. <i>Cancer Biomarkers</i> , 2021, 32, 281-291.	0.8	2

#	ARTICLE	IF	CITATIONS
1966	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
1967	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
1968	Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , 2021, 6, 100106.	2.0	9
1969	High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. <i>Cancer Science</i> , 2021, 112, 3314-3323.	1.7	15
1970	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 695-710.	2.3	25
1972	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. <i>Frontiers in Pharmacology</i> , 2021, 12, 707930.	1.6	12
1973	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2021, 9, 634.	2.1	8
1974	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 15413-15432.	1.4	9
1975	Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. <i>Cancer Letters</i> , 2021, 507, 55-69.	3.2	53
1976	Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. <i>Viruses</i> , 2021, 13, 1234.	1.5	10
1977	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	0.9	12
1978	Macrophages as a "weapon" in anticancer cellular immunotherapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 749-758.	0.8	38
1979	Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. <i>Journal of Cancer Policy</i> , 2021, 28, 100279.	0.6	3
1980	The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 677900.	1.6	13
1981	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2882.	1.7	6
1982	Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. <i>Frontiers in Immunology</i> , 2021, 12, 599207.	2.2	18
1983	Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 3126.	1.7	12
1984	Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1822-1830.	1.0	5

#	ARTICLE	IF	CITATIONS
1985	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
1986	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
1987	Metronomic Therapy in Oral Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2818.	1.0	5
1988	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
1989	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 3349.	5.8	142
1990	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
1991	Treatment delay in early-stage oral squamous cell carcinoma and its relation to survival. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2021, 49, 462-467.	0.7	8
1992	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq1 1.0.784314 rgBT / Ov	1.8	1
1993	Clear cell urethral adenocarcinoma – a case report of an exceptional response to immunotherapy in a metastatic rare tumour. <i>Journal of Clinical Urology</i> , 0, , 205141582110226.	0.1	1
1994	Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 748-759.	1.3	3
1995	Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model. <i>Cancer Science</i> , 2021, 112, 3041-3049.	1.7	15
1996	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
1997	Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2021, 12, 1214-1229.	0.8	37
1998	The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	4
1999	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. , 2021, 9, e002718.		23
2001	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
2002	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4
2003	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	3.3	23

#	ARTICLE	IF	CITATIONS
2004	Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis. <i>Current Cancer Drug Targets</i> , 2021, 21, .	0.8	1
2005	A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1812-1821.	1.0	43
2006	Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. <i>Case Reports in Oncology</i> , 2021, 14, 972-976.	0.3	11
2007	Characterization and clinicopathological significance of circulating tumour cells in patients with oral squamous cell carcinoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2022, 51, 289-299.	0.7	10
2008	Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. <i>Cell</i> , 2021, 184, 3998-4015.e19.	13.5	92
2009	Immunotherapy in Malignant Pleural Mesothelioma. , 0, , .		0
2010	Inmunoterapia en oncologÃa de las vÃas aerodigestivas superiores. <i>EMC - OtorrinolaringologÃa</i> , 2021, 50, 1-20.	0.0	0
2011	Tumour infiltrating lymphocytes in oropharyngeal carcinoma: prognostic value and evaluation of a standardised method. <i>Pathology</i> , 2021, 53, 836-843.	0.3	7
2012	Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Cancers</i> , 2021, 13, 3545.	1.7	9
2013	Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
2014	Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. <i>PLoS ONE</i> , 2021, 16, e0252041.	1.1	4
2015	Cardiotoxicity associated with immune checkpoint inhibitor therapy: a metaâ€analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1739-1747.	2.9	76
2016	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568.	1.7	13
2017	PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 3363-3370.	0.5	3
2018	Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. , 2021, 9, e002773.		28
2019	Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 587862.	1.3	6
2020	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303.	1.8	1
2021	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	0.9	15

#	ARTICLE	IF	CITATIONS
2022	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. <i>Vaccines</i> , 2021, 9, 807.	2.1	2
2023	Current status of systemic therapy in head and neck cancer. <i>Journal of Chemotherapy</i> , 2021, , 1-16.	0.7	1
2024	Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. <i>Journal of Genetics and Genomics</i> , 2021, 48, 582-594.	1.7	12
2025	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 136, 106002.	1.2	6
2026	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
2027	LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 749.	1.1	23
2028	Emerging data on nivolumab for esophageal squamous cell carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 845-854.	1.4	1
2029	é.é.f"ç™CEã®æ™æº—æ²»ç™,. <i>Journal of Otolaryngology of Japan</i> , 2021, 124, 1027-1029.	0.1	0
2030	Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus. <i>Frontiers in Immunology</i> , 2021, 12, 652054.	2.2	20
2031	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
2032	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	2.2	27
2033	Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 836.	1.1	5
2034	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 678409.	1.6	15
2035	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. <i>Future Oncology</i> , 2021, 17, 2593-2603.	1.1	14
2036	Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. <i>Cancers</i> , 2021, 13, 3696.	1.7	30
2037	Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review. <i>Frontiers in Oncology</i> , 2021, 11, 592319.	1.3	10
2038	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
2039	Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682075.	1.3	6

#	ARTICLE	IF	CITATIONS
2040	Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	23
2041	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	1.1	28
2042	A review on the advances and challenges of immunotherapy for head and neck cancer. <i>Cancer Cell International</i> , 2021, 21, 406.	1.8	30
2043	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. <i>Lung Cancer Management</i> , 2021, 10, LMT51.	1.5	10
2044	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1244-1256.	0.9	4
2045	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. <i>BMC Cancer</i> , 2021, 21, 761.	1.1	12
2046	P-187 Regional Audit of the use of Nivolumab for Recurrent Head and Heck Squamous Cell Carcinoma. <i>Oral Oncology</i> , 2021, 118, 4-5.	0.8	0
2047	Antimicrobial immunotherapeutics: past, present and future. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 609-628.	1.1	1
2048	Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	4
2049	Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. <i>Ear, Nose and Throat Journal</i> , 2021, , 014556132110310.	0.4	2
2050	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
2051	Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review. <i>Quality of Life Research</i> , 2022, 31, 645-657.	1.5	7
2052	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	1.3	14
2053	Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis. <i>Frontiers in Oncology</i> , 2021, 11, 636365.	1.3	4
2054	Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666515.	1.8	14
2055	Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 685440.	1.6	17
2056	Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 712944.	1.3	7
2057	The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 649963.	1.3	4

#	ARTICLE	IF	CITATIONS
2058	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1739.	3.3	19
2059	Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2021, 50, 864-873.	1.4	24
2060	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
2061	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
2062	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Current Oncology, 2021, 28, 3227-3239.	0.9	2
2063	Palliative care physicians'™ recognition of patients after immune checkpoint inhibitors and immune-related adverse events. Supportive Care in Cancer, 2022, 30, 775-784.	1.0	0
2064	Immune Checkpoint Inhibitors in the Aged. Current Oncology Reports, 2021, 23, 115.	1.8	3
2066	The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. Acta Oncologica, 2021, 60, 1534-1542.	0.8	11
2067	Autophagy controls programmed death-ligand1 expression on cancer cells (Review). Biomedical Reports, 2021, 15, 84.	0.9	12
2068	Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer. Tumori, 2022, 108, 450-460.	0.6	3
2069	Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery. ESMO Open, 2021, 6, 100178.	2.0	15
2070	CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 132, 202-209.	0.2	11
2071	Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer, 2021, 21, 924.	1.1	17
2072	Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival. Oral Oncology, 2021, 119, 105380.	0.8	8
2073	Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines, 2021, 9, 894.	2.1	9
2074	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology, 2021, 163, 274-280.	0.6	59
2075	Metavariables Resuming Host Immune Features and Nodal Involvement Are Associated with Oncological Outcomes in Oral Cavity Squamous Cell Carcinoma. Cells, 2021, 10, 2203.	1.8	2
2076	The functional GRHL3-flaggrin axis maintains a tumor differentiation potential and influences drug sensitivity. Molecular Therapy, 2021, 29, 2571-2582.	3.7	5

#	ARTICLE	IF	CITATIONS
2077	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717038.	1.6	2
2078	Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer. <i>Scientific Reports</i> , 2021, 11, 15696.	1.6	9
2079	Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. <i>Clinical and Translational Oncology</i> , 2022, 24, 161-192.	1.2	31
2080	Anti-PD-1 Immune Checkpoint Blockade for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 751-759.	0.5	1
2082	Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 16134.	1.6	31
2083	Ferroptosis Driver SOCS1 and Suppressor FTH1 Independently Correlate With M1 and M2 Macrophage Infiltration in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 727762.	1.8	33
2084	Evaluation of programmed death ligand 1 immunohistochemistry in cytology specimens of head and neck squamous cell carcinoma. <i>Cancer Cytopathology</i> , 2022, 130, 91-95.	1.4	3
2085	Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series. <i>Beyond Rheumatology</i> , 2021, 3, .	0.3	1
2086	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.3	4
2087	Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma. <i>Future Oncology</i> , 2021, 17, 3037-3050.	1.1	7
2088	Improving function of cytotoxic T lymphocytes by transforming growth factor- β inhibitor in oral squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4037-4049.	1.7	31
2089	Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	2.2	47
2090	A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions. <i>Value in Health</i> , 2021, 24, 1651-1659.	0.1	3
2091	RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. <i>European Journal of Radiology</i> , 2021, 141, 109823.	1.2	4
2092	Biologics in Otolaryngology. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 675-687.	0.5	2
2093	Biologics in Otolaryngology. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, i.	0.5	0
2094	Immunotherapeutic Strategies for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 729-742.	0.5	3
2095	Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 657951.	2.2	2

#	ARTICLE	IF	CITATIONS
2096	Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. <i>Oral Oncology</i> , 2021, 119, 105368.	0.8	15
2097	Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04545.	0.2	5
2098	Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 221.	0.4	2
2099	Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. <i>Immunotherapy</i> , 2021, 13, 931-940.	1.0	1
2100	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	1.7	31
2101	Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 729207.	1.3	5
2102	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. <i>Scientific Reports</i> , 2021, 11, 16992.	1.6	13
2103	Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGF β 2/PD-L1 blockade-treated squamous cell carcinoma. <i>Communications Biology</i> , 2021, 4, 1005.	2.0	10
2104	Augmented clearance of nivolumab is associated with renal functions in chronic renal disease model rats. <i>Drug Metabolism and Disposition</i> , 2021, , DMD-AR-2021-000520.	1.7	1
2105	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.2	2
2106	APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 97, 107675.	1.7	11
2107	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	15.2	197
2108	The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 719650.	2.2	3
2109	Clinical outcomes in relapsed oropharyngeal cancer after definitive (chemo) radiotherapy. <i>Oral Diseases</i> , 2023, 29, 595-603.	1.5	0
2110	Induction Chemotherapy for Advanced Oral Cavity Cancer. <i>Current Oncology Reports</i> , 2021, 23, 129.	1.8	11
2111	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13
2112	Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy. <i>Neoplasia</i> , 2021, 23, 811-822.	2.3	3
2113	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <i>Journal of Modern Oncology</i> , 2021, 23, 319-326.	0.1	4

#	ARTICLE	IF	CITATIONS
2114	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 851-863.	2.0	6
2115	Quantitative analysis of KLF4 and SOX2 expression in oral carcinomas reveals independent association with oral tongue subsite location and histological grade. <i>Cancer Biomarkers</i> , 2021, 32, 37-48.	0.8	1
2117	Tumor microenvironment is not an "innocent bystander"™ in the resistance to treatment of head and neck cancers (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1128.	0.8	5
2118	Characterization and ex vivo expansion of rare in situ cytokine secreting T cell populations from tumor tissue and blood of oral squamous cell carcinoma patients. <i>Journal of Immunological Methods</i> , 2021, 496, 113086.	0.6	3
2119	Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy. <i>Auris Nasus Larynx</i> , 2022, 49, 279-285.	0.5	4
2120	PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. <i>Frontiers in Immunology</i> , 2021, 12, 693881.	2.2	20
2121	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 727433.	1.3	57
2122	Extracellular acidity in tumor tissue upregulates programmed cell death ligand 1 expression on tumor cells via proton-sensing G protein-coupled receptors. <i>International Journal of Cancer</i> , 2021, 149, 2116-2124.	2.3	12
2123	Prognostic association of starvation-induced gene expression in head and neck cancer. <i>Scientific Reports</i> , 2021, 11, 19130.	1.6	6
2124	The Impact of m1A Methylation Modification Patterns on Tumor Immune Microenvironment and Prognosis in Oral Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10302.	1.8	19
2125	éé,éf"ç™CEã«ã~3/4ãªMã,«ã...ç-«ãfã,Sãffã,ãfã,ãf³ãf~é»ã®³è-→. Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho, 2021, 124, 1251-1255.		
2126	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1535-1544.	1.0	10
2127	Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 680955.	2.2	16
2128	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7012-7020.	1.3	8
2129	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. <i>Journal of Personalized Medicine</i> , 2021, 11, 914.	1.1	2
2131	Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany. <i>Head and Neck</i> , 2021, 43, 3540-3551.	0.9	8
2132	Impact of Oncogenic Targets by Tumor-Suppressive miR-139-5p and miR-139-3p Regulation in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9947.	1.8	8
2133	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4548.	1.7	16

#	ARTICLE	IF	CITATIONS
2134	CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. <i>Cell Stem Cell</i> , 2021, 28, 1597-1613.e7.	5.2	127
2135	Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study. <i>Cancers</i> , 2021, 13, 4813.	1.7	7
2136	Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 871.	1.2	34
2137	DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2021, 19, 274.	0.8	10
2138	Outcomes of salvage treatment in patients with recurrent oral squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 3764-3774.	0.9	3
2139	HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise. <i>Journal of Surgical Oncology</i> , 2021, 124, 962-966.	0.8	12
2140	Role of Organ Preservation in Locally Advanced Hypopharyngeal Carcinoma. , 0, , .		0
2141	Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 98, 107789.	1.7	39
2142	Characterization of Molecular Subtypes in Head and Neck Squamous Cell Carcinoma With Distinct Prognosis and Treatment Responsiveness. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 711348.	1.8	13
2143	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	1.7	8
2144	Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 17789.	1.6	15
2145	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2021, 11, 705614.	1.3	19
2146	Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. <i>Oral Oncology</i> , 2021, 120, 105420.	0.8	20
2147	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 738626.	1.3	9
2148	Hypopharyngeal Cancer: Staging, Diagnosis, and Therapy. , 0, , .		1
2149	Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 952-961.	0.8	1
2150	Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. <i>Cancers</i> , 2021, 13, 4861.	1.7	5
2151	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. <i>Cell Reports</i> , 2021, 36, 109699.	2.9	37

#	ARTICLE	IF	CITATIONS
2152	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. <i>Acta Oncologica</i> , 2021, 60, 1597-1603.	0.8	13
2153	Head and neck cancer. <i>Lancet, The</i> , 2021, 398, 2289-2299.	6.3	280
2154	Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 733530.	2.2	23
2155	Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. <i>Cancer</i> , 2021, 127, 4565-4573.	2.0	24
2156	Current strategies for intratumoural immunotherapy “Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510.	1.3	28
2157	Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 717601.	1.8	6
2158	Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors. <i>European Journal of Haematology</i> , 2021, 107, 650-657.	1.1	4
2159	TAS-116 (Pimipib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). <i>Clinical Cancer Research</i> , 2021, 27, 6709-6715.	3.2	20
2160	Mechanism of interaction between autophagy and apoptosis in cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2021, 26, 512-533.	2.2	100
2161	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. <i>Journal of Critical Care</i> , 2021, 65, 126-132.	1.0	6
2162	TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. <i>Oral Oncology</i> , 2021, 121, 105472.	0.8	30
2163	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 361-370.	1.0	5
2164	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
2165	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
2166	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1021-1037.	0.9	8
2167	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	1.7	13
2168	The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. <i>Phytomedicine</i> , 2021, 92, 153758.	2.3	26
2169	Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis. <i>Pharmacological Research</i> , 2021, 173, 105866.	3.1	10

#	ARTICLE	IF	CITATIONS
2170	Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021, 157, 190-197.	1.3	6
2171	Consistent multimodality approach to oral cavity and high-risk oropharyngeal cancer in veterans. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 103166.	0.6	7
2172	An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112238.	2.5	7
2173	Tissue-resident memory T cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 122, 105508.	0.8	7
2174	Modification of Metal-Organic Framework Nanoparticles Using Dental Pulp Mesenchymal Stem Cell Membranes to Target Oral Squamous Cell Carcinoma. <i>Journal of Colloid and Interface Science</i> , 2021, 601, 650-660.	5.0	19
2175	Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 522, 198-210.	3.2	20
2176	Epidemiology of oral cancer and its relationship with inflammation. , 2022, , 1-18.		0
2177	Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis. <i>Oncology Research and Treatment</i> , 2021, 44, 538-546.	0.8	5
2178	A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect. <i>Pharmaceutical Statistics</i> , 2021, 20, 528-550.	0.7	6
2179	Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers. , 2021, , 75-106.		0
2180	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	1.6	38
2181	A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor. <i>International Journal of Hematology</i> , 2021, 113, 606-610.	0.7	4
2182	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. , 2021, , 119-137.		0
2183	Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?. , 2021, , 205-219.		1
2184	Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer. , 2021, , 155-179.		1
2185	Immunologic "Cold" Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis. <i>Frontiers in Medicine</i> , 2021, 8, 622330.	1.2	23
2186	B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1882743.	2.1	11
2187	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 12.	7.1	68

#	ARTICLE	IF	CITATIONS
2188	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2
2189	Tumors: <i>Oto-Rhino-Laryngology.</i> , 2021, , 1-12.		0
2190	Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC). , 2021, , 83-91.		1
2191	Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Practica Otologica</i> , 2021, 114, 405-411.	0.0	0
2192	PD-L2 based immune signature confers poor prognosis in HNSCC. <i>Oncolmmunology</i> , 2021, 10, 1947569.	2.1	21
2193	Immune checkpoint inhibitors for recurrent or metastatic head and neck cancer .: <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 10-14.	0.0	0
2194	Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. <i>Journal of Translational Medicine</i> , 2021, 19, 43.	1.8	17
2195	Innovation and Advances in Precision Medicine in Head and Neck Cancer. , 2021, , 355-373.		2
2196	Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Gerontology</i> , 2021, 67, 379-385.	1.4	6
2197	Immunotherapy for head and neck cancer “ The current scenario. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2021, 5, 146-150.	0.1	0
2198	Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 1253-1259.	0.6	5
2200	Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1263-1276.	1.9	12
2201	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	46
2202	Sinonasal Undifferentiated Carcinoma. <i>Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)</i> , 2021, 60, 159-168.	0.0	0
2203	Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival. <i>Oncolmmunology</i> , 2021, 10, 1944554.	2.1	19
2204	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199628.	0.6	33
2205	Personalized cancer vaccination in head and neck cancer. <i>Cancer Science</i> , 2021, 112, 978-988.	1.7	34
2206	Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2021, 26, e494-e501.	0.7	6

#	ARTICLE	IF	CITATIONS
2207	Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers. <i>JAMA Network Open</i> , 2020, 3, e2022906.	2.8	32
2208	Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. <i>Cancer Medicine</i> , 2020, 9, 2106-2112.	1.3	28
2209	Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. <i>Cancer Medicine</i> , 2020, 9, 5015-5024.	1.3	28
2210	Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 848-852.	0.2	5
2211	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
2212	Treatment Strategies in Head and Neck Cancers. , 2020, , 273-294.		1
2213	Sample Size Determination Under Non-proportional Hazards. <i>Springer Proceedings in Mathematics and Statistics</i> , 2019, , 157-165.	0.1	1
2214	The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 293-325.	0.2	4
2215	P53 in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 249-274.	0.2	1
2216	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
2217	Mechanisms of Resistance to Checkpoint Blockade Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 83-117.	0.8	22
2218	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.	0.8	5
2219	The role of molecularly targeted therapies and immunotherapy in head and neck cancer. , 2020, , 33-47.		1
2220	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. <i>Oral Oncology</i> , 2020, 107, 104754.	0.8	7
2221	Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. <i>Bulletin Du Cancer</i> , 2020, 107, eS16-eS21.	0.6	8
2222	Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas. <i>Bioscience Reports</i> , 2020, 40, .	1.1	7
2223	Correlation between patients' age and cancer immunotherapy efficacy. <i>Oncolimmunology</i> , 2019, 8, e1568810.	2.1	44
2224	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. <i>Oncolimmunology</i> , 2020, 9, 1710398.	2.1	30

#	ARTICLE	IF	CITATIONS
2225	Immune checkpoint inhibitor-associated hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1598-1608.	0.4	12
2226	Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. <i>Anti-Cancer Drugs</i> , 2021, 32, 95-101.	0.7	16
2227	Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 108-118.	2.1	27
2230	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
2231	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
2232	250â€¦SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement. , 2020, , .		1
2233	Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity. <i>Cancer Research</i> , 2021, 81, 1375-1387.	0.4	17
2234	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 632-644.	3.2	49
2235	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	0.7	17
2236	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	44
2237	Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	21
2238	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019, 4, .	2.3	168
2239	Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. <i>JCI Insight</i> , 2019, 4, .	2.3	25
2240	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
2241	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	3.9	94
2242	PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. <i>Journal of Clinical Investigation</i> , 2020, 130, 3603-3620.	3.9	90
2243	Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 58.	0.9	9
2244	Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-associated Squamous Cell Carcinoma of the Oropharynx. <i>JCO Oncology Practice</i> , 2020, 16, 20s-24s.	1.4	8

#	ARTICLE	IF	CITATIONS
2245	Immunotherapy-Induced Colitis: An Emerging Problem for the Hospitalist. <i>Journal of Hospital Medicine</i> , 2018, 13, 413-418.	0.7	25
2246	Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 4100-4108.	0.3	4
2247	Isolated Adrenocorticotrophic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 358-362.	0.6	23
2248	Role of the tumor microenvironment in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, R519-R544.	1.6	13
2249	Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck. <i>Opuholi Golovy I Sei</i> , 2020, 10, 10-21.	0.1	4
2250	Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment. <i>Opuholi Golovy I Sei</i> , 2020, 10, 111-117.	0.1	1
2251	B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. <i>Aging</i> , 2021, 13, 2310-2329.	1.4	10
2252	Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. <i>Oncoscience</i> , 2018, 5, 75-87.	0.9	36
2253	Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. <i>Oncotarget</i> , 2017, 8, 51830-51839.	0.8	2
2254	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. <i>Oncotarget</i> , 2017, 8, 20558-20571.	0.8	49
2255	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	0.8	95
2256	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	0.8	69
2257	Excellent response to chemotherapy post immunotherapy. <i>Oncotarget</i> , 2017, 8, 91795-91802.	0.8	51
2258	Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 113120-113128.	0.8	19
2259	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	0.8	76
2260	A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 3001-3013.	0.8	12
2261	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119.	0.8	34
2262	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2

#	ARTICLE	IF	CITATIONS
2263	Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 12400-12407.	0.8	13
2264	Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. <i>Oncotarget</i> , 2018, 9, 20769-20780.	0.8	20
2265	Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 22480-22497.	0.8	32
2266	Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. <i>Oncotarget</i> , 2018, 9, 22038-22046.	0.8	14
2267	Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. <i>Oncotarget</i> , 2018, 9, 23482-23493.	0.8	17
2268	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. <i>Oncotarget</i> , 2018, 9, 27460-27470.	0.8	53
2269	Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. <i>Oncotarget</i> , 2018, 9, 37581-37588.	0.8	3
2270	Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. <i>Oncotarget</i> , 2019, 10, 5605-5621.	0.8	15
2271	Window of opportunity trials in head and neck cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	7
2272	Novel immunotherapeutic approaches in head and neck cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	9
2273	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
2274	Immunotherapy for head and neck cancer: where are we now and where are we going?. <i>Annals of Translational Medicine</i> , 2019, 7, S75-S75.	0.7	35
2275	Immunotherapy for mucosal melanoma. <i>Annals of Translational Medicine</i> , 2019, 7, S118-S118.	0.7	23
2276	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 651-651.	0.7	18
2277	Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. <i>Translational Cancer Research</i> , 2019, 8, S404-S420.	0.4	5
2278	Immunotherapy in Head and Neck Squamous Cell Cancer. <i>Clinical and Experimental Otorhinolaryngology</i> , 2018, 11, 217-223.	1.1	18
2279	Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors. <i>Current Pharmaceutical Design</i> , 2018, 23, 7003-7024.	0.9	6
2280	Targeting PD-L1 Protein: Translation, Modification and Transport. <i>Current Protein and Peptide Science</i> , 2018, 20, 82-91.	0.7	20

#	ARTICLE	IF	CITATIONS
2281	Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2021, 21, 386-400.	0.8	11
2282	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 768-776.	0.9	6
2283	Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. <i>Open Dentistry Journal</i> , 2018, 12, 455-465.	0.2	9
2284	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. <i>Current Radiopharmaceuticals</i> , 2020, 13, 24-31.	0.3	6
2285	Squamous Cell Carcinoma Antigen-encoding Genes SERPINB3/B4 as Potentially Useful Markers for the Stratification of HNSCC Tumours. <i>Anticancer Research</i> , 2018, 38, 1343-1352.	0.5	11
2286	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.	0.5	25
2287	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. <i>Immunotherapy</i> , 2020, 12, 481-510.	1.0	7
2288	Non-coding RNA and immune-checkpoint inhibitors: friends or foes?. <i>Immunotherapy</i> , 2020, 12, 513-529.	1.0	16
2289	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
2290	Evaluation of Nivolumab Use and Factors related to Treatment Outcomes in a Cancer Center of a Top Tier General Hospital. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 88-94.	0.0	3
2291	Immunoterapia z użyciem przeciwciał, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
2292	Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials. <i>Radiology and Oncology</i> , 2020, 54, 377-393.	0.6	16
2293	A case of non-comatose acute hepatic failure: An immune-related adverse event due to sequential administration of nivolumab and ipilimumab. <i>Acta Hepatologica Japonica</i> , 2019, 60, 83-90.	0.0	5
2294	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
2296	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
2297	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
2298	Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 240.	1.8	101
2299	Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 247.	1.8	14

#	ARTICLE	IF	CITATIONS
2300	LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 379.	1.8	24
2301	The Abscopal Effect in Head-and-Neck Squamous Cell Carcinoma Treated with Radiotherapy and Nivolumab: A Case Report and Literature Review. <i>Current Oncology</i> , 2020, 27, 330-335.	0.9	13
2302	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2137-2151.	1.4	99
2303	Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	14
2304	Gene targets of sulforaphane in head and neck squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2019, 20, 5335-5344.	1.1	6
2305	A novel anti-EGFR monoclonal antibody (EMab17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. <i>Oncology Letters</i> , 2020, 19, 2809-2816.	0.8	21
2306	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020, 20, 14.	0.8	10
2307	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immune evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
2308	Selective inhibition of PI3K110 α as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma. <i>Oncology Reports</i> , 2020, 44, 863-872.	1.2	6
2309	PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 113-116.	0.3	7
2310	Indian clinical practice consensus guidelines for the management of very advanced disease of squamous cell carcinoma of head and neck. <i>Indian Journal of Cancer</i> , 2020, 57, 22.	0.2	4
2311	Pathophysiology of diabetes: An overview. <i>Avicenna Journal of Medicine</i> , 2020, 10, 174.	0.3	141
2312	Immunotherapy and its advances in the management of head-and-neck cancer. <i>CHRISMED Journal of Health and Research</i> , 2019, 6, 199.	0.1	4
2313	Low doses in immunotherapy: Are they effective?. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 54.	0.1	12
2314	Is pulmonary metastasectomy beneficial in head and neck squamous cell carcinoma? A review of literature. <i>Indian Journal of Cancer</i> , 2017, 54, 2.	0.2	4
2315	Cancer Immunotherapy: An Impossible Dream for the Common Man?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 312-316.	0.1	1
2316	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients' Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 7-18.	0.6	40
2317	Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 36-39.	0.6	3

#	ARTICLE	IF	CITATIONS
2318	Epigenetics in oral squamous cell carcinoma. <i>Journal of Oral and Maxillofacial Pathology</i> , 2017, 21, 252.	0.3	69
2319	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. <i>South Asian Journal of Cancer</i> , 2019, 08, 65-68.	0.2	4
2320	Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis. <i>Immune Network</i> , 2020, 20, e7.	1.6	12
2321	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
2322	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
2323	Systemic treatment of advanced or recurrent biliary tract cancer. <i>BioScience Trends</i> , 2020, 14, 328-341.	1.1	29
2324	Collaboration in medical treatment to use Nivorumab against oral cancer, Clinical Oncologist and Oral and Maxillofacial surgeon. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 135-143.	0.0	1
2325	Clinical analysis for head and neck cancer cases treated with nivolumab in Osaka International Cancer Institute. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 46-50.	0.0	1
2326	A case of platinum-refractory residual oropharyngeal carcinoma with carotid sinus syndrome that responded to nivolumab. <i>Japanese Journal of Head and Neck Cancer</i> , 2020, 46, 73-78.	0.0	1
2327	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 278-285.	2.3	12
2328	Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 873-898.	2.3	633
2329	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 899-906.	2.3	24
2330	Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. <i>ELife</i> , 2020, 9, .	2.8	31
2331	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2017, 9, e1774.	0.2	17
2332	Induction of the Abscopal Effect with Immunotherapy and Palliative Radiation in Metastatic Head and Neck Squamous Cell Carcinoma: A Case Report and Review of the Literature. <i>Cureus</i> , 2019, 11, e4201.	0.2	14
2333	Head and Neck Cancers. <i>UNIPA Springer Series</i> , 2021, , 707-729.	0.1	0
2334	Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110458.	0.8	2
2335	A novel defined hypoxia-related gene signature to predict the prognosis of oral squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1565-1565.	0.7	11

#	ARTICLE	IF	CITATIONS
2336	Immunotherapy in head and neck squamous cell carcinoma: a narrative review. <i>Frontiers of Oral and Maxillofacial Medicine</i> , 0, 4, 28-28.	0.1	4
2337	Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors. <i>Annals of Palliative Medicine</i> , 2021, 10, 11244-11254.	0.5	7
2338	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110464.	0.8	0
2339	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10
2340	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	3.2	45
2341	Activation of Cascade-Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102080.	3.9	5
2342	Overexpression of LAG3, TIM3, and A2aR in adenoid cystic carcinoma and mucoepidermoid carcinoma. <i>Oral Diseases</i> , 2023, 29, 175-187.	1.5	2
2344	Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 314.	3.5	1
2345	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. <i>Communications Biology</i> , 2021, 4, 1178.	2.0	10
2346	The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 761379.	1.3	38
2347	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
2348	DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 763086.	2.2	9
2349	Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 811-815.	0.6	2
2350	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	1.3	9
2351	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1355-1370.	1.1	6
2352	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Medicina (Lithuania)</i> , 2021, 57, 1151.	0.8	8
2353	Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma. <i>BMC Oral Health</i> , 2021, 21, 506.	0.8	11
2354	Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 714550.	1.3	3

#	ARTICLE	IF	CITATIONS
2355	The Balance between Differentiation and Terminal Differentiation Maintains Oral Epithelial Homeostasis. <i>Cancers</i> , 2021, 13, 5123.	1.7	7
2356	The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. <i>Cancers</i> , 2021, 13, 5206.	1.7	30
2357	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
2358	Pembrolizumab in the first-line treatment of advanced head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1321-1331.	1.1	11
2359	The tumor immune microenvironments of HPV ⁺ and HPV ⁻ head and neck cancers. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1539.	1.5	13
2360	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100411.	3.3	18
2361	PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	1
2362	NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11057.	1.8	4
2363	Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 3875-3887.	0.9	64
2364	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , 2021, 158, 47-62.	1.3	32
2365	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The II cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	1.3	33
2366	Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC). <i>Oral Oncology</i> , 2021, 122, 105546.	0.8	4
2367	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. <i>Biomaterials</i> , 2021, 279, 121182.	5.7	22
2368	Head and neck cancer specialists require knowledge of oral complications and medical dental collaboration. <i>Japanese Journal of Head and Neck Cancer</i> , 2017, 43, 499-504.	0.0	1
2369	Evaluation of prognostic factor for anaplastic thyroid carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2017, 43, 483-487.	0.0	0
2370	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
2371	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2017, , 1-11.		0
2372	Effectiveness and prognostic factors of Cetuximab plus chemotherapy for recurrent or metastatic head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2017, 43, 493-498.	0.0	1

#	ARTICLE	IF	CITATIONS
2391	Treatment Paradigms in HPV-Associated SCCHN. <i>Current Cancer Research</i> , 2018, , 585-615.	0.2	0
2392	Inflammation and Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 353-364.	0.2	0
2393	The guideline on optimal usage of nivolumab and the collaboration with medical oncologists and oral surgeons. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 130-134.	0.0	0
2394	A Case of Head and Neck Cancer Died of Lung Failure after a Single Administration of Nivolumab. <i>Practica Otologica</i> , 2018, 111, 693-699.	0.0	0
2395	Transforming Growth Factor Beta (TGF- β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018, , 89-115.	0.2	0
2396	Drug Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Plans. <i>Practica Otologica</i> , 2018, 111, 577-582.	0.0	0
2397	Innovative New Drug for Head and Neck Cancer Treatment " Management of Nivolumab ". <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2018, 69, 181-182.	0.0	0
2398	c-MET in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 63-88.	0.2	1
2399	Besides and beyond histopathology; for adjuvant treatment in early tongue cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018, 39, 355.	0.1	1
2400	Chemotherapy for Temporal Bone Cancer. , 2018, , 403-410.		0
2401	Targeted Therapy in Recurrent or Metastatic Head and Neck Carcinoma. <i>Hospice and Palliative Medicine International Journal</i> , 2018, 2, .	0.2	1
2402	Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src. <i>Anticancer Research</i> , 2018, 38, 2723-2731.	0.5	6
2403	Enjeux et difficultés de la gestion des médicaments onco-neurologiques non inscrits dans la liste en sus pour un hôpital traitant des cancers. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1003-1012.	0.0	0
2404	PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin's Lymphoma. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 213-219.	0.1	3
2405	「喉頭癌に対する免疫チェックポイント阻害剤の効果」. <i>Journal of Otolaryngology of Japan</i> , 2018, 121, 826-828.		
2406	Non-HPV-Associated Oropharyngeal Cancer. , 2018, , .		0
2407	「免疫チェックポイント阻害剤の効果」. <i>Journal of Otolaryngology of Japan</i> , 2018, 121, 941-943.	0.1	0
2408	The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer. <i>Cureus</i> , 2018, 10, e3519.	0.2	7

#	ARTICLE	IF	CITATIONS
2409	A review of statistical methods on testing time-to-event data. <i>Biometrics & Biostatistics International Journal</i> , 2018, 7, 570-572.	0.2	0
2410	é.é.f.ç™CEã«ã~3/4ã™ã,«è—ç%©ç™,æ³•ã®é€²æ©. <i>Journal of Otolaryngology of Japan</i> , 2018, 121, 1458-1462.	0.1	0
2411	First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy. <i>Opuholi Golovy I Sei</i> , 2019, 8, 14-20.	0.1	1
2412	Nivolumab in the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN): A Report of 16 Cases at a Single Institution. <i>Practica Otologica</i> , 2019, 112, 625-628.	0.0	0
2413	Elective neck dissection is useful in what cases?. <i>Journal of Japanese Society of Oral Oncology</i> , 2019, 31, 122-130.	0.0	0
2414	Carboplatin plus Paclitaxel in patients with recurrent/metastatic head and neck carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 420-425.	0.0	0
2415	Response to salvage chemotherapy after progression on nivolumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 41-45.	0.0	1
2416	Clinicopathological analysis of local recurrence of oral squamous cell carcinoma. <i>Journal of Japanese Society of Oral Oncology</i> , 2019, 31, 143-149.	0.0	0
2417	A study for the development of oral functional management and community medical cooperation on cancer treatment in Aichi Cancer Center Hospital. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 286-293.	0.0	0
2418	Molecular mechanisms of resistance to monoclonal antibodies therapy patients with squamous cell carcinoma of the tongue and mucosa of the oral cavity. <i>Malignant Tumours</i> , 2019, 8, 13-25.	0.1	1
2419	é.é.f.ç™CEã®ã...ç—«ç™,æ³•ã«ãšããã,ç³/4çš¶ã®è²é;E. <i>Journal of Otolaryngology of Japan</i> , 2019, 122, 22-28.	0.1	0
2420	A Case of Lung Metastasis from Laryngeal Cancer Showing a Good Response to Chemotherapy with Docetaxel. <i>Practica Otologica</i> , 2019, 112, 405-410.	0.0	0
2421	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2019, , 1-13.		0
2422	Treatment of Advanced Anal Cancer. , 2019, , 95-111.		0
2423	Investigation of Recurrent Cases of Head and Neck Cancer after Initial Treatment. <i>Practica Otologica</i> , 2019, 112, 697-703.	0.0	0
2424	Clinical analysis of palliative care alone in end-stage head and neck cancer treatment. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 34-40.	0.0	0
2425	Clinical features of 10 patients with recurrent and/or metastatic head and neck carcinomas treated by Nivolumab:. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2019, 28, 313-318.	0.0	1
2426	Squamous Cell Carcinoma of the Head and Neck. , 2019, , 697-720.		1

#	ARTICLE	IF	CITATIONS
2427	Leadership in immuno-oncology network 2 (LION:2) immunotherapy oncology - A present status. International Journal of Molecular and Immuno Oncology, 0, 4, 3-5.	0.0	0
2428	A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. Japanese Journal of Lung Cancer, 2019, 59, 60-65.	0.0	0
2429	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. Journal of the Advanced Practitioner in Oncology, 2019, 10, 37-46.	0.2	5
2430	Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, S22-S22.	0.7	2
2432	Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions. Translational Cancer Research, 2019, 8, S188-S194.	0.4	1
2433	2. Cancer Immunotherapy: A Novel Approach to Cancer Treatment. Japanese Journal of Clinical Pharmacology and Therapeutics, 2019, 50, 107-111.	0.1	0
2434	Biomarkers in immuno-oncology: A review article. International Journal of Molecular and Immuno Oncology, 2019, 4, 41-49.	0.0	1
2436	Immunotherapy in head and neck cancer. Pomeranian Journal of Life Sciences, 2019, 65, 15-19.	0.1	2
2437	HPV infections in head and neck cancers (HNSCC) – clinical course and efficiency of therapy. Pomeranian Journal of Life Sciences, 2019, 65, 36-40.	0.1	0
2438	あ...ç-«ãfã,Šãfã,ãfã,ãfã³ãfãé»ã³è-ãĈEã^ã,Šæ«ããtç™ãf»è»çš»éé,éf”ç™Ĉæ²»ç™,., Journal of Otolaryngology of Japan, 2019, 12		
2439	Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2019, 62, 487-498.	0.0	1
2440	OPTIMAL TREATMENT STRATEGY FOR PATIENTS WITH PROGRESSIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Issledovaniã I Praktika V Medicine, 2019, 6, 115-128.	0.1	0
2442	Malignancy, Staging and Surgical Management. , 2020, , 77-104.		0
2443	Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer. , 2020, , 117-128.		0
2445	Hematologic Malignancies: PET/CT for Response Assessment of Hematologic Malignancies Following Immunotherapy. , 2020, , 81-90.		0
2447	Marked anti-tumor effects of nivolumab on recurrent/metastatic head and neck cancer: 4 case reports. Tenri Medical Bulletin, 2019, 22, 79-85.	0.1	0
2448	Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2019, 62, 712-719.	0.0	0
2449	A Case of Tongue Cancer with Induction of the Abscopal Effect Treated with Nivolumab. Practica Otologica, 2020, 113, 575-579.	0.0	0

#	ARTICLE	IF	CITATIONS
2450	Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma. , 2020, , 333-354.		0
2453	Nivolumab in the treatment of recurrent or methastatic head and neck cancer. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overlock	0.0	0
2454	DÄ¼zenleyici B HÄ¼creleri ve Kanserdeki RolÄ¼. Sakarya Medical Journal, 0, , .	0.1	0
2456	Vigilancia clÄnica de los pacientes que reciben inmunoterapia. Medicina ClÄnica, 2020, 154, 493-495.	0.3	0
2457	Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Factors for Serious Nivolumab-Induced Immune-Related Adverse Events. Iryo Yakugaku (Japanese Journal of Pharmaceutical) Tj ETQq0 0.0rgBT /Overlock 10	0.0	0
2459	A case of simultaneous double cancer of oral malignant melanoma and lung adenocarcinoma with nivolumab-induced destructive thyroiditis. Nihon Koku Geka Gakkai Zasshi, 2020, 66, 376-381.	0.0	0
2460	PD-1é~â@3â%oi¼^éé,éf"ç™CEi¼%. Nihon Kikan Shokudoka Gakkai Kaiho, 2020, 71, 338-340.	0.0	1
2461	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
2462	FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus. Anticancer Research, 2020, 40, 5621-5630.	0.5	2
2463	Topical Delivery of Nivolumab, a Therapeutic Antibody, by Fractional Laser and Pneumatic Injection. Lasers in Surgery and Medicine, 2021, 53, 154-161.	1.1	10
2464	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
2465	Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatologic Therapy, 2021, 34, e15184.	0.8	4
2466	Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 769534.	2.2	12
2467	The Role of B Cells in Head and Neck Cancer. Cancers, 2021, 13, 5383.	1.7	10
2468	Attempt at Outpatient Chemotherapy with Nivolumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Utilizing the Services of a Part-time Surgeon. Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho, 2021, 124, 1406-1412.	0.0	0
2469	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
2470	Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncology, 2021, 123, 105587.	0.8	2
2471	Molecular Targeted Therapy for Advanced Oral Cancer. Textbooks in Contemporary Dentistry, 2020, , 359-385.	0.2	0

#	ARTICLE	IF	CITATIONS
2472	Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics. , 2021, , 195-214.		0
2473	Is hyperprogressive disease a specific phenomenon of immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	1
2474	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
2475	Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes"â€œImmunological Dose Paintingâ€œ, Medicina (Lithuania), 2021, 57, 6.	0.8	6
2476	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	8
2477	Principles of Management of Head and Neck Cancers. , 2021, , 409-425.		0
2478	Neoplasms of the Oral Cavity and Oropharynx. , 2021, , 427-447.		0
2479	Chemoradiotherapy in Oral Cavity Cancer. Textbooks in Contemporary Dentistry, 2020, , 291-301.	0.2	1
2480	Chemotherapy: Where we have been and where we are going. , 2020, , 17-38.		0
2481	Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease. , 2020, , 297-318.		0
2482	Improving responses to immunotherapy in head and neck squamous cell carcinoma. , 2020, , 107-133.		0
2483	Overview of head and neck cancer management. , 2020, , 1-32.		0
2484	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2020, , 759-771.		0
2485	Immunotherapeutic approaches in HNSCC. , 2020, , 117-142.		1
2486	Two Cases of Immune-Related Colitis that Occurred After S-1 Therapy Following Nivolumab Therapy for Recurrent Head and Neck Carcinomas. Practica Otologica, 2020, 113, 727-732.	0.0	0
2487	Clinical Study on recurrent and metastatic head and neck cancer patients treated with Nivolumab. Japanese Journal of Head and Neck Cancer, 2020, 46, 278-283.	0.0	1
2488	Chemotherapy for older patients with head and neck cancer. Journal of Japanese Society of Oral Oncology, 2020, 32, 186-192.	0.0	0
2489	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0

#	ARTICLE	IF	CITATIONS
2490	Recent Advances in Head and Neck Tumor Microenvironmentâ€‘Based Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 11-31.	0.8	3
2491	Introduction: Leaps and bounds. , 2020, , 1-15.		0
2492	Immunotherapy in Advanced Prostate Cancer. <i>European Oncology and Haematology</i> , 2020, 16, 44.	0.0	0
2493	Cancer des voies aÃ©rodigestives et supÃ©rieures. , 2020, , 178-189.e4.		0
2494	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
2495	Development of chemotherapy for head and neck cancer, and current status of treatment strategy in clinical practice. <i>Journal of Japanese Society of Oral Oncology</i> , 2020, 32, 130-133.	0.0	0
2496	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098371.	1.4	7
2497	Laryngeal Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 79-101.	0.8	3
2498	Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 596-601.	1.2	3
2499	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 1442-1447.	1.2	0
2500	Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2020, 11, 1493-1504.	0.8	3
2502	Combination of Performance Status and Lymphocyte-monocyte Ratio as a Novel Prognostic Marker for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 353-361.	0.3	2
2503	Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 692079.	2.2	7
2504	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100426.	3.3	28
2505	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review. <i>BMC Oral Health</i> , 2021, 21, 559.	0.8	4
2506	Novel Antigenic Targets of HPV Therapeutic Vaccines. <i>Vaccines</i> , 2021, 9, 1262.	2.1	16
2507	The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	9
2508	New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 5515.	1.7	12

#	ARTICLE	IF	CITATIONS
2509	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. <i>Clinical Immunology</i> , 2021, 232, 108876.	1.4	4
2510	Quimioterapia y terapias dirigidas en otorrinolaringología. <i>EMC - Otorrinolaringología</i> , 2020, 49, 1-6.	0.0	0
2511	Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 982-984.	2.3	0
2512	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 4173-4187.	0.4	2
2514	éé,éf"ç™CEã«ã-3/4ã™ã,« NKT ç™èfžã,'á^©ç™"ã-ãŸãf-ã,ãfãf³æ²»ç™,. <i>Journal of Otolaryngology of Japan</i> , 2020, 123,1543-546.		
2516	è»çç\$»ãf»ã†ç™éé,éf"ãCEã,“ã«ã-3/4ã™ã,«ã^†ãe™çš,,è-ã*ã...ç-«ãfã,šãfãfã,ãfã,ãf³ãf~é~»ã³è-ããã,ãf“ãf†ãf³ã,1 <i>Journal of Otolary</i>		
2518	Squamous cell carcinoma of head and neck: what internists should know. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1031-1044.	0.7	19
2520	Immunotherapy for regional, recurrent and metastatic head and neck cancer: recent advances and future directions. <i>Medical Alphabet</i> , 2020, , 60-69.	0.0	0
2521	ã†ç™ã³/4ãŸãééš”è»çç\$»ã,'æœ%ã™ã,éé,éf"ç™CEæ²»ç™,ãœæ-°ãŸãé,æšžè,ç. <i>Journal of Otolaryngology of Japan</i> , 2020, 123, 1204-1		
2522	Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck. <i>Opuholi Golovy I Sei</i> , 2020, 10, 41-47.	0.1	0
2523	Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. <i>Oncotarget</i> , 2020, 11, 4253-4265.	0.8	1
2524	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. <i>Onkologie (Czech Republic)</i> , 2020, 14, 199-204.	0.0	0
2525	Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 864-869.	0.5	1
2526	Development of New IDO Inhibitors with Coumarin Pyrimidine Scaffolds as the Potential Anti Cancer Agents. <i>Current Bioactive Compounds</i> , 2020, 16, 1172-1180.	0.2	1
2527	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8
2528	Advances in Collaborative Practice for Patients With Head and Neck Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 261-265.	0.2	0
2530	Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. <i>American Journal of Cancer Research</i> , 2020, 10, 1821-1826.	1.4	2
2533	The clinical significance of apolipoprotein L1 in head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2020, 20, 377.	0.8	2

#	ARTICLE	IF	CITATIONS
2534	Down-regulation of ULL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 6509-6523.	0.0	1
2536	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
2537	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Aging, 2020, 12, 22509-22526.	1.4	4
2538	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Frontiers in Oncology, 2021, 11, 683502.	1.3	2
2539	A case report of oropharyngeal clear cell carcinoma with revised pathological diagnosis after multi-gene cancer panel testing. Japanese Journal of Head and Neck Cancer, 2021, 47, 342-347.	0.0	0
2540	Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. Journal of Atrial Fibrillation, 2021, 13, 2461.	0.5	9
2541	Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncology, 2022, 124, 105634.	0.8	9
2542	Tumoren im Kopf-Hals-Bereich. , 2022, , 230-241.		0
2543	Imaging of Complications of Chemoradiation. Neuroimaging Clinics of North America, 2022, 32, 93-109.	0.5	1
2544	Predictive Value of Maxâ€™s Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2021, 9, 728647.	1.8	0
2545	Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	2
2547	Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. Frontiers in Surgery, 2021, 8, 753049.	0.6	1
2548	Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. Current Oncology, 2021, 28, 4587-4596.	0.9	4
2549	Deregulation of AKTâ€™mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma. Molecular Cancer Research, 2022, 20, 425-433.	1.5	3
2550	Setting up clinical trials for success: Applying preclinical advances in combined TGFÎ²/PDâ€™L1 inhibition to ongoing clinical studies. Molecular Carcinogenesis, 2021, , .	1.3	2
2551	Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer. Cancers, 2021, 13, 5772.	1.7	25
2552	Panâ€™cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Medicine, 2021, , .	1.3	10
2553	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Current Oncology, 2021, 28, 4894-4928.	0.9	0

#	ARTICLE	IF	CITATIONS
2554	Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5889.	1.7	21
2555	Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24113.	0.9	12
2556	Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a Key Immunosuppressive Mechanism in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 984-992.	3.2	4
2557	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists. <i>Cancers</i> , 2021, 13, 5716.	1.7	13
2558	Molecular and Cellular Mechanisms of Perineural Invasion in Oral Squamous Cell Carcinoma: Potential Targets for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 6011.	1.7	7
2559	What's New in Molecular Targeted Therapies for Head and Neck Cancer?. <i>Korean Society for Head and Neck Oncology</i> , 2021, 37, 11-17.	0.1	0
2560	Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. <i>Head and Neck</i> , 2022, 44, 562-571.	0.9	12
2561	Vaccine-Based Immunotherapy for Head and Neck Cancers. <i>Cancers</i> , 2021, 13, 6041.	1.7	16
2562	Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2022, 113, 53-64.	1.7	8
2563	Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, , .	1.2	8
2564	Is There an Interplay between Oral Microbiome, Head and Neck Carcinoma and Radiation-Induced Oral Mucositis?. <i>Cancers</i> , 2021, 13, 5902.	1.7	14
2565	Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5890.	1.7	2
2566	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5733.	1.7	13
2567	Surveillance for Patients with Oral Squamous Cell Carcinoma after Complete Surgical Resection as Primary Treatment: A Single-Center Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 5843.	1.7	7
2568	Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. <i>International Journal of Clinical Oncology</i> , 2021, 27, 95.	1.0	7
2569	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. , 2021, 9, e002996.		24
2570	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. <i>Cell Biology and Toxicology</i> , 2021, , 1.	2.4	5
2571	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2022, 237, 1285-1298.	2.0	20

#	ARTICLE	IF	CITATIONS
2572	Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709865.	1.3	1
2573	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11
2574	Immuno-Oncology 免疫療法の新展開. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaishi</i> , 2021, 11, 1-10.	0.0	0
2575	Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005–2018. <i>Cancers</i> , 2021, 13, 6060.	1.7	7
2576	Pan-Asian adaptation of the EHS—ESMO—ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. <i>ESMO Open</i> , 2021, 6, 100309.	2.0	29
2577	Genome-Wide Copy Number Variation of Circulating Cell-Free DNA As a Biomarker in Head and Neck Cancer Patients Treated With Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2578	A study of 44 cases of recurrent or metastatic head and neck cancer treated with nivolumab. <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 284-289.	0.0	2
2579	Leukoplakia and Squamous Cell Carcinoma. , 2021, , 351-362.		0
2580	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2021, 9, 232470962110584.	0.3	6
2581	Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer. <i>Documenta Ophthalmologica</i> , 2022, 144, 153-162.	1.0	5
2582	PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF- κ B/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 802795.	2.2	14
2583	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	1.9	18
2584	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	2.1	10
2585	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	2.5	38
2586	PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103324.	0.6	8
2587	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. <i>Journal of Surgical Research</i> , 2022, 272, 37-50.	0.8	4
2588	Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2020, 46, 481-488.	0.0	1
2589	The clinical significance of apolipoprotein L1 in head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8

#	ARTICLE	IF	CITATIONS
2590	Prognostic value of immune-related genes in laryngeal squamous cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 6287-6302.	0.4	2
2591	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Aging</i> , 2020, 12, 22509-22526.	1.4	7
2592	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
2593	Tumors: <i>Oto-Rhino-Laryngology</i> . , 2021, , 5279-5291.		0
2594	A case of recurrent metastatic tongue cancer with complete response and drug therapy discontinuation after 2 years of nivolumab administration. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 195-202.	0.0	0
2595	Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. <i>OncoImmunology</i> , 2021, 10, 1997385.	2.1	23
2596	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 683502.	1.3	21
2597	OUP accepted manuscript. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	4
2598	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121527.	2.6	16
2599	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
2600	Recent Advanced in the Treatment of Advanced SCC Tumors. <i>Cancers</i> , 2022, 14, 550.	1.7	1
2601	Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 922-933.	2.2	15
2602	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
2603	Genopathomic Profiling Identifies Signatures for Immunotherapy Response of Lung Cancer Via Confounder-Aware Representation Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2604	Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma. <i>Anticancer Research</i> , 2022, 42, 981-989.	0.5	6
2606	Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression. <i>Frontiers in Immunology</i> , 2021, 12, 798424.	2.2	7
2607	Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy. <i>Clinical and Translational Immunology</i> , 2022, 11, e1363.	1.7	2
2608	Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. <i>OncoImmunology</i> , 2022, 11, 2021619.	2.1	19

#	ARTICLE	IF	CITATIONS
2609	Prediction Model of Distant Metastasis in Oral Cavity Squamous Cell Carcinoma With or Without Regional Lymphatic Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 713815.	1.3	5
2610	Age-specific oncogenic pathways in head and neck squamous cell carcinoma—Are elderly a different subcategory?. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1-18.	2.1	5
2611	Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer. <i>Scientific Reports</i> , 2022, 12, 572.	1.6	13
2613	Immune-related lncRNA classification of head and neck squamous cell carcinoma. <i>Cancer Cell International</i> , 2022, 22, 25.	1.8	8
2614	Development and Validation of a Pathomic Biomarker for Immunotherapy Response via Confounder-Aware Representation Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2615	Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma. <i>PLoS ONE</i> , 2022, 17, e0262549.	1.1	8
2616	Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. <i>Drug Resistance Updates</i> , 2022, 60, 100806.	6.5	41
2617	The Renaissance of Cyclin Dependent Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 293.	1.7	27
2618	Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103569.	2.0	13
2619	Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 796197.	1.3	11
2620	A 25 Gene Panel Predicting the Benefits of Immunotherapy in Head and Neck Squamous Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2621	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
2622	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85
2623	A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 761428.	1.3	4
2624	Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 752025.	1.1	4
2625	Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. <i>Frontiers in Oncology</i> , 2021, 11, 799993.	1.3	28
2626	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1560-1571.	3.2	33
2627	A Case of Acquired Factor V Inhibitor Following Nivolumab Administration. <i>Cureus</i> , 2022, 14, e21670.	0.2	2

#	ARTICLE	IF	CITATIONS
2628	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1335-1344.	3.2	14
2629	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. <i>Frontiers in Oncology</i> , 2022, 12, 730785.	1.3	1
2630	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022, 2, 39-48.	0.7	4
2631	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
2632	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. <i>Genes and Immunity</i> , 2022, 23, 1-11.	2.2	24
2633	Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. <i>Molecular Cancer</i> , 2022, 21, 31.	7.9	42
2634	Which test for crossing survival curves? A userâ€™s guideline. <i>BMC Medical Research Methodology</i> , 2022, 22, 34.	1.4	23
2635	HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 306-327.	12.5	236
2637	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2022, 386, 449-462.	13.9	419
2638	Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
2639	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	2.9	45
2640	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103596.	2.0	76
2641	Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112661.	2.5	11
2642	IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. <i>Translational Oncology</i> , 2022, 18, 101358.	1.7	5
2643	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
2644	Management of elderly patients with head and neck cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 313-321.	0.6	3
2645	m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Cell-Infiltration Characterization in Head and Neck Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 803141.	1.8	4
2646	Neutrophilâ€™toâ€™lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Metaâ€™analysis. <i>Head and Neck</i> , 2022, 44, 1237-1245.	0.9	20

#	ARTICLE	IF	CITATIONS
2647	Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, 2025.	1.6	5
2648	Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas. <i>Cells</i> , 2022, 11, 561.	1.8	18
2649	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
2650	Identification and Validation of a Hypoxia-Immune-Based Prognostic mRNA Signature for Oral Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	3
2651	A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 557-576.	0.5	0
2652	Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer. <i>Acta Oto-Laryngologica</i> , 2022, 142, 206-212.	0.3	2
2653	Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study. <i>Journal of Palliative Care</i> , 2022, , 082585972210783.	0.4	0
2654	Characterization of Two Ferroptosis Subtypes With Distinct Immune Infiltration and Gender Difference in Gastric Cancer. <i>Frontiers in Nutrition</i> , 2021, 8, 756193.	1.6	7
2655	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 7348.	5.8	96
2656	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. <i>Nature Communications</i> , 2021, 12, 7338.	5.8	104
2657	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 ⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
2658	Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 12.	1.1	5
2659	Importance of immune cell infiltration in tumor microenvironment of head and neck cancer. <i>Onkologie (Czech Republic)</i> , 2021, 15, 67-72.	0.0	0
2660	Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy. <i>In Vivo</i> , 2022, 36, 907-917.	0.6	10
2663	Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1345-1352.	3.2	38
2664	Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2022, 44, 1192-1205.	0.9	5
2665	Pyroptosis patterns and immune infiltrates characterization in head and neck squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24292.	0.9	8
2666	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38

#	ARTICLE	IF	CITATIONS
2667	A comprehensive profile of TCF1+ progenitor and TCF1 ^{hi} terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. <i>International Journal of Oral Science</i> , 2022, 14, 8.	3.6	18
2668	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842220.	1.8	8
2669	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. <i>Cancers</i> , 2022, 14, 955.	1.7	9
2670	Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer. <i>Auris Nasus Larynx</i> , 2022, , .	0.5	1
2671	Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1101.	1.0	9
2672	Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1607-1613.	0.5	1
2673	PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. <i>Anticancer Research</i> , 2022, 42, 1547-1554.	0.5	13
2674	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. <i>Future Oncology</i> , 2022, 18, 1669-1678.	1.1	15
2675	Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Auris Nasus Larynx</i> , 2022, 49, 834-844.	0.5	5
2676	First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. <i>World Journal of Clinical Oncology</i> , 2022, 13, 147-158.	0.9	2
2677	Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. , 2022, 10, e004346.		15
2678	ISA101 and nivolumab for HPV-16 ⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
2680	Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 254-267.	1.3	4
2681	Molecular drivers of oral cavity squamous cell carcinoma in non-smoking and non-drinking patients: what do we know so far?. <i>Oncology Reviews</i> , 2022, 16, 549.	0.8	5
2682	Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 781348.	1.3	6
2683	Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 467-474.	0.4	5
2684	Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): a prospective, randomized, controlled clinical trial. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 4505-4514.	0.8	1
2685	Harnessing radiotherapy-induced NK-cell activity by combining DNA damage response inhibition and immune checkpoint blockade. , 2022, 10, e004306.		36

#	ARTICLE	IF	CITATIONS
2686	Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2022, , 1.	1.2	15
2687	Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
2688	Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study. <i>Biomedicines</i> , 2022, 10, 710.	1.4	1
2689	Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2094-2109.	3.2	60
2690	Strategies for Manipulating T Cells in Cancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
2691	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	2.2	13
2692	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
2693	Disproportional enrichment of FoxP3 ⁺ CD4 ⁺ regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e753.	1.7	2
2694	Viral and Clinical Oncology of Head and Neck Cancers. <i>Current Oncology Reports</i> , 2022, 24, 929-942.	1.8	8
2695	Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 794251.	2.2	16
2697	Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review. <i>Journal of Neuro-Oncology</i> , 2022, 157, 271-276.	1.4	6
2698	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1157-1166.	3.2	16
2699	FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment. <i>PLoS ONE</i> , 2022, 17, e0263895.	1.1	1
2700	Precision drugging of the MAPK pathway in head and neck cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 20.	1.7	22
2701	Impact of miR-1/miR-133 Clustered miRNAs: PFN2 Facilitates Malignant Phenotypes in Head and Neck Squamous Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 663.	1.4	4
2702	A Case in which Mycophenolate Mofetil Administration Was Effective against Steroid-Refractory Liver Dysfunction Arising as a Nivolumab-Induced Immune-Related Adverse Event. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho</i> , 2022, 125, 285-290.	0.0	0
2703	Continuous particle separation of microfluidic chip with integrated inertial separation and dielectrophoresis separation. <i>AIP Advances</i> , 2022, 12, .	0.6	2
2704	EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 813732.	2.2	9

#	ARTICLE	IF	CITATIONS
2706	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
2707	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
2708	Preoperative immunotherapy for head and neck cancers: state of art. <i>Current Opinion in Oncology</i> , 2022, 34, 185-195.	1.1	10
2709	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	2.7	18
2710	The Predictive Individual Effect for Survival Data. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 492-500.	0.8	1
2711	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2
2712	Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients. <i>Cancer Medicine</i> , 2022, 11, 4104-4111.	1.3	11
2713	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
2714	Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hypopharynx, Larynx, Trachea and Parapharyngeal Space. <i>Head and Neck Pathology</i> , 2022, 16, 31-39.	1.3	13
2715	Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3043-3053.	0.8	4
2716	PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. <i>Discover Oncology</i> , 2022, 13, 19.	0.8	14
2717	Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma. <i>Ear, Nose and Throat Journal</i> , 2022, , 014556132210819.	0.4	3
2718	Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2329-2338.	3.2	31
2719	Treatment for Locoregionally Recurrent Head and Neck Cancers. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2022, 65, 133-142.	0.0	0
2720	Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory. <i>Anti-Cancer Drugs</i> , 2022, Publish Ahead of Print, .	0.7	1
2721	Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. <i>Cancer Biology and Therapy</i> , 2022, 23, 309-317.	1.5	3
2722	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	0.8	79
2723	Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2022, Publish Ahead of Print, .	1.1	0

#	ARTICLE	IF	CITATIONS
2724	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
2725	Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
2726	An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 800315.	1.3	2
2727	Use of Fluoro- ¹⁸ F-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 268.	1.2	3
2728	Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 837547.	1.3	5
2729	Prognosis and Characterization of Immune Microenvironment in Head and Neck Squamous Cell Carcinoma through a Pyroptosis-Related Signature. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	3
2730	In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4077.	1.8	4
2731	Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 127, 105772.	0.8	7
2732	Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. <i>Oral Oncology</i> , 2022, 127, 105787.	0.8	10
2733	Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma. , 2022, 000, 000-000.		0
2734	Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , 1.	0.2	0
2735	Impact of HPV status on immune responses in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 127, 105774.	0.8	11
2736	PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. <i>Apmis</i> , 2022, 130, 295-313.	0.9	10
2737	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
2738	Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 123.	3.5	10
2739	¹⁸ F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2022, 51, 13.	0.9	1
2740	Predictive biomarkers for the efficacy of nivolumab as 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. <i>BMC Cancer</i> , 2022, 22, 378.	1.1	16
2741	Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers. <i>Cancer Treatment Reviews</i> , 2022, 105, 102361.	3.4	12

#	ARTICLE	IF	CITATIONS
2742	Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation. <i>International Journal of Oral Science</i> , 2022, 14, 18.	3.6	3
2743	Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2022, 17, 213-222.	1.5	2
2744	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 406-416.e11.	2.3	31
2745	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
2746	Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13087.	1.8	6
2747	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021, 13, eabf8495.	5.8	16
2748	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 794099.	2.2	34
2749	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
2750	The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. <i>Cancer Biomarkers</i> , 2022, 34, 189-199.	0.8	4
2751	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
2752	Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2022, 61, 225-238.	1.3	9
2753	Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 744304.	1.1	9
2754	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	1.1	5
2755	DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon- γ Signature, Signatures of Immune Infiltrates, and Survival. <i>Journal of Immunotherapy</i> , 2022, 45, 194-206.	1.2	6
2756	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, .	0.5	3
2758	Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience. <i>South Asian Journal of Cancer</i> , 2022, 11, 058-061.	0.2	1
2759	Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 915-927.	3.2	19
2760	Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. <i>Cancers</i> , 2021, 13, 6309.	1.7	10

#	ARTICLE	IF	CITATIONS
2761	Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. , 2021, , .		0
2762	[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2010-2022.	3.3	11
2763	Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 776979.	1.3	2
2764	Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 803410.	2.2	25
2765	Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report. <i>BMC Infectious Diseases</i> , 2022, 22, 306.	1.3	3
2766	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10
2767	A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients. <i>OncImmunology</i> , 2022, 11, 2059878.	2.1	3
2768	Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. <i>Molecular Carcinogenesis</i> , 2022, 61, 664-676.	1.3	3
2769	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	25
2770	Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. , 2022, 10, e004601.		8
2771	Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma. <i>Molecular Oncology</i> , 2022, 16, 3001-3016.	2.1	7
2772	Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer. <i>Cells</i> , 2022, 11, 1370.	1.8	15
2773	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
2774	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
2775	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. <i>Uro</i> , 2022, 2, 74-92.	0.3	3
2776	Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 793403.	1.6	4
2777	Cells to Surgery Quiz: April 2022. <i>Journal of Investigative Dermatology</i> , 2022, 142, e51-e57.	0.3	0
2778	A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. <i>Oral Oncology</i> , 2022, 128, 105860.	0.8	4

#	ARTICLE	IF	CITATIONS
2779	Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma. <i>Cancer Letters</i> , 2022, 537, 215690.	3.2	11
2780	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. <i>International Immunopharmacology</i> , 2022, 108, 108775.	1.7	4
2781	Therapeutic approaches for the treatment of head and neck squamous cell carcinoma—An update on clinical trials. <i>Translational Oncology</i> , 2022, 21, 101426.	1.7	33
2890	A variety of “exhausted” T cells in the tumor microenvironment. <i>International Immunology</i> , 2022, 34, 563-570.	1.8	13
2895	In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer. <i>Methods in Molecular Biology</i> , 2022, 2451, 151-162.	0.4	1
2896	Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 527-540.	1.8	9
2897	Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta-analysis. <i>Oral Diseases</i> , 2023, 29, 1905-1919.	1.5	2
2898	Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 868490.	1.3	0
2899	Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 511-526.	1.8	9
2900	Effectiveness of Pembrolizumab in Patients with HNSCC in Japanese Real-World Clinical Practice. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 78-79.	0.0	0
2901	Clinical Use and Future Prospects of Immune Checkpoint Inhibitors in Head and Neck Carcinoma. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 80-82.	0.0	0
2902	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF β 2RII agent: Current status. <i>Experimental Biology and Medicine</i> , 2022, 247, 1124-1134.	1.1	7
2903	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
2904	Clinical significance of panendoscopy in initial staging of oral squamous cell carcinoma and detection of synchronous second malignancies of the upper aerodigestive tract—Insights from a retrospective population-based cohort study. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2022, , .	0.7	1
2905	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
2906	Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa. <i>Cancers</i> , 2022, 14, 2351.	1.7	0
2907	Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies (Review). <i>Oncology Letters</i> , 2022, 23, 196.	0.8	4
2908	Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 848841.	1.1	5

#	ARTICLE	IF	CITATIONS
2909	Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 687-692.	0.6	3
2910	EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 2407.	1.7	1
2911	Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 757-765.	0.6	3
2912	Evaluation of Safety of Treatment With Anti-EPidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2022, 8, 1042.	3.4	15
2913	Pseudoprogression during Immunotherapy in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Radiology Imaging Cancer</i> , 2022, 4, e220037.	0.7	0
2914	The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 236, 153934.	1.0	9
2915	Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis. <i>Oral Oncology</i> , 2022, 129, 105871.	0.8	1
2916	A Bit More Here and a Little Less There: The Trials (and Tribulations) of Adjuvant and Neoadjuvant Head and Neck Studies in 2021. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 243-251.	0.4	0
2917	CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis. <i>Current Research in Translational Medicine</i> , 2022, 70, 103345.	1.2	3
2918	Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN. <i>Cancers</i> , 2022, 14, 2431.	1.7	4
2919	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
2920	Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2022, 51, 21.	0.9	1
2921	Development of a LAG-3 immunohistochemistry assay for melanoma. <i>Journal of Clinical Pathology</i> , 2023, 76, 591-598.	1.0	5
2922	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. <i>Cancer Immunology Research</i> , 2022, 10, 885-899.	1.6	7
2924	Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. <i>Journal of Dermatology</i> , 2022, 49, 862-871.	0.6	6
2925	Construction and validation of immune-related lncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
2926	Mast cell marker gene signature in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	14
2927	The impact of ALDH7A1 variants in oral cancer development and prognosis. <i>Aging</i> , 2022, 14, 4556-4571.	1.4	5

#	ARTICLE	IF	CITATIONS
2928	Bleeding complications and possible resistance patterns of anti-angiogenesis treatments in recurrent/metastatic head-and-neck squamous cell carcinoma – Reflections from a phase II study of pazopanib in recurrent/metastatic head-and-neck squamous cell carcinoma. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 52.	0.2	1
2929	EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC. <i>NAR Cancer</i> , 2022, 4, .	1.6	5
2930	PET-CT in Clinical Adult Oncology – V. Head and Neck and Neuro Oncology. <i>Cancers</i> , 2022, 14, 2726.	1.7	6
2931	Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2499.	1.7	2
2932	Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	14
2933	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
2934	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2935	Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. <i>PLoS ONE</i> , 2022, 17, e0269136.	1.1	6
2936	Immunotherapy for Squamous Esophageal Cancer: A Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 862.	1.1	10
2937	Multomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	2
2938	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2939	Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. <i>World Journal of Clinical Oncology</i> , 2022, 13, 388-411.	0.9	13
2940	Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
2941	Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 662.	1.2	2
2942	Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. <i>Biosensors and Bioelectronics</i> , 2022, 213, 114445.	5.3	14
2943	Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 3464-3472.	3.2	8
2944	Prognostic and clinicopathological significance of cytocapsular tubes in oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2022, 51, 520-528.	1.4	2
2945	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	7

#	ARTICLE	IF	CITATIONS
2946	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
2947	Cancer germline antigen gene MAGEB2 promotes cell invasion and correlates with immune microenvironment and immunotherapeutic efficiency in laryngeal cancer. <i>Clinical Immunology</i> , 2022, 240, 109045.	1.4	9
2948	Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study. <i>Oral Oncology</i> , 2022, 130, 105932.	0.8	4
2949	Head and neck cancers. , 2023, , 376-382.		0
2950	Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years. <i>In Vivo</i> , 2022, 36, 1881-1886.	0.6	3
2951	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
2952	A Case of Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. <i>Internal Medicine</i> , 2022, , .	0.3	5
2953	Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 0, , .	0.7	0
2954	Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?. <i>Current Opinion in Oncology</i> , 2022, 34, 196-203.	1.1	3
2955	<i>CD3D</i>: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma. <i>Bioengineered</i> , 2022, 13, 13784-13800.	1.4	4
2956	T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. , 2022, 10, e004512.		14
2957	Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. <i>Cancers</i> , 2022, 14, 2810.	1.7	6
2958	Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st—2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	3
2959	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
2960	Role of Adenoviruses in Cancer Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2961	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st—2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
2962	Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1890-1902.	1.2	3
2963	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	3

#	ARTICLE	IF	CITATIONS
2964	Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6473.	1.8	2
2965	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
2966	Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2022, 14, 2826.	1.7	2
2967	EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	9
2968	Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	16
2969	A Case of Complete Remission of Nasal Cavity Poorly Differentiated Carcinoma With Targeted Therapy, to Which Surgery and Concurrent Chemoradiotherapy Was Ineffective. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2023, 66, 192-197.	0.0	0
2970	Durable complete response rates following radiotherapy and immunotherapy combination in recurrent and metastatic head and neck squamous cell carcinoma: A retrospective single-centre cohort study. <i>Clinical Otolaryngology</i> , 2022, 47, 606-610.	0.6	1
2971	Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	18
2972	Preoperative prediction model to evaluate salvage surgery in patients with recurrent or second primary oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 131, 105951.	0.8	5
2973	Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. <i>Translational Oncology</i> , 2022, 23, 101469.	1.7	6
2974	Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3268-3276.	3.2	24
2975	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
2976	A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
2977	Updates in the Management of Recurrent Glioblastoma Multiforme. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2023, 84, 174-187.	0.4	3
2978	A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2979	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. <i>JCO Precision Oncology</i> , 2022, , .	1.5	19
2980	Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2023, 50, 641-645.	0.5	7
2981	Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. <i>Journal of Medical Economics</i> , 2022, 25, 954-965.	1.0	4

#	ARTICLE	IF	CITATIONS
2982	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
2983	Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
2984	Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e417-e427.	2.0	11
2985	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
2986	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
2988	Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. <i>Modern Pathology</i> , 2022, 35, 1529-1539.	2.9	14
2989	Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2990	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. <i>Oncologist</i> , 2022, 27, 778-789.	1.9	2
2991	Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2992	SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study. <i>Anticancer Research</i> , 2022, 42, 3361-3372.	0.5	1
2993	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
2994	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
2995	A signature of immune-related gene pairs (IRGPs) for risk stratification and prognosis of oral cancer patients. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	0
2996	Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7889.	1.8	18
2997	Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3476.	1.7	9
2998	Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122034.	2.6	6
2999	Oligometastasis in head and neck squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	2
3000	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5

#	ARTICLE	IF	CITATIONS
3001	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
3002	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). <i>ESMO Open</i> , 2022, 7, 100529.	2.0	23
3003	Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study. <i>Oral Oncology</i> , 2022, 132, 106018.	0.8	6
3004	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). <i>Neoplasia</i> , 2022, 31, 100813.	2.3	14
3005	Berberine inhibited the formation of metastasis by intervening the secondary homing of colorectal cancer cells in the blood circulation to the lung and liver through HEY2. <i>Phytomedicine</i> , 2022, 104, 154303.	2.3	4
3006	A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2022, 110, 108846.	1.7	4
3007	Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?. <i>Oral Oncology</i> , 2022, 132, 105997.	0.8	0
3008	Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 442-450.	1.2	2
3009	Observation of dynamic changes in neutrophil-to-lymphocyte ratio is useful for evaluating treatment response to nivolumab in PD-L1-negative advanced oral cancer. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022, , .	0.2	1
3010	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
3011	Interferon- β predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
3012	Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0272080.	1.1	2
3013	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
3014	Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. <i>Cancer Research Communications</i> , 2022, 2, 806-813.	0.7	7
3015	Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. <i>Nature Communications</i> , 2022, 13, .	5.8	43
3016	Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 641-651.	0.9	2
3017	Diversity of the Origin of Cancer Stem Cells in Oral Squamous Cell Carcinoma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 3588.	1.7	7
3018	Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.7	1

#	ARTICLE	IF	CITATIONS
3019	Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	9
3020	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	1.0	1
3021	PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 0, , .	0.8	0
3022	Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. <i>Cancer Medicine</i> , 2023, 12, 3201-3221.	1.3	6
3023	8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
3024	Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review. <i>Medicina (Lithuania)</i> , 2022, 58, 1000.	0.8	7
3025	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials. <i>JAMA Oncology</i> , 2022, 8, 1294.	3.4	12
3026	Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. <i>PLoS ONE</i> , 2022, 17, e0271907.	1.1	5
3028	Mechanisms of immune evasion by head and neck cancer stem cells. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	4
3029	Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8530.	1.8	11
3030	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
3032	Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	10
3033	Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
3034	An <i>In Vivo</i> Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line. <i>Anticancer Research</i> , 2022, 42, 4293-4303.	0.5	0
3035	Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. <i>Anticancer Research</i> , 2022, 42, 4477-4484.	0.5	8
3036	Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. <i>Acta Oncologica</i> , 2022, 61, 972-978.	0.8	1
3037	Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 935.	1.2	1
3038	Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor. <i>Anticancer Research</i> , 2022, 42, 4273-4283.	0.5	1

#	ARTICLE	IF	CITATIONS
3039	TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
3040	Live Biotherapeutic <i>Lactococcus lactis</i> GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. <i>Cancers</i> , 2022, 14, 4083.	1.7	7
3041	Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. <i>European Journal of Cancer</i> , 2022, 174, 287-298.	1.3	14
3042	Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study. <i>Head and Neck</i> , 2022, 44, 2040-2045.	0.9	3
3043	Current perspectives on recurrent HPV-mediated oropharyngeal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
3044	Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2022, 5, e2226252.	2.8	10
3045	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3046	T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8590.	1.8	12
3047	Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis. <i>Targeted Oncology</i> , 2022, 17, 507-515.	1.7	1
3048	Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. <i>Investigational New Drugs</i> , 2022, 40, 1282-1289.	1.2	7
3049	Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 1990.	1.4	2
3050	Neoadjuvant immunotherapy of locoregionally advanced solid tumors. , 2022, 10, e005036.		9
3051	Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. , 2022, 10, e005147.		24
3052	Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2022, 127, 1497-1506.	2.9	3
3053	Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
3054	Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 918.	1.2	4
3055	Computational design of PD-L1 small molecule inhibitors for cancer therapy. <i>Molecular Diversity</i> , 2023, 27, 1633-1644.	2.1	7
3056	Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Revista Espanola De Patologia</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
3057	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114505.	6.6	15
3058	Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer. <i>Head and Neck</i> , 2022, 44, 2555-2563.	0.9	4
3059	Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9195.	1.8	5
3060	Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects. <i>Vaccines</i> , 2022, 10, 1272.	2.1	2
3061	Head Neck Squamous Cell Cancer Genomics: Oncogenes, Tumor Suppressor Genes and Clinical Implications. , 0, , .		0
3062	Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. <i>Head and Neck</i> , 0, , .	0.9	2
3063	Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. , 2022, 10, e004752.		15
3064	POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3065	The microbiota and radiotherapy for head and neck cancer: What should clinical oncologists know?. <i>Cancer Treatment Reviews</i> , 2022, 109, 102442.	3.4	8
3066	Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 134, 106086.	0.8	0
3067	Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4293-4306.	3.3	10
3068	Mortality during In-Hospital Treatment for Head and Neck Cancer in Germany: A Diagnosis-Related Group-Based Nationwide Analysis, 2005-2018. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	1
3069	Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 407-415.	1.0	1
3070	Current Trends in Anticancer Drug Delivery System for Oral Cancer- A PRISMA complaint Systematic Review. <i>Open Dentistry Journal</i> , 2022, 16, .	0.2	0
3071	The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. <i>Cells</i> , 2022, 11, 2866.	1.8	4
3072	Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. <i>Cancers</i> , 2022, 14, 4413.	1.7	7
3073	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. <i>ESMO Open</i> , 2022, 7, 100577.	2.0	11
3074	Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. <i>Immunotherapy</i> , 2022, 14, 1121-1131.	1.0	1

#	ARTICLE	IF	CITATIONS
3075	The CC ligand chemokine family members CCL17/CCL22 predict the survival and response to immune checkpoint blockade therapy of patients with head and neck squamous cell carcinoma. <i>Current Problems in Cancer</i> , 2022, 46, 100896.	1.0	1
3076	Prognostic signature related to the immune environment of oral squamous cell carcinoma. <i>Open Life Sciences</i> , 2022, 17, 1135-1147.	0.6	0
3077	Phase separation in Cancer: From the Impacts and Mechanisms to Treatment potentials. <i>International Journal of Biological Sciences</i> , 2022, 18, 5103-5122.	2.6	18
3078	Novel Multidisciplinary Paradigms: Surgery/Radiation, Immunotherapy, Organ Preservation. , 2022, , 13-23.		0
3079	Effects of Nivolumab for the Head and Neck Carcinoma Patients. <i>Practica Otologica</i> , 2022, 115, 875-881.	0.0	0
3080	Oxidative Stress Player in Head and Neck Cancer Therapy Response. , 2022, , .		0
3081	Available immunotherapies and future opportunities to prevent HPV-associated cancers. , 2022, , 165-204.		0
3082	Radiotherapy and Immunotherapy for Head and Neck Cancer. , 2022, , 91-113.		0
3083	Epidemiology and Genomics of Head and Neck Squamous Cell Carcinoma. , 2022, , 115-128.		0
3084	Biomarkers in Head and Neck Cancer. , 2022, , 129-151.		0
3085	Systemic Therapy Advances in Head and Neck Cancer. , 2022, , 61-72.		0
3086	MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3087	Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
3088	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 0, , 1-12.	1.0	1
3089	Relationships among microbiota, gastric cancer, and immunotherapy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
3090	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. <i>Aging</i> , 2022, 14, 7824-7850.	1.4	1
3091	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
3092	New Therapeutic Strategies in the Treatment of Stomal Recurrence After Total Laryngectomy: Role of Immunotherapy. <i>Ear, Nose and Throat Journal</i> , 0, , 014556132211212.	0.4	2

#	ARTICLE	IF	CITATIONS
3093	PI3K Inhibition for Squamous Cell Head and Neck Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 369-376.	1.0	0
3094	Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. <i>Clinical Cancer Research</i> , 2022, 28, 4968-4982.	3.2	16
3096	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. <i>PLoS ONE</i> , 2022, 17, e0274451.	1.1	1
3097	Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101380.	0.5	1
3098	Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 4472.	1.7	1
3099	Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 354-362.	1.0	5
3100	Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 5171.	1.0	2
3101	Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	7
3102	Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4 ⁺ and CD8 ⁺ T cells for immunotherapy of cancer. , 2022, 10, e004709.		7
3103	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. <i>Cells</i> , 2022, 11, 3028.	1.8	7
3104	A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	26
3105	Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3
3106	CD8 ⁺ and FoxP3 ⁺ Cell Cellular Density and Spatial Distribution After Programmed Death-1 Check Point Inhibition. <i>Laryngoscope</i> , 0, , .	1.1	3
3107	A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis. <i>Journal of Thoracic Disease</i> , 2022, 14, 3211-3220.	0.6	0
3108	Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3109	In vitro models as tools for screening treatment options of head and neck cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
3110	Aurora Kinases as Therapeutic Targets in Head and Neck Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 387-400.	1.0	2
3111	STING Agonists in Head and Neck Squamous Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 401-406.	1.0	4

#	ARTICLE	IF	CITATIONS
3112	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3113	Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors. <i>Biomedicines</i> , 2022, 10, 2205.	1.4	5
3114	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3115	Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	3
3116	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
3117	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	2
3118	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
3119	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
3120	Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211268.	0.4	2
3121	The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	24
3122	Head and neck surgical oncology. <i>Journal of Surgical Oncology</i> , 2022, 126, 860-864.	0.8	1
3123	The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 377-380.	1.0	2
3124	éééf¨ç™(Eæ²»ç™,ã®æœ€â%œ.š. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho</i> , 2022, 125, 1409-1413.	0.0	0
3125	Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. <i>Cell Reports Medicine</i> , 2022, 3, 100659.	3.3	9
3126	A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). <i>Ecanermedalscience</i> , 0, 16, .	0.6	0
3127	The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4694.	1.7	5
3128	Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	2
3129	Immunotherapy in Head and Neck Cancer When, How, and Why?. <i>Biomedicines</i> , 2022, 10, 2151.	1.4	6

#	ARTICLE	IF	CITATIONS
3130	Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 177, 175-185.	1.3	106
3131	Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 4605-4615.	1.3	12
3134	Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 4907-4912.	0.5	2
3135	Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1. <i>AAPS Journal</i> , 2022, 24, .	2.2	1
3136	Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. <i>Molecular Cell</i> , 2022, 82, 3901-3918.e7.	4.5	19
3137	Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. <i>Cancer Letters</i> , 2022, 550, 215937.	3.2	6
3138	Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer. , 2022, , .		0
3139	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Cancer Control</i> , 2022, 29, 107327482211305.	0.7	4
3140	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
3141	Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. , 2022, , .		0
3142	Immunotherapy in head and neck squamous cell carcinoma: An updated review. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100649.	0.7	11
3143	Clinical Application of Immunotherapy in the Perioperative Management of Head and Neck Cancer. , 2022, , .		0
3144	The Role of Immune Checkpoint Inhibitors in the Treatment of Less Common Head and Neck Cancers. , 2022, , .		0
3145	Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 4811.	1.7	1
3146	Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. , 2022, 10, e005158.		7
3147	Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). <i>Kreativna Hirurgija I Onkologija</i> , 2022, 12, 205-216.	0.1	0
3148	How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. <i>Biomedicines</i> , 2022, 10, 2498.	1.4	6
3149	EBV-associated diseases: Current therapeutics and emerging technologies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15

#	ARTICLE	IF	CITATIONS
3150	Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3151	Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. <i>Siberian Journal of Oncology</i> , 2022, 21, 135-141.	0.1	0
3152	Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
3153	Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	3
3154	Influence of chemoradiation on the immune microenvironment of cervical cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 121-130.	1.0	7
3155	Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 222-232.	0.8	58
3156	Nectin-4 is widely expressed in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2022, 13, 1166-1173.	0.8	6
3157	Targeting tumour-intrinsic N ⁷ -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy. <i>Gut</i> , 2023, 72, 1555-1567.	6.1	22
3158	The Role of Immune Checkpoint Inhibitors in Pharyngolaryngeal Cancer: A Current Review. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 318-324.	0.0	0
3159	Salivary Exosomal MicroRNA-486-5p and MicroRNA-10b-5p in Oral and Oropharyngeal Squamous Cell Carcinoma. <i>Medicina (Lithuania)</i> , 2022, 58, 1478.	0.8	15
3160	Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3161	Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3162	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	1.7	5
3163	Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 847-860.	0.4	2
3165	<sc>7</sc> Epitaxol induces apoptosis in cisplatin-resistant head and neck squamous cell carcinoma via suppression of <sc>AKT</sc> and <sc>MAPK</sc> signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5807-5819.	1.6	6
3166	Immune-related gene <i>TM4SF18</i> could promote the metastasis of gastric cancer cells and predict the prognosis of gastric cancer patients. <i>Molecular Oncology</i> , 2022, 16, 4043-4059.	2.1	4
3168	Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	4
3169	Bifunctional anti-PD-L1/TGF- β 2RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. <i>BMC Medicine</i> , 2022, 20, .	2.3	16

#	ARTICLE	IF	CITATIONS
3172	Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. <i>Pharmacogenomics</i> , 2022, 23, 887-901.	0.6	5
3173	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
3174	CT radiomics nomogram for prediction of the Ki-67 index in head and neck squamous cell carcinoma. <i>European Radiology</i> , 2023, 33, 2160-2170.	2.3	8
3175	Impaired intratumoral natural killer cell function in head and neck carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
3176	<scp>MAPK</scp> inhibition augments the Tâ€cell response against <scp> <i>HOXB7</i> </scp> â€expressing tumor through <scp>HLA</scp> upregulation. <i>Cancer Science</i> , 0, , .	1.7	3
3177	Hypercalcemia. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1624.	3.8	36
3178	Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 790-802.	0.8	82
3179	Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
3180	First-line pembrolizumabâ€%Â±â€%chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1805-1817.	1.0	5
3181	Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2022, 14, 5285.	1.7	2
3182	Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3183	Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. <i>Annals of Oncology</i> , 2023, 34, 101-110.	0.6	39
3184	Consensuses, controversies, and future directions in treatment deintensification for human papillomavirusâ€associated oropharyngeal cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 164-197.	157.7	16
3185	Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
3186	Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 170-172.	0.8	8
3187	Regulation of epigenetic modifications in the head and neck tumour microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3188	The role of regenerative invariant NKT cells in cancer immunotherapy for head and neck cancer. <i>Personalized Medicine Universe</i> , 2022, 11, 14-19.	0.1	1
3189	Selection of a <scp>PD</scp> â€1 blocking antibody from a novel fully human phage display library. <i>Protein Science</i> , 2022, 31, .	3.1	7

#	ARTICLE	IF	CITATIONS
3190	<scp>SOD2</scp> confers anlotinib resistance via regulation of mitochondrial damage in <scp>OSCC</scp>. Oral Diseases, 0, , .	1.5	3
3191	<scp>GPRASP1</scp> is a candidate anti-oncogene and correlates with immune microenvironment and immunotherapeutic efficiency in head and neck cancer. Journal of Oral Pathology and Medicine, 2023, 52, 232-244.	1.4	2
3192	Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. IScience, 2022, 25, 105382.	1.9	0
3193	The application of salvage surgery improves the quality of life and overall survival of extensively recurrent head and neck cancer after multiple operation plus radiotherapy. Frontiers in Oncology, 0, 12, .	1.3	0
3194	Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India. Ecancermedicalsecience, 0, 16, .	0.6	3
3195	The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	8
3196	A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2022, 135, 106219.	0.8	5
3197	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
3198	A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research, 2023, 281, 289-298.	0.8	3
3199	Peri-tumoral infiltrate in OSCC: "The simpler, the better" temptation. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2023, 44, 103666.	0.6	0
3200	Adjunctive PD-1 inhibitor <i>versus</i> standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211374.	1.4	0
3201	Myeloid checkpoints for cancer immunotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 460-482.	0.7	7
3202	Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis. Apoptosis: an International Journal on Programmed Cell Death, 2023, 28, 348-361.	2.2	5
3203	Clinical significance of interstitial lung abnormalities and immune checkpoint <scp>inhibitor-induced</scp> interstitial lung disease in patients with <scp>non-small</scp> cell lung cancer. Thoracic Cancer, 2023, 14, 73-80.	0.8	3
3204	Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	6
3205	Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 5511.	1.7	1
3206	A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. Surgical Case Reports, 2022, 8, .	0.2	0
3207	Outcomes of organ preservation treatment in advanced laryngeal carcinoma: A retrospective analysis from a single institution. Molecular and Clinical Oncology, 2022, 18, .	0.4	1

#	ARTICLE	IF	CITATIONS
3208	Identification of a novel prognostic ADME-related signature associated with tumor immunity for aiding therapy in head and neck squamous cell carcinoma. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0
3209	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3210	Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3211	Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. <i>Clinical Radiology</i> , 2022, , .	0.5	0
3212	Self-â€Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	5
3213	Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1659-1666.	1.2	3
3214	Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2022, 35, 439-450.	0.8	5
3215	The efficacy of <scp>PD</scp> â€1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study. <i>Laryngoscope Investigative Otolaryngology</i> , 0, , .	0.6	1
3216	Challenges in neoantigen-directed therapeutics. <i>Cancer Cell</i> , 2023, 41, 15-40.	7.7	27
3217	Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. <i>Current Problems in Cancer Case Reports</i> , 2022, 8, 100202.	0.1	0
3218	Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. <i>Cancers</i> , 2022, 14, 5662.	1.7	8
3219	Somatic 9p24.1 alterations in HPV ^{â€“} head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
3220	Tumoren im Kopf-Hals-Bereich. , 2023, , 585-626.		0
3221	Oropharyngeal and Hypopharyngeal Tumours and Their Treatment. , 2022, , 147-167.		0
3222	Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis. <i>In Vivo</i> , 2022, 36, 2840-2843.	0.6	1
3223	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
3224	A case of Trousseau syndrome caused by tongue cancer with lung metastases during pharmacotherapy in an adolescent and young adult patient. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2022, 68, 362-369.	0.0	0
3225	Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3

#	ARTICLE	IF	CITATIONS
3226	Differential Immunomodulatory Effects of Head and Neck Cancer-Derived Exosomes on B Cells in the Presence of ATP. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14446.	1.8	1
3227	Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat. <i>Head and Neck</i> , 2023, 45, 391-397.	0.9	4
3228	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
3229	Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3230	A CT-Based Deep Learning Radiomics Nomogram to Predict Histological Grades of Head and Neck Squamous Cell Carcinoma. <i>Academic Radiology</i> , 2023, 30, 1591-1599.	1.3	4
3231	Harnessing immunomodulation during DNA damage in Ewing sarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3232	Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An Analysis from an endemic tertiary center. <i>Cancer Medicine</i> , 2023, 12, 6802-6810.	1.3	1
3233	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5727.	1.7	9
3234	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
3235	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. <i>Cancers</i> , 2022, 14, 5689.	1.7	0
3236	Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. <i>Cancer Management and Research</i> , 0, Volume 14, 3293-3302.	0.9	2
3238	Efficacy and Synergy with Cisplatin of an Adenovirus Vected Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice. <i>Cancer Immunology Research</i> , 2023, 11, 261-275.	1.6	5
3239	Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 1132-1146.	0.8	17
3240	Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3242	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
3243	Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15835.	1.8	0
3244	Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2023, 23, 173-188.	12.8	37
3245	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15384.	1.8	12

#	ARTICLE	IF	CITATIONS
3246	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
3247	Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
3248	Kopf-Hals-Tumoren: Checkpoint-Inhibitor verlÄngert Äberleben bei erhaltener LebensqualitÄt. , 0, , .		0
3249	The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients. <i>Cancer Medicine</i> , 2023, 12, 7699-7712.	1.3	7
3250	A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHolangiocarcinoma (NATCHO). <i>BMC Cancer</i> , 2022, 22, .	1.1	1
3251	Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender. <i>Opuholi Golovy I Sei</i> , 2022, 12, 114-126.	0.1	0
3252	A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	16
3253	Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 5751-5761.	0.5	0
3255	Suppression of PDÄ€L1 release from small extracellular vesicles promotes systemic antiÄ€tumor immunity by targeting ORAI1 calcium channels. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	7
3256	Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 7259.	1.0	3
3257	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
3258	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. <i>JAMA Oncology</i> , 2023, 9, 102.	3.4	11
3259	Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma. <i>Oral Diseases</i> , 0, , .	1.5	2
3260	Immune-based combination therapy for esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3261	Safety and preliminary activity of pembrolizumabÄ€carboplatinÄ€paclitaxel in heavily pretreated and/or fragile patients with PDL1Ä€positive recurrent/metastatic head and neck cancer. <i>Oncology Letters</i> , 2022, 25, .	0.8	0
3262	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. <i>British Journal of Cancer</i> , 2023, 128, 1196-1207.	2.9	28
3263	Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
3264	Establishment of a diverse head and neck squamous cancer cell bank using conditional reprogramming culture methods. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6

#	ARTICLE	IF	CITATIONS
3265	Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1505-1521.	2.0	6
3266	TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 3236.	1.4	3
3267	Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 560-570.	3.2	11
3268	Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. <i>Journal of Clinical Oncology</i> , 2023, 41, 2166-2180.	0.8	32
3269	Establishment and validation of a redox-related long non-coding RNAs prognostic signature in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3270	T-cell repertoire diversity: friend or foe for protective antitumor response?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	11
3271	Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 2453-2461.	0.8	3
3272	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
3273	A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
3275	Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. <i>Drugs</i> , 2023, 83, 217-248.	4.9	22
3276	Targeted therapy for head and neck cancer: signaling pathways and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
3277	CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus-Driven Oropharyngeal Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 306-319.	1.6	4
3278	Anti-PD-1-induced type 1 diabetes mellitus in patient with recurrent oropharyngeal squamous cell cancer. <i>Medical Alphabet</i> , 2023, , 28-34.	0.0	0
3279	Salivary and serum neopterin and interleukin 6 as biomarkers in patients with oral and oropharyngeal squamous cell carcinoma. <i>Pteridines</i> , 2022, 33, 78-86.	0.5	0
3280	Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	7
3281	A Collaborative Approach for the Development of a Standardized Set of Patient-Centered Outcomes in Head and Neck Cancers. <i>Acta Medica Portuguesa</i> , 2023, 36, 475-486.	0.2	1
3282	Spatial PD-L1, immune cell microenvironment, and genomic copy number alteration patterns and drivers of invasive disease transition in prospective oral precancer cohort. <i>Cancer</i> , 2023, 129, 714-727.	2.0	3
3283	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. <i>Cancer Cell International</i> , 2023, 23, .	1.8	5

#	ARTICLE	IF	CITATIONS
3284	Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
3286	Radiation-Induced Immunoediting of Cancer. , 2023, , 1-20.		0
3287	Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug-activating suicide gene therapies. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	0
3288	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
3289	Strahlentherapie und Immuntherapie. <i>Springer Reference Medizin</i> , 2023, , 1-20.	0.0	0
3290	The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. <i>Esophagus</i> , 2023, 20, 524-532.	1.0	5
3291	Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. , 2023, 11, e005940.		12
3292	Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3293	Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. <i>Cancer Medicine</i> , 2023, 12, 10045-10061.	1.3	1
3294	Radiotherapy, Chemotherapy and Immunotherapy-Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma. <i>Diagnostics</i> , 2023, 13, 99.	1.3	2
3295	Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma. <i>Biomolecules</i> , 2023, 13, 90.	1.8	2
3296	A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
3297	miR-551a and miR-551b-3p target GLIPR2 and promote tumor growth in high-risk head and neck cancer by modulating autophagy. <i>Advances in Cancer Biology Metastasis</i> , 2022, , 100085.	1.1	1
3298	HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0
3299	Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. <i>Immunotherapy</i> , 2022, 14, 1419-1427.	1.0	1
3300	Oropharynx und Larynx. , 2022, , 171-187.		0
3301	Medikamentöse Tumorthherapie des Älteren Menschen. , 2022, , 297-315.		0
3302	Karzinome der Mundhöhle. , 2022, , 147-170.		0

#	ARTICLE	IF	CITATIONS
3303	Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. <i>JAMA Network Open</i> , 2023, 6, e2250607.	2.8	9
3304	Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?. <i>Drugs and Aging</i> , 2023, 40, 135-143.	1.3	2
3305	Top advances of the year: Head and neck cancer. <i>Cancer</i> , 0, , .	2.0	0
3307	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). <i>Journal of Thoracic Disease</i> , 2023, , .	0.6	1
3308	Tumor immunology. , 2023, , 245-452.		0
3309	Single-cell analysis of myeloid cells in HPV+ tonsillar cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3310	Immunotherapy in HPV-Related Oropharyngeal Cancers. <i>Current Treatment Options in Oncology</i> , 2023, 24, 170-183.	1.3	7
3311	Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME). , 2023, , .		0
3312	Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 1344-1359.	3.2	5
3313	Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
3314	Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01). <i>Cancers</i> , 2023, 15, 471.	1.7	0
3315	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0
3316	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. <i>Cancers</i> , 2023, 15, 852.	1.7	6
3317	Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 1528-1534.	3.2	0
3318	Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis. <i>Critical Reviews in Oncogenesis</i> , 2023, 28, 11-44.	0.2	2
3319	Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer. <i>Cancers</i> , 2023, 15, 672.	1.7	2
3320	Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. <i>Cancers</i> , 2023, 15, 657.	1.7	2
3321	BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
3322	Bibliometric study on the knowledge graph of immunotherapy for head and neck cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
3323	C.E. Credit. Embracing Precision and Data Science in Dentistry. <i>Journal of the California Dental Association</i> , 2022, 50, 441-451.	0.0	0
3324	Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer. <i>Anti-Cancer Drugs</i> , 2023, 34, 695-698.	0.7	2
3325	Immune Checkpoint Inhibition and Radiotherapy in Head and Neck Squamous Cell Carcinoma: Synergisms and Resistance Mechanisms. , 2023, , 11-21.		0
3326	New Systemic Therapies in Salivary Gland Cancer. , 2023, , 327-345.		2
3327	Immunotherapy: Targeting Cancer Cells. <i>Biological and Medical Physics Series</i> , 2023, , 179-217.	0.3	0
3328	æ¬¡ä,-ä»£ãfªãf¼ãf€ãf¼ã®è,²æ^ê•éé,éf`ç™CEã«ã³¼ãªã,ã...ç-«ç™,æ³•ã®æœ€ã%ç.šâ€. Nihon Jibi Inkoka Tohoku Gekko Gakkai Ka		
3329	Private Payerâ€Negotiated Rates for FDAâ€Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 169, 954-961.	1.1	1
3330	Prognostic value of O6-methylguanine-DNA methyltransferase hypermethylation and expression in head and neck cancer: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e33472.	0.4	1
3331	Current concepts in PD-L1 testing in head and neck squamous cell carcinoma: overview, developments and challenges. <i>Diagnostic Histopathology</i> , 2023, 29, 225-231.	0.2	0
3332	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
3333	Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
3334	Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 880-887.	15.2	12
3335	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
3336	Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery. <i>Clinical and Translational Radiation Oncology</i> , 2023, 40, 100623.	0.9	0
3337	Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients. <i>Oral Oncology</i> , 2023, 140, 106364.	0.8	1
3338	Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2023, 184, 30-38.	1.3	5
3339	CTLA-4 blockade induces tumor pyroptosis via CD8+ TÂcells in head and neck squamous cell carcinoma. <i>Molecular Therapy</i> , 2023, 31, 2154-2168.	3.7	9

#	ARTICLE	IF	CITATIONS
3340	The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy. <i>Molecular Cancer</i> , 2023, 22, .	7.9	8
3341	PVT1 inhibition stimulates anti-tumor immunity, prevents metastasis, and depletes cancer stem cells in squamous cell carcinoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	6
3342	Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2023, 9, 779.	3.4	18
3343	Global research trends in immunotherapy for head and neck neoplasms: A scientometric study. <i>Heliyon</i> , 2023, 9, e15309.	1.4	0
3345	Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. <i>Oral Oncology</i> , 2023, 138, 106311.	0.8	1
3346	Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin. <i>Current Treatment Options in Oncology</i> , 2023, 24, 147-161.	1.3	1
3347	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
3348	HSF1 activates the FOXO3a- β -Np63 β -CDK4 axis to promote head and neck squamous cell carcinoma cell proliferation and tumour growth. <i>FEBS Letters</i> , 2023, 597, 1125-1137.	1.3	0
3350	Therapeutic Vaccination for HPV-Mediated Cancers. <i>Current Otorhinolaryngology Reports</i> , 2023, 11, 44-61.	0.2	8
3351	Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
3352	MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	5
3353	Effect of lymphoid volume irradiation on radiation-induced lymphopenia in head and neck cancers. <i>Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2023, 27, 145-153.	0.6	2
3354	Medical treatment for ocular surface squamous neoplasia. <i>Eye</i> , 2023, 37, 885-893.	1.1	1
3355	The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer. <i>Nutrients</i> , 2023, 15, 880.	1.7	8
3356	Transcriptional analysis links B cells and TERT expression to favorable prognosis in head and neck cancer. , 2023, 2, .		2
3357	Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting. <i>Cancer Medicine</i> , 2023, 12, 7189-7206.	1.3	6
3358	Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges. <i>British Journal of Cancer</i> , 0, , .	2.9	2
3359	Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16. <i>Seminars in Immunopathology</i> , 2023, 45, 273-277.	2.8	2

#	ARTICLE	IF	CITATIONS
3361	Immunotherapy for Head and Neck Cancers. , 2023, , 1-28.		0
3362	Platinum-refractory oral cancers could have a poorer therapeutic response to immunotherapy than their non-oral counterparts. Cancer Research Statistics and Treatment, 2022, 5, 779.	0.1	1
3363	CTHRC1 is associated with immune cell infiltration and functions as an adverse marker for prognosis in head and neck squamous cell carcinoma. Oncology Letters, 2023, 25, .	0.8	2
3364	Immunotherapy in recurrent head-and-neck cancer: Making the juice worth the squeeze. Cancer Research Statistics and Treatment, 2022, 5, 782.	0.1	1
3365	Are we spoiled for choice in advanced squamous cell carcinoma of the head-and-neck?. Cancer Research Statistics and Treatment, 2022, 5, 712.	0.1	5
3366	Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center. Cancer Research Statistics and Treatment, 2022, 5, 630.	0.1	3
3367	Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. Cancer Medicine, 2023, 12, 9373-9383.	1.3	7
3368	Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-25.	1.9	1
3369	Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma. Journal of Personalized Medicine, 2023, 13, 363.	1.1	5
3370	Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2023, 29, 2066-2074.	3.2	5
3371	“Timing is Everything” the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma. Annals of Oncology, 2023, 34, 213-214.	0.6	1
3372	Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials. Head and Neck, 2023, 45, 862-871.	0.9	3
3373	Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. Diagnostics, 2023, 13, 793.	1.3	1
3374	Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors. Cancer Medicine, 2023, 12, 9384-9391.	1.3	5
3375	Tumor Immune Microenvironment Heterogeneity at the Invasion Front and Tumor Center in Oral Squamous Cell Carcinoma as a Perspective of Managing This Cancer Entity. Journal of Clinical Medicine, 2023, 12, 1704.	1.0	1
3376	Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial. Clinical Cancer Research, 2023, 29, 1906-1915.	3.2	3
3377	Bibliometric analysis of immunotherapy for head and neck squamous cell carcinoma. Journal of Dental Sciences, 2023, 18, 872-882.	1.2	6
3379	Chemoprevention of oral cancer: A review and future perspectives. Head and Neck, 2023, 45, 1045-1059.	0.9	3

#	ARTICLE	IF	CITATIONS
3380	The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination. <i>British Journal of Cancer</i> , 2023, 128, 1777-1787.	2.9	3
3381	Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. <i>Diagnostics</i> , 2023, 13, 862.	1.3	4
3382	Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 3122-3134.	0.8	20
3383	Journal of Japanese Society for Head and Neck Cancer. 2023; 15(1): 1-10.	0.0	0
3384	Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
3385	Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer. <i>Anticancer Research</i> , 2023, 43, 1273-1282.	0.5	2
3386	Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2023, 8, 100784.	2.0	1
3388	The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study. <i>Translational Cancer Research</i> , 2023, 12, 558-571.	0.4	0
3389	PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	1
3390	Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer. <i>Strahlentherapie Und Onkologie</i> , 0, , .	1.0	0
3391	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
3393	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
3394	First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened?. <i>Journal of Clinical Oncology</i> , 2023, 41, 2134-2137.	0.8	1
3395	Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan. <i>In Vivo</i> , 2023, 37, 747-755.	0.6	1
3396	Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	12
3397	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
3398	Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2021. <i>PLoS ONE</i> , 2023, 18, e0281983.	1.1	1
3399	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	1.7	4

#	ARTICLE	IF	CITATIONS
3400	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
3401	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
3402	The relationship between autophagy and PD-L1 and their role in antitumor therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
3403	Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. <i>Advances in Clinical Medicine</i> , 2023, 13, 3702-3708.	0.0	0
3404	Association between human papillomavirus and oral cancer: a literature review. <i>International Journal of Clinical Oncology</i> , 2023, 28, 982-989.	1.0	3
3405	Extracellular Vesicles as Biomarkers in Head and Neck Squamous Cell Carcinoma: From Diagnosis to Disease-Free Survival. <i>Cancers</i> , 2023, 15, 1826.	1.7	2
3406	Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3407	Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. <i>ESMO Open</i> , 2023, 8, 100877.	2.0	3
3408	Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncology and Therapy</i> , 2023, 11, 185-198.	1.0	2
3410	Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. <i>Cell Reports</i> , 2023, 42, 112303.	2.9	6
3411	Correlation between 18F-FDG PET/MR parameters with the expression level of epidermal growth factor receptor and the diagnostic value of PET/MR in head and neck squamous cell carcinoma. <i>Heliyon</i> , 2023, 9, e14822.	1.4	1
3412	Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
3413	Human Papillomavirus in Sinonasal Malignancies. <i>Current Otorhinolaryngology Reports</i> , 0, , .	0.2	0
3414	Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 166-177.	1.1	1
3415	Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2023, 27, 1423-1433.	1.4	1
3416	Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 158-165.	1.1	1
3417	Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?. <i>Current Opinion in Oncology</i> , 2023, 35, 178-185.	1.1	1
3418	Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. , 2023, , 217-228.		0

#	ARTICLE	IF	CITATIONS
3419	Novel Immune Oncology Targets Beyond PD-1/PD-L1 in Head and Neck Cancer. , 2023, , 51-61.		0
3420	Stereotactic Body Radiation Therapy in the Management of Recurrent and/or Oligometastatic Head and Neck Cancer. , 2023, , 229-236.		0
3421	Immune Checkpoint Inhibitors in the Curative Setting: Pre-clinical and Clinical Data. , 2023, , 165-178.		0
3422	Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer. , 2023, , 199-215.		0
3423	Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers, 2023, 15, 1959.	1.7	3
3424	Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma. Current Medical Science, 2023, 43, 213-222.	0.7	2
3426	Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. British Journal of Cancer, 2023, 128, 2126-2139.	2.9	5
3427	Randomized Phase II Trial of Ficlatazumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal of Clinical Oncology, 2023, 41, 3851-3862.	0.8	2
3428	CDK4/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma. Cancers, 2023, 15, 2005.	1.7	4
3429	Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancers, 2023, 15, 2021.	1.7	6
3430	The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens. Cancers, 2023, 15, 2024.	1.7	8
3431	Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment. , 2023, 11, e006721.		3
3432	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab. British Journal of Oral and Maxillofacial Surgery, 2023, , .	0.4	2
3433	Clinical relevance of serum lipids in the carcinogenesis of oral squamous cell carcinoma. BMC Oral Health, 2023, 23, .	0.8	0
3434	Newly developed 3D in vitro models to study tumor-immune interaction. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	11
3435	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. Molecular and Cellular Biochemistry, 2024, 479, 127-170.	1.4	1
3436	The Evolving Concept of Viruses and Immune System Interaction in Head and Neck Neoplasms. , 2023, , .		0
3437	Genes transcriptional activity features in different histological subtypes of tongue squamous cell carcinoma. Uspehi Molekularnoj Onkologii, 2023, 10, 57-78.	0.1	0

#	ARTICLE	IF	CITATIONS
3439	Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	7
3441	The relation between hypoxia and proliferation biomarkers with radiosensitivity in locally advanced laryngeal cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 0, , .	0.8	2
3442	Head and neck cancer treatment in the era of molecular medicine. <i>Advances in Cancer Research</i> , 2023, , 205-252.	1.9	2
3443	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
3444	Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7114.	1.8	1
3445	Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	3
3446	High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFN γ Signaling Pathway Defects. <i>Cancer Immunology Research</i> , 2023, 11, 895-908.	1.6	6
3447	Research Progress on the Treatment of Hypopharyngeal Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 5527-5535.	0.0	0
3448	Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 680-692.	1.3	4
3449	Antibiotics Significantly Decrease the Survival of Head and Neck Carcinoma Patients with Immunotherapy: A Real-World Analysis of More Than 3000 Cases. <i>Cancers</i> , 2023, 15, 2342.	1.7	1
3450	Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 2346.	1.7	0
3451	Identification of an immune-related genes signature to predict risk of recurrence for patients with laryngeal squamous cell carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2023, 37, 039463202311720.	1.0	0
3452	Cancer Traits; Present and Future. , 2023, , 12-51.		0
3453	Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. <i>European Journal of Cancer</i> , 2023, 188, 29-38.	1.3	5
3454	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0
3456	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7592.	1.8	1
3480	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
3508	Palliative radiotherapy in the head and neck. , 2024, , 141-154.		0

#	ARTICLE	IF	CITATIONS
3531	Basics of Tumor Surgery. , 2023, , 473-494.		0
3555	The contribution of automated cytometry in immuno-oncology. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
3565	A Case of Cholangitis as a Nivolumab-Induced Immune-Related Adverse Event in a Patient with Pulmonary Metastasis After Surgery for Oral Cancer. <i>Journal of Maxillofacial and Oral Surgery</i> , 0, , .	0.6	0
3585	Small-Molecule Inhibitors of Proteinâ€“Protein Interactions as Therapeutics. , 2023, , 343-428.		0
3591	Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	34
3601	Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	2
3603	Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer. <i>Oncogene</i> , 2023, 42, 2939-2955.	2.6	1
3620	Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma. <i>Targeted Oncology</i> , 2023, 18, 643-655.	1.7	2
3626	Conversion surgery after successful response to chemotherapy (S-1â€“oxaliplatinâ€“nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report. <i>International Cancer Conference Journal</i> , 0, , .	0.2	0
3631	Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm colorectal cancer. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
3676	Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3679	Radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma: biological angle. <i>Oral and Maxillofacial Surgery</i> , 0, , .	0.6	0
3680	Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. <i>Head and Neck Pathology</i> , 2023, 17, 969-975.	1.3	1
3689	Comprehensive genomic profiling for oncological advancements by precision medicine. , 2024, 41, .		2
3699	The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. <i>Japanese Journal of Radiology</i> , 0, , .	1.0	0
3746	Molecular Pathology of Head and Neck Tumors. , 2023, , 493-516.		0
3749	Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway. <i>Oncogene</i> , 2024, 43, 388-394.	2.6	0
3771	Predicting Tertiary Lymphoid Structures in Head and Neck Contrast-Enhanced CT Images using a 3D CNN. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
3776	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
3792	Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event. European Archives of Oto-Rhino-Laryngology, 2024, 281, 2037-2040.	0.8	0
3809	Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. European Archives of Oto-Rhino-Laryngology, 0, , .	0.8	0
3837	Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing "PD-1 Microclusters". Advances in Experimental Medicine and Biology, 2024, , 197-205.	0.8	0